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The Molecular Pathogenesis Of Cerebral Cavernous Malformations
Abstract
Cerebral cavernous malformation (CCM) is a human genetic, cerebrovascular disease that is caused by loss of
function mutations in three non-homologous protein coding genes: KRIT1, CCM2, and PDCD10. These
proteins form a heterotrimeric CCM adaptor complex that is required in endothelial cells to prevent disease.
How loss of this complex causes disease remains unknown. Here, utilizing a neonatal mouse model of disease,
we demonstrate that the CCM complex negatively regulates Mitogen-Activated Protein Kinase Kinase Kinase
3 (MAP3K3 aka MEKK3) signaling in endothelial cells. During disease, loss of the CCM complex results in
gain of MEKK3 signaling and pathologic overexpression of downstream target transcription factors Kruppel-
like Factor 2 and Kruppel-like factor 4 (KLF2 and KLF4). This endothelial MEKK3-KLF2/4 signaling
pathway represents the proximal signaling events that are required for lesion formation. If the CCM complex
negatively regulates MEKK3 signaling, what are the upstream activators of MEKK3 in the context of disease?
We demonstrate that gram-negative bacterial infection and lipopolysaccharide (LPS) activation of endothelial
Toll-like receptor 4 (TLR4) drives MEKK3 signaling to stimulate lesion formation. Commensal bacteria in
the gut microbiome produce the vast majority of endogenous LPS. We further show through germ-free and
broad-spectrum antibiotic experiments, along with 16S fecal analysis of mice spontaneously resistant to lesion
formation, that the gram-negative, bacterial microbiome is a primary driver of lesion formation. These studies
reveal that endothelial TLR4—MEKK3—KLF2/4 signaling is required for lesion formation and that
inhibition of this pathway may be of therapeutic value for CCM patients. They further demonstrate an
unexpected role for the gut microbiome in this cerebrovascular disease and suggest that manipulation of host-
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ABSTRACT  
  
THE  MOLECULAR  PATHOGENESIS  OF  CEREBRAL  CAVERNOUS  MALFORMATIONS  
Alan  T.  Tang  
Mark  L.  Kahn,  MD  
   Cerebral  cavernous  malformation  (CCM)  is  a  human  genetic,  cerebrovascular  disease  
that  is  caused  by  loss  of  function  mutations  in  three  non-­homologous  protein  coding  genes:  
KRIT1,  CCM2,  and  PDCD10.  These  proteins  form  a  heterotrimeric  CCM  adaptor  complex  that  is  
required  in  endothelial  cells  to  prevent  disease.  How  loss  of  this  complex  causes  disease  remains  
unknown.  Here,  utilizing  a  neonatal  mouse  model  of  disease,  we  demonstrate  that  the  CCM  
complex  negatively  regulates  Mitogen-­Activated  Protein  Kinase  Kinase  Kinase  3  (MAP3K3  aka  
MEKK3)  signaling  in  endothelial  cells.  During  disease,  loss  of  the  CCM  complex  results  in  gain  of  
MEKK3  signaling  and  pathologic  overexpression  of  downstream  target  transcription  factors  
Kruppel-­like  Factor  2  and  Kruppel-­like  factor  4  (KLF2  and  KLF4).  This  endothelial  MEKK3-­KLF2/4  
signaling  pathway  represents  the  proximal  signaling  events  that  are  required  for  lesion  formation.  
If  the  CCM  complex  negatively  regulates  MEKK3  signaling,  what  are  the  upstream  activators  of  
MEKK3  in  the  context  of  disease?  We  demonstrate  that  gram-­negative  bacterial  infection  and  
lipopolysaccharide  (LPS)  activation  of  endothelial  Toll-­like  receptor  4  (TLR4)  drives  MEKK3  
signaling  to  stimulate  lesion  formation.  Commensal  bacteria  in  the  gut  microbiome  produce  the  
vast  majority  of  endogenous  LPS.  We  further  show  through  germ-­free  and  broad-­spectrum  
antibiotic  experiments,  along  with  16S  fecal  analysis  of  mice  spontaneously  resistant  to  lesion  
formation,  that  the  gram-­negative,  bacterial  microbiome  is  a  primary  driver  of  lesion  formation.  
These  studies  reveal  that  endothelial  TLR4—MEKK3—KLF2/4  signaling  is  required  for  lesion  
formation  and  that  inhibition  of  this  pathway  may  be  of  therapeutic  value  for  CCM  patients.  They  
further  demonstrate  an  unexpected  role  for  the  gut  microbiome  in  this  cerebrovascular  disease  
and  suggest  that  manipulation  of  host-­microbiome  interactions  may  be  a  viable  therapeutic  
strategy  for  this  lifelong,  progressive  disease.  
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CHAPTER  1:  Introduction    
Summary  
This  chapter  will  present  background  information  relevant  to  the  experimental  studies  that  
will  be  discussed  in  later  chapters.  The  first  part  will  introduce  cerebral  cavernous  malformations  
(CCMs),  a  human  genetic  cerebrovascular  disease  and  the  scientific  community’s  efforts  to  
understand  its  pathogenesis,  including  prior  work  from  our  laboratory.  The  second  part  will  
introduce  TLR4  signaling  and  innate  immune  signaling  pathways  in  endothelial  cells.  The  third  
part  will  discuss  aspects  of  the  gut  microbiome  particularly  relevant  to  my  thesis  work.    
  
1.1  Clinical  features  of  cerebral  cavernous  malformations  
  
Cerebral  cavernous  malformations  (CCMs)  are  thin-­walled,  dilated  vascular  
malformations  that  predominantly  occur  in  the  central  nervous  system  (CNS)  with  a  prevalence  of  
0.1  to  0.5  percent  in  the  general  population1.  These  blood-­filled  “bubbles”  arise  from  small  blood  
vessels  (capillary-­vein  distribution),  distinguishing  them  from  other  vascular  malformations  such  
as  aneurysms  or  arteriovenous  malformations2.  Patients  typically  present  in  middle  age  with  a  
variety  of  neurologic  symptoms  ranging  from  headaches  to  focal  deficits  to  seizures.  A  definitive  
diagnosis  can  be  made  with  advanced  magnetic  resonance  imaging  (MRI)  techniques  (Figure  
1.1).  The  most  dangerous  complication  of  CCM  disease  is  rupture  of  a  lesion  and  subsequent  
hemorrhagic  stroke.  Current  standard  of  care  remains  symptomatic  management  (e.g.  anti-­
epileptics)  and  neurosurgical  resection  or  embolization  of  advanced  lesions1,3.  Complicating  the  
care  of  these  patients  is  the  fact  that  disease  course  with  regards  to  lesion  burden  and  
concomitant  symptoms  is  highly  variable—eloquently  described  by  Elizabeth  Tournier-­Lasserve,  
the  physician-­scientist  who  discovered  the  genetic  basis  for  CCM  disease,  as  a  “disease  without  
natural  history”.  Despite  being  a  recognized  clinical  disease  for  over  thirty  years,  there  remain  no  
established,  consensus  guidelines  for  the  long-­term  medical  management  of  CCM  disease3.  
1.2  Human  genetics  of  CCM  disease  
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The  recognition  of  CCM  disease  as  a  distinct  clinical  entity  was  quickly  followed  by  the  
realization  that  patients  could  be  split  into  two  distinct  categories:  familial  or  sporadic.  While  the  
majority  of  CCM  patients  have  no  family  history  of  disease  and  are  categorized  as  sporadic,  in  
some  cases,  disease  is  inherited  in  an  autosomal  dominant  fashion.  Efforts  by  Elizabeth  Tournier-­
Lasserve  and  Douglas  Marchuk  in  the  1990s  to  gather  families  with  CCM  disease  allowed  them  
to  positionally  clone  and  identify  causal,  loss-­of-­function  mutations  in  three  distinct  genes:  KRIT1  
(CCM1),  CCM2,  and  PDCD10  (CCM3),  which  encode  three  non-­homologous  proteins4-­9.  Patients  
with  familial  CCM  disease  are  germline  heterozygous  for  any  of  the  three  “CCM  genes”  and  
typically  present  with  multiple  lesions,  experience  a  progressive  disease  course,  and  over  their  
lifetimes  can  development  hundreds  of  lesions.  It  is  thought  that  lesions  in  familial  patients  arise  
from  a  loss-­of-­heterozygosity  event  and  evidence  for  bi-­allelic  somatic  and  germline  mutation  
have  been  found  in  resected  human  CCM  tissue10.  Notably,  no  homozygous  null  patient  has  yet  
to  be  identified.  Patients  with  sporadic  disease  are  thought  to  develop  de  novo  mutations  during  
life  and  typically  present  with  a  single  lesion  that  has  become  symptomatic.  
In  one  of  the  largest  cross-­sectional  studies  of  familial  KRIT1  patients  involving  over  two-­
hundred  individuals,  the  mean  age  of  clinical  onset  was  thirty  years  with  approximately  fifty  
percent  presenting  with  seizures  and  thirty  percent  presenting  with  cerebral  hemorrhage11.  In  
patients  greater  than  fifty  years  of  age,  almost  fifty  percent  were  symptom-­free  and  several  did  
not  have  any  detectable  lesions  upon  MRI,  demonstrating  the  incomplete  penetrance  of  this  
disease.  
  
1.3  Early  experimental  findings  in  mice  demonstrate  an  endothelial  requirement  for  CCM  
proteins  
  
   The  identification  of  the  genes  responsible  for  CCM  disease  spurred  an  intense  effort  to  
understand  the  role  of  the  three  non-­homologous  proteins  that  they  encode.  KRIT1,  CCM2,  and  
PDCD10  are  highly  conserved  between  humans  and  mice  at  the  amino  acid  level.  Targeted,  null  
alleles  of  Krit1,  Ccm2,  and  Pdcd10  were  generated  in  mice  and  homozygous  null  animals  exhibit  
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fully-­penetrant  embryonic  lethality12-­16.  Krit1  and  Ccm2  global  knockout  animals  die  at  E11  due  to  
a  developmental  defect  in  the  branchial  arch  arteries  in  which  they  do  not  become  fully  patent  
and  cannot  support  proper  blood  circulation17.  In  contrast,  Pdcd10  knockout  animals  exhibit  
severe  growth  deficits  and  die  at  E9  prior  to  the  onset  of  blood  circulation16.  The  vascular  defects  
in  Krit1  and  Ccm2  animals  suggested  an  endothelial  cell  requirement  for  these  proteins.  
Endothelial  cell  specific  deletion  of  Krit1  or  Ccm2,  using  conditional  (floxed)  alleles  and  an  
endothelial  cell  Cre-­driver  phenocopies  the  respective  global  knockout13,15,18.  Interestingly,  the  
endothelial  cell  specific  deletion  of  Pdcd10  phenocopies  the  endothelial  cell  deletion  of  Krit1  and  
Ccm2,  suggesting  that  the  early  embryonic  lethality  of  the  Pdcd10  global  knockout  is  due  to  a  role  
for  PDCD10  in  other  cell  types16.  
   While  the  embryonic  deletion  of  the  CCM  proteins  provided  valuable  insight  into  their  
developmental  roles,  they  did  not  allow  for  study  of  CCM  biology  in  the  context  of  CCM  disease.  
Heterozygous  mice  do  not  develop  detectable  CCM  lesions  even  at  a  year  of  age,  precluding  
their  use  as  a  disease  model.  This  hurdle  was  overcome  in  a  seminal  study  that  utilized  a  
tamoxifen  inducible,  endothelial  cell-­specific  Cre  (Cdh5(PAC)-­Cre/ERT2)  to  delete  the  CCM  
genes  shortly  after  birth  in  neonatal  mice19.  Within  ten  days  of  gene  deletion,  a  profound  
spontaneous  lesion  phenotype  appears  most  prominently  in  the  cerebellum  and  retinal  
vasculature,  closely  resembling  human  CCM  disease17,19.  Neonatal  endothelial  cell  deletion  of  
any  of  the  three  CCM  genes  results  in  a  similar  phenotype,  consistent  with  the  embryonic  studies,  
and  strongly  suggest  that  CCM  lesions  arise  from  an  endothelial  cell-­autonomous  mechanism19.  
This  “neonatal  CCM  model”  is  a  highly  tractable  disease  model  that  will  be  heavily  featured  in  
later  chapters.  
1.4  CCM  proteins  form  a  heterotrimeric  adaptor  complex  
  
   KRIT1,  CCM2,  and  PDCD10  mutations  cause  indistinguishable  disease  in  humans  and  
endothelial  cell-­specific  deletion  of  these  proteins  in  mice  phenocopy  each  other  during  
embryonic  development  and  neonatal  life.  How  does  loss  of  any  one  of  three  non-­homologous  
proteins  result  in  a  single  phenotype?  A  key  advance  in  our  understanding  of  CCM  biology  was  
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the  finding  that  KRIT1,  CCM2  and  PDCD10  directly  interact  to  form  a  single  cytoplasmic  
complex—KRIT1  binds  directly  to  CCM2  and  CCM2  binds  directly  to  PDCD1020-­25.  This  
heterotrimeric  “CCM  complex”  has  been  defined  at  the  atomic-­level  by  multiple  crystal  structures  
and  the  key  interacting  domains  have  been  identified20  (Figure  1.2).  Moreover,  causative  point  
mutations  have  been  identified  in  familial  CCM  patients  that  disrupt  binding  between  KRIT1,  
CCM2,  and  PDCD1020.    
Our  increased  biochemical  understanding  of  CCM  proteins  further  confirmed  that  these  
proteins  do  not  have  any  known  enzymatic  domains  or  function  and  that  the  CCM  complex  is  a  
pure  adaptor  or  scaffolding  complex22.  This  suggested  that  the  CCM  complex  affects  endothelial  
cell  signaling  through  interaction  with  other  proteins.  Which  proteins  interact  with  the  CCM  
complex?  
1.5  CCM2  interacts  with  MEKK3,  a  MAP3-­kinase  essential  for  endothelial  cell  
homeostasis  
  
   Independent  of  the  CCM  scientific  community,  Gary  Johnson’s  laboratory  was  deeply  
invested  in  studying  mitogen  activated  protein  kinase  (MAPK)  signaling  pathways.  They  were  
interested  in  finding  proteins  that  interact  with  MEKK3  (gene  name  MAP3K3),  a  MAP3-­kinase.  To  
accomplish  this,  they  performed  a  yeast  two-­hybrid  screen  with  an  N-­terminal  fragment  of  MEKK3  
as  bait  and  identified  CCM2  as  an  interacting  protein.  At  the  time,  CCM2  was  a  novel  protein  that  
they  named  OSM  for  its  role  in  sensing  external  osmolarity  in  yeast26.  Follow-­up  studies  in  
cultured  human  cells  recapitulated  this  interaction,  and  our  laboratory  demonstrated  that  this  
interaction  occurs  in  live,  cultured  human  endothelial  cells  using  an  MEKK3-­birA  (biotin  ligase)  
fusion  protein25,27.  More  recently,  two  independently  derived  crystal  structures  demonstrating  the  
exact  nature  of  the  CCM2—MEKK3  interaction  were  published,  confirming  that  the  CCM2  helical  
harmonin  domain  interacts  with  the  N-­terminal  PB1  domains  of  MEKK328,29.  
   Map3k3  null  mice  are  embryonic  lethal,  displaying  impaired  angiogenesis,  loss  of  
vascular  integrity  and  defective  heart  development30.  The  endothelial  cell-­specific  deletion  of  
Map3k3  phenocopies  the  global  knockout,  suggesting  that  MEKK3  has  an  essential  role  in  
	   5	  
endothelial  cell  signaling  (data  from  our  lab  not  published).  Vascular  malformations  of  unknown  
etiology  are  commonly  found  in  the  general  population  and  a  recent  study  identified  several  
somatic  MEKK3  mutations  in  resected  human  verrucous  venous  malformations31.  Given  the  
importance  of  the  CCM  complex  and  MEKK3  in  endothelial  cells,  we  believed  that  further  
investigation  of  the  relationship  between  these  interacting  partners  would  be  important  in  
understanding  CCM  pathogenesis.  
1.6  Endocardial  deletion  of  CCM-­genes  reveals  the  relationship  between  the  CCM  
complex  and  MEKK3  
  
   Studying  the  in  vivo  role  of  the  CCM  complex  during  development  was  complicated  by  
the  fact  that  endothelial  cell-­specific  deletion  led  to  non-­patent  branchial  arch  arteries  and  growth  
arrest  by  E9—a  timepoint  at  which  the  embryos  are  difficult  to  analyze,  particularly  for  any  sort  of  
molecular  information  e.g.  transcriptional  profiling.  To  overcome  this  hurdle,  our  laboratory  utilized  
a  newly  developed  Nfatc1-­Cre  knock-­in  allele,  in  which  an  IRES-­Cre  cassette  was  inserted  into  
the  3’  UTR  of  Nfatc132.  This  Cre-­driver  is  expressed  in  the  endocardium,  cardiac  endothelium  
lining  the  atria  and  ventricles,  during  development.  Importantly,  it  spares  the  peripheral  
vasculature,  including  the  branchial  arch  arteries,  preventing  the  early  embryonic  lethality  from  
pan-­endothelial  deletion  of  the  CCM  complex.  Deletion  of  Krit1,  Ccm2,  or  Pdcd10  with  the  Nfatc1-­
Cre  resulted  in  embryonic  lethality  between  E14  and  E15.  Analysis  of  the  heart  at  earlier  
timepoints  revealed  the  premature  loss  of  cardiac  jelly,  extracellular  matrix  comprised  primarily  of  
versican  and  hyaluronic  acid  which  separates  the  endocardium  and  myocardium  and  is  thought  to  
support  proper  trabeculation  of  the  heart27.  A  critical  next  experiment  was  to  compare  the  Nfatc1-­
Cre;;Krit1  fl/fl  and  Nfatc1-­Cre;;  Map3k3  fl/fl  phenotypes.  Nfatc1-­Cre  deletion  of  Map3k3  also  
resulted  in  midgestational  lethality,  but  did  not  phenocopy  Krit1  deletion,  suggesting  that  the  roles  
of  the  CCM  complex  were  very  different  from  MEKK3  in  the  endocardium  during  development  
despite  a  direct  interaction  between  CCM2  and  MEKK3.  
   To  address  this  conundrum,  our  laboratory  profiled  gene  expression  changes  in  Nfatc1-­
Cre;;Krit1  fl/-­  and  Nfatc1-­Cre;;Map3k3  fl/-­  hearts  at  E10.5  compared  to  controls.  This  critical  
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experiment  revealed  that  gene  expression  changes  due  to  loss  of  KRIT1  were  the  inverse  of  
those  due  to  MEKK3  loss  at  many  loci,  suggesting  that  the  CCM  complex  was  negatively  
regulating  MEKK3  signaling.  Several  of  the  most  significantly  changed  genes  included  the  genes  
encoding  transcription  factors  Kruppel  like-­factor  2  and  4  (Klf2  and  Klf4),  which  were  previously  
described  downstream  targets  of  endothelial  MEKK3  signaling,  as  well  as  Adamts4  and  Adamts5,  
which  encode  metalloproteases  that  degrade  extracellular  matrix  components  such  as  versican.  
Klf2/4  and  Adamts4/5  expression  was  elevated  in  Nfatc1-­Cre;;Krit1  fl/-­  hearts  but  downregulated  
in  Nfatc1-­Cre;;Map3k3  fl/-­  hearts,  consistent  with  a  role  for  the  CCM  complex  in  the  negative  
regulation  of  MEKK3  signaling.    
   Further  studies  in  a  variety  of  in  vivo  and  in  vitro  model  systems  demonstrated  that  upon  
loss  of  the  endocardial  CCM  complex,  gain  of  MEKK3—KLF2/4  signaling  and  subsequent  
endocardial  overexpression  of  ADAMTS4/5  was  responsible  for  the  premature  degradation  of  
cardiac  jelly,  disruption  of  proper  trabeculation  and  embryonic  lethality.  Importantly,  these  
transcriptional  changes  could  be  reversed  by  introducing  the  endocardial  haploinsufficiency  of  
MEKK3  (Nfatc1-­Cre;;Krit1  fl/fl;;  Map3k3  fl/+),  partially  rescuing  the  Nfatc1-­Cre;;  Krit1  fl/fl  cardiac  
jelly  phenotype.  Thus,  these  results  suggest  that  the  CCM  complex  negatively  regulates  MEKK3  
signaling  through  a  direct  interaction  between  CCM2  and  MEKK3.  Loss  of  the  CCM  complex  
results  in  aberrant  gain  of  MEKK3  signaling  and  pathologic  overexpression  of  KLF2/4  and  
ADAMTS4/5  resulting  in  the  premature  degradation  of  cardiac  jelly  (Figure  1.3).  
1.7  Other  signaling  pathways  affected  upon  loss  of  the  CCM  complex  
  
   The  identification  of  the  three  causative  CCM  genes  and  the  findings  in  mice  that  they  
putatively  function  in  an  endothelial  cell  autonomous  manner  have  spurred  intense  scientific  
interest  from  numerous  laboratories  around  the  world.  As  such,  it  is  perhaps  unsurprising  that  
numerous  signaling  pathways  have  been  implicated  as  downstream  effectors  of  the  CCM  
complex.  Here,  I  will  briefly  discuss  several  pathways  that  will  be  relevant  for  later  chapters,  
particularly  Chapter  2.    
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   Initial  in  vitro  studies  of  the  CCM  complex  in  cultured  endothelial  cells  demonstrated  that  
KRIT1  was  localized  to  the  cell  membrane  and  particularly  concentrated  at  the  cell-­cell  junction33.  
Further  studies  showed  that  KRIT1  was  associated  with  key  endothelial  junction  proteins,  namely  
VE-­cadherin  through  binding  to  RAP1,  a  small  GTPase33.  This  association  is  thought  to  sequester  
β-­catenin  at  the  cell  periphery,  preventing  it  from  activating  Wnt-­signaling  pathways34.  
Accordingly,  upon  loss  of  the  CCM  complex,  it  was  shown  that  endothelial  cells  exhibit  increased  
Wnt-­signaling,  although  there  are  conflicting  reports  in  the  literature19,35.  Lastly,  the  
pharmacologic  inhibition  of  Wnt-­signaling  was  shown  to  partially  prevent  lesion  formation  in  the  
neonatal  CCM  model35.  
Consistent  with  the  localization  of  the  CCM  complex  at  the  cell  membrane,  our  laboratory  
demonstrated  that  the  CCM  complex  interacts  with  the  transmembrane  protein  Heart  of  Glass-­1  
(HEG1)  through  an  interaction  between  KRIT1  and  the  cytoplasmic  domain  of  HEG114.  Using  
knockout  mice,  we  could  demonstrate  that  HEG1  and  CCM2  genetically  interact;;  however,  it  
remains  unclear  what  the  role  of  HEG1  is  in  CCM  pathology  as  neonatal  endothelial  cell-­specific  
deletion  of  HEG1  does  not  result  in  vascular  malformations36.  
Perhaps  the  most  studied  downstream  effector  in  the  CCM  field  has  been  the  Rho-­
associated  protein  kinase  (ROCK)  pathway.  Loss  of  the  CCM  complex  in  endothelial  cells  results  
in  upregulation  of  RhoA  activity  and  increased  ROCK1/2  signaling,  leading  to  cytoskeletal  
rearrangement,  which  can  be  detected  by  classical  staining  methods  (actin/phalloidin)  and  
antibodies  against  phosphorylated-­Myosin  Light  Chain  (pMLC)13,37,38.  Numerous  ROCK-­inhibitors  
have  been  developed  and  one  small-­molecule  inhibitor,  Fasudil,  has  been  shown  in  CCM  mouse  
models  to  be  efficacious  in  limiting  CCM  lesion  progression,  consistent  with  the  combinatorial  
genetic  result38.  
Lastly,  TGF-­β/BMP  signaling  and  associated  endothelial  to  mesenchymal  transition  
(EndMT)  has  been  proposed  be  an  important  part  of  CCM  pathogenesis39.  This  hypothesis  stems  
from  observations  in  the  neonatal  CCM  model  that  lesions  exhibit  markers  of  EndMT—notably  
loss  of  junctional  VE-­cadherin,  ectopic  expression  of  N-­cadherin,  and  increased  expression  of  
SLUG,  ID1,  SCA1,  and  KLF4  in  lesional  endothelium.  TGF-­β/BMP  signaling  is  an  important  
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inducer  of  EndMT  in  other  cellular  contexts  and  cultured  endothelial  cells  deficient  for  KRIT1,  
were  found  to  have  increased  TGF-­β  pathway  signaling  through  analysis  of  phosphorylated  
SMAD  and  known  downstream  transcriptional  targets.  Notably,  one  of  the  most  upregulated  
genes  upon  deletion  of  Krit1  in  cultured  endothelial  cells  was  Bmp6,  a  secreted  TGF-­β  receptor  
ligand,  suggesting  an  autocrine  signaling  mechanism  whereby  the  endothelium  promotes  SMAD  
phosphorylation  through  the  secretion  of  its  own  ligand.  Lastly,  the  in  vivo  use  of  TGF-­β  pathway  
inhibitors  partially  prevented  lesion  formation  in  the  neonatal  CCM  model39.    
1.8  Outstanding  questions  in  CCM  pathogenesis  to  be  addressed  
  
   As  I  previously  discussed,  the  study  of  CCM  biology  has  implicated  perhaps  every  major  
signaling  pathway  known  to  vascular  biology.  So,  what  is  the  molecular  mechanism  by  which  the  
CCM  complex  signals  in  the  endothelium?  Does  gain  of  MEKK3—KLF2/4  signaling  have  a  role  in  
CCM  lesion  formation?  The  most  pressing  question  for  our  laboratory  at  the  time  was  to  test  
whether  the  MEKK3—KLF2/4  pathway,  revealed  from  our  studies  of  the  CCM  complex  in  the  
developing  heart,  had  a  conserved  role  in  CCM  pathogenesis.  To  test  this,  we  would  utilize  the  
neonatal  CCM  model  and  a  combinatorial  genetic  rescue  approach  (Chapter  2).  
   If  the  CCM  complex  negatively  regulates  MEKK3  signaling,  what  are  the  upstream  
activators  of  MEKK3  in  the  context  of  disease?  Our  prior  studies  of  the  MEKK3  signaling  pathway  
in  endothelial  cells  demonstrated  that  hemodynamic  forces  such  as  shear  stress  were  capable  of  
activating  MEKK3—KLF2/4  signaling27.  Further  understanding  of  MEKK3  pathway  activation  
would  be  critical  to  understanding  disease  pathogenesis  and  potentially  reveal  molecular  
therapeutic  targets  (Chapter  3).  
1.9  Toll-­like  receptor  4  (TLR4)  is  a  pattern  recognition  receptor  for  lipopolysaccharide  
(LPS)  
  
   This  background  information  is  relevant  for  Chapter  3.  As  TLR4  biology  is  vast  and  
complex,  I  will  only  discuss  aspects  particularly  relevant  to  my  studies.  TLR4  is  a  member  of  a  
large  family  of  Toll-­like  receptors  that  function  as  transmembrane  pattern  recognition  receptors  for  
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a  variety  of  pathogenic  molecules40,41.  These  TLRs  link  pathogen-­associated  molecules  to  innate  
immune  responses,  particularly  the  activation  of  NF-­κB  and  expression  of  inflammatory  cytokines  
(classically  TNFα,  IL-­6  and  IL-­1β)  as  well  as  the  interferon  response.  TLR4  recognizes  
lipopolysaccharide  (LPS),  an  essential  membrane  component  of  gram-­negative  bacteria  and  
TLR4  signaling  has  an  essential  role  in  the  response  to  gram  negative  bacterial  infection40,42,43.  
Accordingly,  in  laboratory  mice,  Tlr4-­null  animals  are  resistant  to  LPS-­challenge,  but  are  highly  
susceptible  to  gram-­negative  bacterial  infection/sepsis.    
   LPS  signaling  to  TLR4  is  highly  complex.  LPS  is  comprised  of  two  distinct  halves—a  lipid  
and  a  polysaccharide  chain.  The  lipid  moiety  (Lipid  A)  is  thought  to  be  the  critical  entity  that  
primarily  elicits  TLR4  signaling,  while  variations  in  the  polysaccharide  chain  (O-­sidechain)  can  
alter  TLR4  sensitivity  and  immune  response  strength.  Hundreds  of  different  LPS  variations  from  
different  gram-­negative  bacterial  species  have  been  characterized  and  they  are  broadly  
categorized  into  two  major  groups.  LPS  containing  O-­sidechains  are  considered  “smooth  LPS”  
whereas  LPS  with  short  or  no  O-­sidechains  are  considered  “rough  LPS”44.  Previous  studies  have  
documented  that  smooth  versus  rough  LPS  can  have  variable  effects  on  the  host  immune  
response  through  TLR4  and  differential  activation  of  downstream  signaling  pathways45,46.  
   Generally,  in  mammals,  LPS  is  bound  in  the  blood  stream  to  LPS-­binding  protein  (LBP),  
CD14,  and  MD-­2  (aka  LY96)47-­49.  While  LBP  is  a  secreted  acute  phase  protein,  CD14  and  MD-­2  
exist  as  both  membrane-­bound  and  soluble  forms.  LBP  and  CD14  are  thought  to  promote  the  
efficient  loading  of  LPS  onto  the  TLR4  receptor,  but  are  not  absolutely  required  for  TLR4  
signaling  as  Lbp-­  or  Cd14-­null  mice  are  still  able  to  respond  to  higher  doses  of  LPS50-­52.  LPS  
recognition  by  TLR4  induces  the  homodimerization  of  TLR4  on  the  cell  membrane,  a  process  that  
is  essential  for  downstream  signaling.  MD-­2  is  required  for  this  process  and  crystal  structures  
have  demonstrated  that  LPS-­bound  MD-­2  heterodimerizes  with  TLR4  to  induces  TLR4  
dimerization53.  Accordingly,  Ly96-­null  mice  are  nonresponsive  to  LPS  challenge54.      
   The  LPS-­induced  homodimerization  of  TLR4  brings  its  intracellular  TIR  domains  in  tight  
proximity  and  is  thought  to  elicit  a  conformational  change  that  promotes  recruitment  of  
downstream  effectors55-­57.  Numerous  TIR-­domain  interacting  partners  have  been  identified  that  
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signal  downstream  of  TLR4  including  MyD88,  TIRAP  (aka  MAL),  TRIF,  TRAM,  and  SARM  and  
are  thought  to  contribute  to  the  diversity  of  responses  downstream  of  LPS-­TLR4  activation42.    
   Intriguingly,  and  of  high  relevance  to  our  CCM  disease  studies,  MEKK3  was  previously  
reported  to  be  an  essential  component  of  the  TLR4  signaling  pathway  in  cultured  cells58.  Using  
secreted  IL-­6  and  IL-­1  (canonical  transcriptional  targets  of  NF-­κB)  as  a  readout  for  TLR4  
activation,  the  authors  found  that  Map3k3-­null  mouse  embryonic  fibroblasts  were  unresponsive  to  
LPS  stimulation  and  that  LPS-­TLR4  signaling  occurred  through  a  MyD88-­IRAK-­TRAF6  signaling  
axis  to  activate  cellular  innate  immune  responses58.  As  evidenced  in  Chapter  3,  this  previous  
study  linking  TLR4  signaling  to  MEKK3  proved  to  be  of  immense  importance.          
1.10   Roles  of  TLR4  in  endothelial  cells  
  
   Since  Tlr4-­null  mice  are  viable,  fertile,  and  do  not  develop  a  spontaneous  phenotype,  the  
role  of  TLR4  signaling  in  endothelial  biology  in  vivo  has  remained  largely  unexplored.  In  contrast,  
LPS  has  commonly  been  used  as  an  in  vitro  tool  to  induce  inflammatory  changes  in  cultured  
endothelial  cells  to  interrogate  a  variety  of  endothelial  cell  biology59.  For  the  most  part,  TLR4  
signaling  in  endothelial  cells  seems  to  be  well-­conserved,  and  the  endothelium  expresses  all  
necessary  components  required  for  LPS-­TLR4  signaling,  including  MD-­2  and  CD1460.  Signaling  
to  NF-­κB  from  TLR4  also  involves  many  of  the  same,  major  downstream  signaling  proteins  
characterized  in  other  immune  cell  types.    
Perhaps  the  most  interesting  in  vivo  experiment  to  test  the  role  of  endothelial  TLR4  
signaling  came  from  Paul  Kubes’  lab,  where  a  transgenic  mouse  line  that  expresses  TLR4  
exclusively  in  endothelial  cells  was  generated61.  When  placed  over  a  Tlr4-­null  background,  this  
mouse  model  was  used  to  evaluate  the  contribution  of  endothelial  TLR4  signaling  in  a  variety  of  
bacterial  infection  models.  Surprisingly,  the  Kubes  lab  found  that  endothelial-­cell  TLR4  was  
sufficient  to  properly  clear  and  resolve  most  infectious  challenges.  The  only  defects  they  could  
find  were  in  the  rate  and  amount  of  neutrophil  recruitment  in  one  model  of  intra-­tracheal  LPS  
challenge.  This  study  suggested  that  endothelial  TLR4  signaling  was  an  important  aspect  of  the  
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innate  immune  response  to  bacteria,  supporting  a  general  hypothesis  for  the  role  of  endothelial  
cells  as  sentinels  and  important  regulators  of  immune  responses62.  
1.11   The  gut  microbiome  is  a  complex  ecosystem  of  microorganisms  that  interact  and  
influence  host  physiology  
  
   The  gut  microbiome  comprises  all  the  microorganisms  that  reside  in  the  gastrointestinal  
tract  (from  mouth  to  anus)  including  bacteria,  fungi,  eukaryotic  micro-­organisms  such  as  yeast,  
and  viruses  (mostly  bacteriophages)63.  The  best  studied  component  of  the  gut  microbiome  is  the  
bacterial  population.  It  is  estimated  that  anywhere  from  40  to  100  trillion  bacterial  organisms  
reside  within  the  GI  tract  performing  functions  essential  for  host  homeostasis63.  It  is  well-­accepted  
that  the  gut  microbiome  largely  co-­exists  in  a  mutualistic  relationship  with  its  host  organism,  
performing  key  metabolic  functions  (short  chain  fatty  acid  production),  nutrient  production  (vitamin  
synthesis),  as  well  as  protection  from  enteric  pathogens64.  Importantly,  there  are  also  direct  
examples  of  situations  in  which  microbiome  derangements  lead  to  host  pathology  such  as  
Helicobacter  pylori  infection  leading  to  gastric  ulcer  formation  and  Clostridium  difficile-­induced  
colitis65,66.    
With  the  advent  of  next  generation,  high  throughput  sequencing,  our  ability  to  interrogate  
the  diversity  of  the  gut  microbiome  has  greatly  improved.  16S  rDNA  sequencing  is  a  relatively  
inexpensive  method  to  characterize  microbial  diversity,  especially  when  many  samples  need  to  
be  analyzed67-­69.  This  method  entails  the  sequencing  of  one  or  several  hypervariable  regions  in  
the  bacterial  16S  ribosomal  DNA  gene  (rDNA)  based  on  a  sample  that  has  undergone  a  low-­
cycle  PCR  amplification  using  conserved  primers  flanking  the  hypervariable  regions.  The  main  
advantage  of  this  technique  is  the  ease  of  use,  relatively  low  cost  and  simple  downstream  
analysis.  Key  disadvantages  are  the  limited  ability  to  interpret  16S  hypervariable  sequences  to  
classify  bacteria,  the  need  for  PCR  amplification  which  may  not  properly  capture  lower  
abundance  species,  and  the  limited  information  obtained—essentially  the  only  information  readily  
obtained  from  16S  sequencing  is  the  relative  abundance  of  various  bacterial  subtypes.  Other  
techniques  such  as  shotgun  sequencing  attempt  to  directly  sequence  bacterial  DNA  
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(metagenomic  sequencing)68,69.  This  method  remains  extremely  expensive,  but  offers  a  high  
amount  of  functional  information  since  the  entire  bacterial  genome  is  subject  to  sequencing  and  
changes  in  expression  of  bacterial  genes  or  pathways  can  be  detected.    
1.12   The  gut  microbiome  has  far-­reaching  effects  on  host  physiology  that  are  just  
beginning  to  be  characterized  
  
   Recently,  it  has  become  increasingly  apparent  that  the  gut  microbiome  contributes  to  
pathogenesis  of  diseases  beyond  the  intestinal  tract.  Notable  examples  of  this  include  obesity,  
autoimmunity,  non-­alcoholic  fatty  liver  disease  (NAFLD),  neurodegenerative  disorders,  and  a  
range  of  cardiovascular  disorders64,70-­74.  The  overarching  hypothesis  from  such  studies  is  that  
different  gut  microbiomes  can  affect  disease  course  and  that  if  we  understood  these  effects,  there  
may  be  incredibly  valuable  translational  opportunities  to  improve  the  human  condition.  Using  
next-­generation  sequencing  of  the  microbiome,  these  papers  have  associated  classes  of  bacteria  
in  the  gut  microbiome  with  a  variety  of  phenotypes  and  disease  states  while  attempting  to  define  
mechanisms  whereby  the  microbiome  interacts  with  host  physiology.  These  studies  are  incredibly  
challenging  since  the  disease  models  being  used  (e.g.  diet  induced  obesity)  are  not-­genetically  or  
cell-­type  defined  and  have  a  complex  etiology.  Thus,  it  is  not  surprising  that  finding  common  
principles  among  these  studies  remains  a  challenge—the  proposed  mechanisms  whereby  the  gut  
microbiome  influences  health  and  disease  are  perhaps  as  varied  as  the  microbiome  itself.  
1.13   Bacterial  translocation  and  leak  of  bacterial  byproducts  from  the  gut  into  
circulation  occurs  in  health  and  disease  
  
   A  fundamental  question  in  studying  microbiome-­host  interactions  is  how  the  host  
maintains  homeostasis  while  being  colonized  with  massive  amounts  of  potentially  pathogenic  
microbes.  The  gut  “barrier”  refers  to  a  variety  of  mechanisms  (soluble  IgA,  immune  cells,  mucosal  
layers,  epithelial  cells)  whereby  the  host  prevents  gut  microbiota  from  leaking  from  the  gut  lumen  
into  circulation,  yet  this  barrier  must  remain  permeable  to  allow  for  the  absorption  of  dietary  
nutrients  and  water75-­77.  This  “barrier”  divides  trillions  of  bacteria  and  presumably  sterile  blood—a  
gradient  that  is  physically  impossible  to  maintain.  Thus,  a  natural  question  arises  regarding  how  
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much  bacteria  or  bacterial  byproducts  leak  from  the  gut  into  circulation  and  whether  this  is  
significant  to  host  physiology.  It  has  long  been  clinical  dogma  that  circulating  blood  is  sterile  and  
that  bacteremia  is  always  an  abnormal  finding.  For  the  most  part,  in  the  broadest  sense,  this  
clinically-­oriented  approach  to  understanding  bacterial-­host  interactions  is  appropriate.  
Nonetheless,  it  is  likely  that  humans  encounter  transient  bacteremia  daily,  particularly  during  
actions  that  induce  mucosal  trauma  e.g.  brushing  teeth  or  bowel  movements78,79.  Under  normal  
conditions,  such  events  are  cleared  without  issue  although  infective,  bacterial  endocarditis  is  a  
classic  example  of  how  the  transient  presence  of  blood-­borne  bacteria  can  present  a  serious  
health  risk80.  Importantly,  while  this  hypothesis  for  transient  bacteremia  is  reasonable,  there  
remains  no  definitive  evidence  for  the  occurrence  of  transient  bacteremia  in  healthy  individuals  
given  the  difficulty  of  detecting  these  minute  populations.  
   Recently,  a  particularly  relevant  study  demonstrated  the  phenomenon  of  bacterial  
translocation  in  the  setting  of  ischemic  stroke81.  In  both  humans  and  mice,  the  authors  could  
show  that  an  early  post-­stroke  finding  is  the  presence  of  culturable  intestinal  bacteria  in  distal  
organs.  They  hypothesized  that  during  a  significant  insult  such  as  stroke,  there  is  a  wave  of  β-­
adrenergic  signaling  (stress  response)  that  increases  gut  permeability,  allowing  for  the  increased  
translocation  of  bacteria82,83.  Accordingly,  they  partially  prevented  stroke-­induced  bacterial  
translocation  via  pharmacologic  blockade  of  β-­adrenergic  signaling  using  propranolol.  It  is  
interesting  to  consider  the  possibility  that  many  other  pathologies,  especially  acute  injuries,  may  
also  trigger  increased  bacterial  translocation  due  to  a  β-­adrenergic  stress  response.      
If  the  gut  is  an  imperfect  barrier,  what  other  host  mechanisms  exist  to  prevent  bacterial  
infection?  The  intestines  are  drained  by  the  mesenteric  veins,  which  are  tributaries  of  the  portal  
vein  that  feeds  into  the  liver75,84.  Subsequently,  the  liver  sinusoids  in  combination  with  resident  
phagocytic  Kupffer  cells  serve  as  a  major  site  of  bacterial  filtration  from  blood—aptly  described  as  
a  “site  for  vascular  hygiene”75.  The  importance  of  the  gut-­liver  axis  for  vascular  hygiene  is  
exemplified  in  human  diseases  of  the  liver  such  as  cirrhosis  where  bacteremia  and  infections  are  
a  common  finding  and  important  predictors  of  a  poor  prognosis85,86.  While  general  thought  is  that  
the  gut  barrier  and  liver  “firewall”  efficiently  prevent  live  bacteria  from  translocating  into  
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widespread  circulation,  recent  studies  using  heavy-­carbon  labeled  bacteria  (14C  or  13C)  have  
demonstrated  that  there  is  an  extensive  presence  of  bacterial  byproducts  within  virtually  all  host  
tissues  under  homeostatic  conditions84,87.  Whether  this  observation  has  implications  for  host  
physiology  remains  unclear;;  nonetheless,  our  understanding  of  microbiome-­host  interactions  
must  be  revised  to  account  for  this  fundamental  observation.    
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Figure  1.1  
  
Figure  1.1.  Axial  susceptibility-­weighted  MRI  sequence  of  a  familial  CCM  patient  with  advanced  
CCM  disease.  The  dark,  hyperintense  signals  represent  the  hundreds  of  malformations  
throughout  the  brain.  (Adapted  from88)        
Figure  1.2  
	  
Figure  1.2.  Schematic  detailing  the  various  protein  domains  of  KRIT1  (CCM1),  CCM2,  and  
PDCD10  (CCM3).  Reported  binding  partners  are  also  listed.  For  example,  KRIT1  binds  CCM2  
through  an  NPxF—PTB  interaction.  CCM2  binds  to  CCM3  through  a  PTB—FAT-­H  interaction.  
CCM2  binds  MEKK3  through  the  helical  harmonin  domain  (HHD).  (Adapted  from  22)  




Figure  1.3.  Schematic  of  endocardial  CCM  complex  signaling  with  respect  to  MEKK3.  The  CCM  
complex  negatively  regulates  MEKK3  signaling.  Upon  loss  of  the  CCM  complex,  aberrant  over-­
activation  of  MEKK3  leads  to  pathologic  over-­expression  of  downstream  target  genes  KLF2  and  
KLF4.  These  transcription  factors  drive  expression  of  ADAMTS4/5  proteases  that  cleave  
versican,  a  major  component  of  the  cardiac  jelly.
17	  
	  
CHAPTER  2:  Cerebral  cavernous  malformations  arise  from  gain  of  endothelial  MEKK3-­
KLF2/4  signaling  
  




Cerebral  cavernous  malformations  (CCMs)  are  common  inherited  and  sporadic  vascular  
malformations  that  cause  stroke  and  seizures  in  younger  individuals89.    CCMs  arise  from  
endothelial  cell  loss  of  KRIT1,  CCM2,  or  PDCD10,  non-­homologous  proteins  that  form  an  adaptor  
complex90.    How  disruption  of  the  CCM  complex  results  in  disease  remains  controversial,  with  
numerous  signaling  pathways  (including  Rho13,91,  SMAD39  and  Wnt/b-­catenin35)  and  processes  
such  as  endothelial-­mesenchymal  transition  (EndMT)39  proposed  to  play  causal  roles.    CCM2  
binds  MEKK325,26,28,29,92,  and  we  have  recently  demonstrated  that  CCM  complex  regulation  of  
MEKK3  is  essential  during  vertebrate  heart  development27.  Here,  we  investigate  this  mechanism  
in  CCM  disease  pathogenesis.    Using  a  neonatal  mouse  model  of  CCM  disease,  we  find  that  
expression  of  the  MEKK3  target  genes  KLF2  and  KLF4,  as  well  as  Rho  and  ADAMTS  protease  
activity,  are  increased  in  the  endothelial  cells  of  early  CCM  lesions.    In  contrast,  we  find  no  
evidence  of  EndMT  or  increased  SMAD  or  Wnt  signaling  during  early  CCM  formation.    
Endothelial-­specific  loss  of  Mekk3,  Klf2,  or  Klf4  dramatically  prevents  lesion  formation,  reverses  
the  increase  in  Rho  activity,  and  rescues  lethality.    Consistent  with  these  findings  in  mice,  we  
demonstrate  that  endothelial  expression  of  KLF2  and  KLF4  is  elevated  in  human  familial  and  
sporadic  CCM  lesions,  and  that  a  disease-­causing  human  CCM2  mutation  abrogates  MEKK3  
interaction  without  affecting  CCM  complex  formation.  These  studies  identify  gain  of  MEKK3  
signaling  and  KLF2/4  function  as  causal  mechanisms  for  CCM  pathogenesis  that  may  be  
targeted  to  develop  new  CCM  therapeutics.  
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2.2  Nascent  CCMs  exhibit  elevated  Klf2,  Klf4,  and  Adamts4  expression—a  molecular  
signature  consistent  with  gain  of  endothelial  MEKK3  signaling  
  
To  understand  the  cellular  and  molecular  mechanisms  that  underlie  CCM  formation,  we  
first  examined  the  temporal  course  of  lesion  formation  in  mice  with  induced,  endothelial  specific  
deletion  of  Krit1  immediately  after  birth  (iECre;;Krit1fl/fl  termed  “Krit1ECKO  mice”).  Vascular  
malformations  were  first  detected  at  P6  as  dilated  venules  in  the  cerebellar  white  matter  of  
Krit1ECKO  mice,  with  numerous  mature  lesions  present  by  P11  (Fig.  2.1a-­c  and  Fig.  2.6)19.  We  
recently  demonstrated  that  loss  of  KRIT1,  CCM2  or  PDCD10  in  endothelial  cells  of  the  
developing  heart  upregulates  expression  of  KLF2,  KLF4,  ADAMTS4,  and  ADAMTS5  due  to  
increased  activity  of  the  MEKK3  signaling  pathway27.    Analysis  of  isolated  cerebellar  endothelial  
cells  from  neonatal  Krit1ECKO  and  littermate  control  mice  at  P6  revealed  increased  Adamts4  
mRNA  and  protein,  but  not  Adamts5,  in  addition  to  elevated  levels  of  both  Klf2  and  Klf4  (Fig.  
2.1d,  f).    ADAMTS4  cleaves  the  proteoglycan  versican  to  expose  a  neo-­epitope  (DPEAAE)  that  
was  detected  immediately  adjacent  to  the  endothelial  cells  of  both  early  and  late  CCM  lesions  
(Fig.  2.1e).    Elevated  levels  of  nuclear  KLF4  protein  and  Klf2  mRNA  were  also  detected  in  the  
endothelial  cells  of  CCM  lesions  and  other  vessels  in  the  cerebellum  (Fig.  2.1e,  g).    These  
findings  reveal  increased  levels  of  KLF2,  KLF4  and  ADAMTS4  during  the  earliest  phase  of  CCM  
lesion  formation  in  vivo.  
2.3  Nascent  CCMs  exhibit  elevated  Rho-­kinase  signaling,  but  do  not  exhibit  changes  in  
Notch,  TGFβ  or  canonical  Wnt/β-­catenin  signaling  
  
Recent  studies  have  implicated  numerous  signaling  mechanisms  as  causal  for  CCM  
formation,  including  the  Rho13,33,91,  TGF-­β/BMP39,  Wnt/β-­catenin35  and  Notch93  pathways.  To  
determine  if  changes  in  Rho  activity  are  an  early  event  in  CCM  pathogenesis  we  examined  
phospho-­myosin  light  chain  (pMLC),  a  ROCK  substrate.  pMLC  levels  were  markedly  elevated  in  
the  brain  capillary  and  venous  endothelial  cells  of  P6  neonatal  Krit1ECKO  mice  compared  with  
littermate  controls,  including  those  lining  the  earliest  detectable  CCM  lesions  (Fig.  2.2a).    TGF-­
β/BMP  signaling  through  SMAD1  and  SMAD3  and  a  mechanism  of  EndMT  has  been  proposed  to  
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explain  gene  expression  changes  in  KRIT1-­deficient  brain  endothelial  cells,  including  increased  
KLF439,94.      A  recent  study  by  the  same  group  suggested  that  increased  β-­catenin  signaling  is  a  
primary  event  that  culminates  in  later  EndMT35.  To  assess  endothelial  β-­catenin  signaling  during  
CCM  lesion  formation,  we  generated  neonatal  Krit1ECKO  mice  on  a  TCF/Lef:H2B-­GFP  Wnt/β-­
catenin  reporter  background95.      Immunostaining  for  GFP  revealed  β-­catenin  signaling  in  white  
matter  vascular  endothelium  that  was  not  increased  in  P6  CCM  lesions  (Fig.  2.2b),  while  the  
levels  of  both  GFP  protein  and  the  β-­catenin  target  genes  Axin2  and  Lef1  were  unchanged  in  
cerebellar  endothelial  cells  isolated  from  P6  or  P11  neonatal  Krit1ECKO  mice  (Fig.  2.2c,  d).    
Immunostaining  of  brain  sections  and  immunoblotting  of  cerebellar  endothelial  cell  protein  also  
revealed  no  changes  pSMAD3  (Fig  2.2e,  f).  Finally,  analysis  of  cerebellar  endothelial  gene  
expression  analysis  revealed  no  change  in  the  expression  of  Notch  target  genes  at  P6,  although  
an  increase  in  Hes1  was  noted  at  P11  (Fig.  2.7).    These  studies  reveal  that  primary  CCM  lesion  
formation  is  associated  with  increases  in  Klf2,  Klf4  and  Adamts4  expression  and  Rho/ROCK  
activity,  but  not  in  TGF-­β/BMP,  Wnt/β-­catenin,  or  Notch  signaling.  
2.3  Endothelial  haploinsufficiency  of  MEKK3  prevents  CCM  formation,  reverses  
transcriptional  changes  downstream  of  CCM-­complex  deficiency,  and  normalizes  ROCK  
activity  
  
The  above  studies  suggested  that  changes  in  KLF2/4  and  ADAMTS4  expression  may  be  
causal  for  CCM  formation.    The  CCM  complex  directly  binds  MEKK325,26,28,29,92,  a  MAP3  kinase  
known  to  regulate  KLF2  and  KLF4  expression  in  cultured  endothelial  cells27,  and  we  previously  
found  that  Map3k3  haploinsufficiency  rescues  the  loss  of  cardiac  jelly  associated  with  endocardial  
loss  of  CCM  signaling27.    Map3k3  haploinsufficiency  was  also  found  to  rescue  the  early  
embryonic  lethality  conferred  by  pan-­endothelial  loss  of  KRIT1  (Fig.  2.8a  and12),  suggesting  that  
excess  endothelial  MEKK3  signaling  may  play  a  broad  role  in  the  cardiovascular  phenotypes  
associated  with  loss  of  CCM  signaling.  
To  determine  whether  this  paradigm  underlies  CCM  formation,  we  generated  
iECre;;Krit1fl/fl;;Map3k3fl/+  mice  (MEKK3HetRSQ).  Visual  inspection  of  the  hindbrains  of  P11  
	   20	  
MEKK3HetRSQ  mice  compared  with  neonatal  Krit1ECKO  littermate  controls  revealed  a  dramatic  
reduction  in  the  number  and  size  of  vascular  lesions  (Fig.  2.3a).    To  precisely  quantitate  CCM  
formation  we  imaged  P11  hindbrains  using  contrast-­enhanced,  high  resolution  X-­ray  micro  
tomography  (microCT)  and  measured  actual  lesion  volumes  using  semi-­automated  software.    
MEKK3HetRSQ  mouse  hindbrains  exhibited  nearly  complete  prevention  of  the  lesion  phenotype  
compared  with  neonatal  Krit1ECKO  littermates  as  assessed  by  hindbrain  microCT  imaging  (Fig.  
2.3b),  blinded  measurement  of  total  CCM  lesion  volume  (Fig.  2.3c),  and  measurement  of  Klf2,  
Klf4,  and  Adamts4  in  P6  cerebellar  endothelial  cells  (Fig.  2.3d).  While  almost  all  neonatal  
Krit1ECKO  mice  were  dead  by  P30,  all  MEKK3HetRSQ  animals  remained  alive  (Fig.  2.3e),  and  
exhibited  normal  growth  and  development.    Finally,  partial  loss  of  MEKK3  also  fully  rescued  CCM  
lesion  formation  in  Ccm2ECKO  mice  (Fig.  2.8b).    These  genetic  findings  support  the  conclusion  that  
CCM  lesions  arise  from  gain  of  MEKK3  signaling  and  altered  downstream  gene  expression  in  the  
endothelium.    
Elevated  endothelial  pMLC  is  coincident  with  increased  Klf2,  Klf4  and  Adamts4  
expression  in  the  earliest  CCM  lesions  (Figs.  2.1e,  g  and  2.2a),  suggesting  either  that  changes  in  
Rho/ROCK  activity  are  downstream  of  changes  in  MEKK3  activity  or  vice  versa.  The  Rho  
inhibiting  agents  hydroxyfasudil,  Tempol  and  vitamin  D396  failed  to  reverse  the  increase  in  KLF2  
and  KLF4  expression  conferred  by  loss  of  KRIT1  in  cultured  endothelial  cells  (Fig.  2.3f),  
suggesting  that  Rho  is  not  upstream  of  the  KLF2/4  expression  changes  associated  with  loss  of  
CCM  function.    In  contrast,  P6  MEKK3HetRSQ  mice  exhibited  a  complete  normalization  of  
endothelial  pMLC  staining  (Fig.  2.3g),  indicating  that  elevated  Rho  activity  arises  secondary  to  
increased  MEKK3  signaling  during  CCM  formation.  
2.4  Endothelial  deletion  of  Klf2  or  Klf4  prevents  CCM  formation  
  
To  test  the  roles  of  KLF2  and  KLF4  in  CCM  pathogenesis,  we  measured  lesion  formation  
in  Klf2HetRSQ  mice  (iECre;;Krit1fl/fl;;Klf2fl/+),  Klf2HomoRSQ  mice  (iECre;;Krit1fl/fl;;Klf2fl/fl),  and  Klf4HetRSQ  mice  
(iECre;;Krit1fl/fl;;Klf4fl/+)  compared  with  littermate  neonatal  Krit1ECKO  controls  at  P11.  Klf2HetRSQ  and  
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Klf4HetRSQ  mice  exhibited  a  marked  but  incomplete  prevention  of  lesion  formation  (75%  and  80%  
rescue  for  Klf2HetRSQ  and  Klf4HetRSQ  mice,  respectively)  based  on  visual  inspection  of  cerebellar  
lesions  and  quantitation  of  CCM  lesion  volume  following  microCT  imaging  (Fig.  2.4a-­d).  
Remarkably,  Klf2HomoRSQ  mice  exhibited  99%  rescue  (Fig.  2.4a  and  c),  with  only  a  small  amount  of  
venule  dilatation  visible  histologically  (Fig.  2.9).    pMLC  staining  was  normalized  in  P6  Klf2HetRSQ  
mice  (Fig.  2.4e),  indicating  that  elevated  Rho/ROCK  activity  arises  secondary  to  increased  KLF2  
expression.    These  findings  identify  gain  of  KLF2  and  KLF4  as  causal  for  CCM  formation,  and  
suggest  that  these  transcription  factors  are  the  primary  downstream  targets  of  MEKK3  in  this  
disease  model.    They  also  highlight  the  remarkable  molecular  conservation  of  this  endothelial  
pathway:  from  zebrafish  to  mammals,  and  embryonic  vascular  endothelium  and  endocardium  to  
postnatal  brain  endothelium.  
2.5  Human  CCM  lesional  endothelium  exhibit  increased  KLF2  and  KLF4  expression  and  
specific  disruption  of  the  CCM2-­MEKK3  interaction  is  sufficient  to  cause  disease  in  
humans.  
  
To  determine  if  MEKK3-­KLF2/4  signaling  is  increased  in  human  CCMs  we  examined  
resected  lesions  from  two  familial  CCM  patients  bearing  KRIT1  and  PDCD10  germline  mutations,  
and  two  sporadic  CCM  patients  lacking  any  prior  genetic  or  molecular  data.  Markedly  increased  
nuclear  KLF2  and  KLF4  was  observed  in  the  endothelial  cells  of  both  familial  and  sporadic  human  
CCM  lesions  (Fig.  2.5a,  b),  findings  consistent  with  increased  MEKK3  signaling  and  studies  
performed  using  the  mouse  model.    MEKK3  binds  CCM2  through  the  C-­terminal  helical  harmonin  
(HH)  domain  of  CCM2,  and  CCM2  truncation  mutants  lacking  this  domain  do  not  bind  MEKK3  
(Fig.  2.10a-­b  and21,23,28,29).    A  literature  search  identified  a  familial  CCM  patient  with  a  four-­
nucleotide  duplication  in  the  last  exon  of  CCM2  (CCCTdup)  predicted  to  delete  most  of  the  HH  
domain  (Fig.  2.5c)97.  CCM2  CCCTdup  expressed  normally  in  HEK293T  cells  and  bound  KRIT1  
and  PDCD10  in  a  manner  indistinguishable  from  wild-­type  CCM2,  but  failed  to  interact  with  
MEKK3  (Fig.  2.5c-­e  and  2.10c).    These  results  suggest  that  specific  disruption  of  the  CCM2-­
MEKK3  interaction  is  sufficient  to  cause  familial  CCM  disease,  and  that  human  CCMs  also  arise  
due  to  loss  of  MEKK3  regulation  and  increased  expression  of  KLF2  and  KLF4.    
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2.6  Discussion  
  
How  does  gain  of  MEKK3-­KLF2/4  signaling  confer  CCM  formation?  It  has  been  proposed  
that  EndMT  underlies  CCM  pathogenesis35,39,98,  but  we  detect  no  evidence  of  a  change  in  
phenotype  from  endothelial  to  mesenchymal  with  loss  of  CCM  signaling  and  demonstrate  that  
loss  of  the  non-­mesenchymal  transcription  factor  KLF2  is  sufficient  to  fully  rescue  CCM  formation.    
Our  studies  identify  two  effector  pathways  downstream  of  MEKK3-­KLF2/4  signaling  that  may  
drive  early  CCM  pathogenesis,  Rho  signaling  and  ADAMTS  proteolytic  activity.  Elevated  Rho  
activity  has  been  linked  to  increased  stress  fiber  formation,  loosened  junctions  and  decreased  
tube  formation  in  cultured  endothelial  cells13,33,99  and  loss  of  vascular  integrity  in  mice15,91,  but  
whether  and  how  these  changes  might  cause  CCM  formation  is  not  yet  clear.    Increased  
ADAMTS  activity  may  confer  CCM  formation  through  breakdown  of  a  proteoglycan  matrix  that  is  
required  specifically  for  the  CNS  vasculature.  A  proteolytic  mechanism  would  also  explain  the  
autosomal  dominant  inheritance  of  this  disease,  as  CCM-­deficient  endothelial  cells  generated  by  
a  rare  second-­hit  mechanism10,100  could  degrade  the  matrix  supporting  an  entire  vessel,  thereby  
creating  a  cavernous  malformation.    
Finally,  these  studies  may  help  identify  new  therapies  for  CCM  disease.  Since  MEKK3  
up-­regulates  KLF2  and  KLF4  through  the  MEK5  and  ERK5  downstream  MAPKs27,101,  we  
evaluated  the  effects  of  available  inhibitors  on  CCM  formation.    BIX02189  (anti-­MEK5)  and  
XMD17-­109  (anti-­ERK5)  reversed  the  increase  in  KLF2  and  KLF4  expression  associated  with  
loss  of  CCM  signaling  in  cultured  endothelial  cells  (Fig.  2.11  and  Fig.  2.12),  but  failed  to  affect  
CCM  formation  at  the  low  doses  tolerated  by  neonatal  Krit1ECKO  mice  (not  shown).    Therapies  
targeting  Rho  (e.g.  Fasudil38  or  other  recently  identified  agents96)  or  the  ADAMTS  proteases  may  
prove  more  effective,  but  future  studies  that  rigorously  test  the  causal  role  of  these  putative  
downstream  effectors  remain  essential  for  the  rational  development  of  drugs  to  treat  CCM  
disease.    
2.7  Materials  and  Methods  
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Mice  
VECadCreERT2    (“iECre”)  transgenic  mice  were  a  gift  from  Ralf  Adams102.  Tie2Cre,  Krit1fl/fl,  
Ccm2fl/fl,  Map3k3fl/fl,  Klf2fl/fl  and  Klf4fl/fl  animals  have  been  previously  described15,18,27,103-­105.  The  
TCF/LEF:H2B-­GFP  reporter  line  was  obtained  from  Jackson  Laboratories  (#013752)95.  All  
intercrossed  animals  were  maintained  on  mixed  strain  backgrounds.  Breeding  pairs  between  two  
and  eight  months  of  age  were  used  to  generate  the  neonatal  CCM  mouse  model  pups.  The  
University  of  Pennsylvania  Institutional  Animal  Care  and  Use  Committee  approved  all  animal  
protocols,  and  all  procedures  were  performed  in  accordance  with  these  protocols.    
Induction  of  the  neonatal  CCM  mouse  model  
Pups  were  intragastrically  injected  with  25  µg  of  4-­hydroxytamoxifen  (Sigma  Aldrich,  
H7904)  at  intervals  of  1  day,  3  days,  and  5  days  after  birth.  The  4-­hydroxytamoxifen  was  
dissolved  in  warm  10%  Ethanol/Corn  oil  vehicle  and  50  µL  total  volume  was  used  per  injection  
and  delivered  with  a  30-­gauge  needle.  Importantly,  pups  were  injected  in  blinded  fashion  without  
knowledge  of  genotypes,  and  there  were  no  phenotypic  indications  within  the  first  five  days  post-­
birth.  Pups  were  harvested  at  specified  timepoints  6  days  or  11  days  after  birth.  
Mouse  embryos  for  branchial  arch  artery  rescue  
Embryos  were  harvested  at  E10.5,  gross  images  taken,  and  placed  in  4%  
paraformaldehyde  overnight.  Samples  were  processed  for  histology  as  detailed  below.  
Histology  
Embryos  or  mouse  brains  were  fixed  in  4%  formaldehyde  overnight,  dehydrated  in  100%  
ethanol,  and  embedded  in  paraffin.  8  µm  thick  sections  were  used  for  H&E  and  
immunohistochemistry  staining.    Klf2  in  situ  hybridization  was  performed  as  previously  
reported103.  The  following  antibodies  were  used  for  immunostaining:  rat  anti-­PECAM  (1:500,  R&D  
MAB3628),  rat  anti-­PECAM  (1:20,  Histo  Bio  Tech  DIA-­310),  rabbit  anti-­versican  (1:200,  Millipore  
AB1033),  rabbit  anti-­DPEAAE  (1:200,  Pierce-­Antibodies  PA1-­1748A),  mouse  anti-­KLF4  (1:100,  
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R&D  AF3158),  rabbit  anti-­pSmad3  (1:25,  Abcam  ab52903),  rabbit  anti-­pMLC2  (1:200,  Cell  
Signaling  3674S).  
Isolation  of  cerebellar  endothelial  cells  
Cerebellar  endothelial  cells  were  isolated  through  enzymatic  digestion  followed  by  
separation  using  magnetic-­activated  cell  sorting  (MACS  MS  system,  Miltenyi  Biotec).  Mice  were  
first  anesthetized  with  Avertin  (Sigma  Aldrich,  T48402)  and  perfused  with  sterile  phosphate  
buffered  saline  (PBS).  Cerebella  of  the  mice  were  then  digested  by  1  mg/ml  collagenase/dispase  
(Sigma)  and  0.02  mg/ml  DNase  I  (Sigma)  in  complete  DMEM  for  10  min  at  37  °C  with  gentle  
shaking.  The  digestion  was  then  passed  through  a  70  µm  cell  strainer  (BD  Biosciences).  Cells  
were  centrifuged,  resuspended,  and  incubated  with  anti-­mouse  CD31  antibody  conjugated  
microbeads  for  15  min  at  4  °C.  Microbead-­bound  cells  were  then  washed  and  separated  using  
MACS  MS  columns  according  to  vendor  protocol.  Cells  bound  to  the  magnetic  column  were  
eluted  and  centrifuged  for  downstream  applications,  including  western  blotting  and  qPCR  
analysis.    
Western  blotting  of  protein  from  isolated  endothelial  cells  
Protein  of  freshly  isolated  cerebellar  endothelial  cells  was  purified  using  RIPA  buffer  with  
complete  protease  inhibitor  cocktail  (Roche)  and  PhosSTOP  phosphatase  inhibitor  cocktail  
(Roche).  The  following  antibodies  were  used  for  immunoblotting:  rabbit  anti-­GAPDH  (1:5000,  Cell  
Signaling  2118),  rabbit  anti-­ADAMTS4  (1:1000,  Abcam  ab28285),  rabbit  anti-­SMAD3  (1:1000,  
Cell  Signaling  9513),  rabbit  anti-­pSMAD3  (1:1000,  Cell  Signaling  C25A9),  rabbit  anti-­GFP  
(1:1000,  Abcam  ab290).  
Gene  expression  analysis  
Total  RNA  of  isolated  endothelial  cells  was  isolated  with  that  RNeasy  micro  kit  (Qiagen).  
For  qPCR  analysis,  cDNA  was  synthesized  from  150  ng  total  RNA  using  the  Superscript  III  
Reverse  Transcriptase  (Invitrogen).  Real-­time  PCR  was  performed  with  Power  SYBR  Green  PCR  
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Master  Mix  (Applied  Biosciences)  using  the  primers  listed:  
mGapdh  Forward  -­  5’-­  AAATGGTGAAGGTCGGTGTGAACG  -­3’  
mGapdh  Reverse  -­  5’-­  ATCTCCACTTTGCCACTGC  -­3’  
mKlf2  Forward  -­  5’-­  CGCCTCGGGTTCATTTC  -­3’  
mKlf2  Reverse  -­  5’-­  AGCCTATCTTGCCGTCCTTT  -­3’  
mKlf4  Forward  -­  5’-­  GTGCCCCGACTAACCGTTG  -­3’  
mKlf4  Reverse  -­  5’-­  GTCGTTGAACTCCTCGGTCT  -­3’  
mAdamts1  Forward  -­  5’-­  CTCTCACCCTTCGGAATTTCTG  -­3’  
mAdamts1  Reverse  -­  5’-­  GGAGCCACATAAATCCTGTCTG  -­3’  
mAdamts4  Forward  -­  5’-­  CAGTGCCCGATTCATCACT  -­3’  
mAdamts4  Reverse  -­  5’-­  GAGTCAGGACCGAAGGTCAG  -­3’  
mAdamts5  Forward  -­  5’-­  CGACCCTCAAGAACTTTTGC  -­3’  
mAdamts5  Reverse  -­  5’-­  CGTCATGAGAAAGGCCAAGT  -­3’  
mAdamts9  Forward  -­  5’-­  TTGGGACCTGCTCAAGAACG  -­3’  
mAdamts9  Reverse  -­  5’-­  ACCATTGATGTTGAAGTGTTTGC  -­3’  
mAxin2  Forward  -­  5’-­  CAGCCCTTGTGGTTCAAGCT  -­3’  
mAxin2  Reverse  -­  5’-­  GGTAGATTCCTGATGGCCGATGT  -­3’  
mLef1  Forward  -­  5’-­  TAACGAGTCCGAAATCATCCCAGC  -­3’  
mLef1  Reverse  -­  5’-­  TTCATCAGGGTGTTCTCTGGCCTT  -­3’  
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mHes1  Forward  -­  5’-­  AAAGCCTATCATGGAGAAGAGGCG  -­3’  
mHes1  Reverse  -­  5’-­  GGAATGCCGGGAGCTATCTTTCTT  -­3’  
mHey1  Forward  -­  5’-­  GCGCGGACGAGAATGGAAA  -­3’  
mHey1  Reverse  -­  5’-­  TCAGGTGATCCACAGTCATGTG  -­3’  
mHey2  Forward  -­  5’-­  AAGCGCCCTTGTGAGGAAAC  -­3’  
mHey2  Reverse  -­  5’-­  GGTAGTTGTCGGTGAATTGGAC  -­3’  
X-­ray  micro  tomography-­based  quantification  of  neonatal,  cerebellar  lesions  
11-­day-­old  pups  were  anesthetized  with  Avertin  and  underwent  intra-­cardiac  perfusion  
with  PBS  and  2%  paraformaldehyde.  Brains  were  quickly  dissected  and  fixed  overnight  in  a  2.5%  
glutaraldehyde,  4%  formaldehyde  0.1  M  sodium  phosphate  buffer.  Then,  brains  were  rinsed  
several  times  with  0.1  M  sodium  phosphate  buffer  and  hindbrains  were  detached  from  
mid/forebrain  structures  by  severing  the  pons.  Next,  hindbrains  were  soaked  overnight  in  2%  
osmium  tetroxide  solution  (tissue  contrast  agent)  and  washed  several  times  with  water.  
Hindbrains  were  randomized  and  scanned  by  a  blinded  operator  using  Xradia  MicroCT  system  
(Xradia  MicroXCT-­400,  Xradia,  CA,  USA).  Images  were  acquired  at  50  kV,  10W,  721  projections,  
3s  integration  per  180˚  rotation.      
Raw  image  stacks  from  each  scanned  hindbrain  were  analyzed  using  Aviso  3D  image  
processing  software  (Lite  edition,  FEI  Visualization  Sciences  Group).  Each  image  stack  was  
imported,  and  lesions  were  labeled  in  semi-­automated,  blinded  fashion  using  a  region-­growing  
segmentation  algorithm  included  with  the  software.  Labeled  lesions  could  then  be  analyzed  for  
pixel  volume  and  converted  to  cubic  µm.    Importantly,  to  prevent  measurement  bias,  a  single  
individual,  without  direct  experimental  involvement  or  knowledge  of  genotypes,  was  used  to  label  
lesions  of  randomly  ordered  brains.  This  individual  was  trained  prior  to  beginning  analysis  of  the  
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hindbrains.  New-­user  accuracy  was  confirmed  by  comparison  of  results  from  a  test  brain  analysis  
with  the  results  from  an  experienced  user.      
Post-­lesion  labeling,  the  hindbrain  image  stack  was  volume  rendered  and  over-­laced  with  
the  labeled  lesions  in  the  Avizo  3D  environment.  Orientation,  projection  depth,  and  
shadow/lighting  effects  of  each  volume  render  were  adjusted  for  publication  quality  images.  
Importantly,  these  changes  were  made  post-­lesion  labeling,  and  did  not  affect  lesion  detection  or  
their  visual  presentation.  
We  blinded  samples  at  three  distinct  points  in  the  analysis.    First,  neonatal  CCM  model  
pups  were  injected  with  4-­hydroxytamoxifen  without  knowledge  of  genotypes.  Second,  hindbrains  
from  genotyped  animals  were  given  randomized  labels  to  provide  for  blinded  microCT  scanning  
by  an  independent  operator.    Third,  randomized  microCT  image  stacks  were  analyzed  in  a  
blinded  manner  by  a  single  operator  not  involved  in  any  prior  experimental  steps.  
cDNA  constructs  and  transient  expression  in  HEK293T  cells    
The  human  KRIT1-­FLAG  expression  plasmid  was  a  gift  from  Douglas  Marchuk25.  Human  
CCM2-­FLAG,  PDCD10-­FLAG,  and  MEKK3-­FLAG  expression  plasmids  were  purchased  from  
Origene  (RC201418,  RC200235,  and  RC210317).  Further  epitope  tag  modifications  and  CCM2  
truncations  were  generated  through  PCR  and  conventional  cloning  methods.  The  CCM2  
CCCTdup  mutant  was  generated  by  site  directed  mutagenesis  to  generate  the  exact  four-­
nucleotide  duplication  (Agilent  200521).  1  µg  of  each  construct  was  transfected  in  HEK293T  cells  
using  Fugene  6  (Promega  E2691)  and  cells  were  harvested  48  hours  later  with  gentle  lysis  buffer  
(Life  Tech  87787)  supplemented  with  protease  and  phosphatase  inhibitors  (Roche  11873580001  
and  04906845001).    
Co-­immunoprecipitation  (co-­IP)  and  western  blotting  
Anti-­HA  antibody  (5  µg  per  co-­IP,  Sigma  H3663)  conjugated  to  Protein  G  Dynabeads  (50  
µL  per  co-­IP,  Life  Technologies  10003D)  was  used  for  all  experiments.  250  µg  of  protein  from  
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HEK293T  cells  (obtained  directly  from  the  ATCC)  was  used  for  each  co-­IP  with  an  incubation  
period  of  30  minutes  at  room  temperature.  Anti-­FLAG  (1:5000  Santa  Cruz  sc-­807)  and  anti-­HA  
(1:5000  Santa  Cruz  sc-­805)  antibodies  were  used  for  western  blotting  and  re-­probed  with  anti-­
GAPDH  antibody  (1:10,000  Cell  Signaling  2118).  For  co-­IP  blots  of  PDCD10-­FLAG,  HRP-­
conjugated  anti-­FLAG  antibody  (1:2000,  Sigma  A8592)  was  used  to  avoid  antibody  light  chain  
detection.  
Expression  of  tetracycline-­inducible  CCM2  CCCTdup  lentivirus  in  cultured  endothelial  cells  
N-­terminal,  HA-­epitope  tagged,  human  CCM2  CCCTdup  was  cloned  into  the  pLVX-­
TRE3G  lentiviral  vector  (Takara  Clontech)  and  lentivirus  was  generated  from  co-­transfection  with  
packaging  plasmids  in  HEK293T  cells  as  previously  described27.  HUVECs  were  co-­infected  with  
CCM2  CCCTdup  along  with  Tet-­On  3G  lentiviruses  and  varying  doxycycline  amounts  were  added  
as  previously  described27.  Cells  were  harvested  48  hours  post-­doxycycline  addition.  Collected  
cells  were  pelleted,  resuspended,  then  divided  in  half.  One  half  was  used  for  total  RNA  isolated  
by  TRIzol  (Life  Technologies),  and  the  other  half  was  used  for  protein  extracted  by  gentle  lysis  
buffer  as  described  above.  cDNA  was  generated  from  500  ng  of  total  RNA  using  the  Superscript  
III  Reverse  Transcriptase  (Invitrogen).  mRNA  levels  of  the  CCM2  CCCTdup  lentivirus  were  
assessed  by  qPCR  using  both  N-­terminal  and  C-­terminal  human  CCM2  qPCR  primers  as  follows:  
hCCM2  n-­term  Forward:  5’-­CATACCAGGATACCTGAATCCCT-­3’  
hCCM2  n-­term  Reverse:  5’-­AGCTTGACGTTGTACGCAGAC-­3’  
hCCM2  c-­term  Forward:  5’-­GCCTCTATCCACGAGTTCTGCA-­3’  
hCCM2  c-­term  Reverse:  5’-­AAGTGCTGGCTGTCCTTCTCAG-­3’  
Western  blotting  was  performed  as  previously  described  with  75  µg  protein  from  HUVEC  lysate  
for  each  condition.  
siRNA  knockdown  and  adenoviral  overexpression  in  cultured  endothelial  cells  
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siRNA  experiments  in  human  umbilical  vein  endothelial  cells  (HUVECs,  Lonza)  were  
performed  as  previously  described27.  siRNAs  directed  against  KRIT1  (s2510,  Invitrogen),  KLF2  
(s20270,  Invitrogen),  KLF4  (s17793,  Invitrogen),  STK24  (s15993,  Invitrogen)  or  STK25  (s20570,  
Invitrogen)  were  used  for  the  knockdown  experiments.  For  overexpression  studies,  human  
microvascular  endothelial  cells  (HMVECs,  Lonza)  were  infected  with  adenovirus  encoding  either  
mouse  KLF2  (Penn  Vector  Core),  human  KLF4  (Vector  BioLabs),  or  a  LacZ  control  (Penn  Vector  
Core).  Cells  were  harvested  48  hours  post-­infection  and  total  RNA  was  isolated  using  TRIzol  
Reagent  (Life  Technologies).  cDNA  was  generated  from  1  μg  total  RNA  using  SuperScript  First-­
strand  Synthesis  System  (Invitrogen)  and  real  time  qPCR  was  performed  using  Power  SYBR  
Green  PCR  Master  Mix  (Applied  Biosciences).    
Primers  for  qPCR:  
hKLF2  Forward:  5’-­CTACACCAAGAGTTCGCATCTG-­3’  
hKLF2  Reverse:  5’-­CCGTGTGCTTTCGGTAGTG-­3’  
hKLF4  Forward  -­  5’-­  AGAGTTCCCATCTCAAGGCA  -­3’  
hKLF4  Reverse  -­  5’-­  GTCAGTTCATCTGAGCGGG  -­3’  
hADAMTS4  Forward  -­  5’-­  CTGACTTCCTGGACAATGGC  -­3’  
hADAMTS4  Reverse  -­  5’-­  GCGGTCAGCATCATAGTCCT  -­3’  
Drug  treatments  in  cultured  endothelial  cells  with  loss  of  KRIT1    
After  siRNA  knockdown  of  KRIT1,  HUVECs  were  treated  with  BIX02189  (10  uM),  
XMD17-­109  (1  uM),  Hydroxyfasudil  (10  uM),  Tempol  (10  uM)  or  Vit  D3  (10  uM)  for  24  hours  prior  
to  harvest.    
KLF2  and  KLF4  immunostaining  in  human  CCM  lesions  and  control  brain  sections  
Sections  of  human  samples  were  obtained  from  CCM  lesions  resected  at  University  of  
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Chicago  using  IRB  approved  protocols.    Control  samples  were  obtained  from  two  autopsy  
subjects.    Rabbit  anti-­KLF2  (1:200  Abcam  ab203591),  rabbit  anti-­KLF4  (1:50  Cell  Signaling  
4038S)  and  mouse  anti-­PECAM-­1  (1:1000  Cell  Signaling  3528S)  were  used  for  immunostaining.  
Patient  information  pertaining  to  the  human  CCM  samples  studied  is  summarized  below.  
KRIT1  Familial:  female,  age  11,  with  the  CCM1  Common  Hispanic  Mutation,  removed  due  to  
CCM  hemorrhage.  
PDCD10  Familial:  female,  age  19,  PDCD10  474+5G>A  mutation,  removed  due  to  CCM  
hemorrhage.  
Sporadic  1:  female,  age  24,  solitary  sporadic  lesion,  removed  due  to  headaches  and  lesion  
growth.  
Sporadic  2:  male,  age  31,  solitary  sporadic  lesion,  removed  due  to  seizures.  
Statistics  
Sample  sizes  were  estimated  based  on  our  preliminary  findings  for  rescue  of  the  CCM  
phenotype.    These  were  estimated  from  visual  analysis  of  the  hindbrains  of  P11  animals  from  
which  lesion  numbers  and  sizes  can  be  directly  assessed,  an  observation  corroborated  by  
microCT-­based  volume  rendering  of  lesions.      These  preliminary  assessments  suggested  that  
there  were  very  large  differences  between  genetic  rescue  and  non-­rescue  samples  
(conservatively  eighty  percent  rescue)  that  would  allow  statistical  interpretation  with  relatively  
small  Ns.    All  experimentals  and  controls  were  littermates,  and  none  were  excluded  from  
analysis.  P  values  were  calculated  using  an  unpaired  2-­tailed  Student’s  t-­test,  ANOVA,  or  Chi  
Square  analysis  as  indicated.    The  mean  and  standard  error  of  mean  (SEM)  are  shown  in  the  bar  
graphs.  
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Figure  2.1.    KLF2,  KLF4  and  ADAMTS4  are  increased  in  the  earliest  CCM  lesions.  a-­b,  Early  
CCM  lesions  (arrow)  appear  as  hemorrhagic,  dilated  venules  in  the  white  matter  of  the  
cerebellum.  White  bars,  1mm;;  black  bars,  50  µm.    c,  Mature  CCM  lesions  are  detected  as  blood-­
filled  caverns  in  the  hindbrain  of  P11  Krit1ECKO  animals.  White  bars,  1mm;;  black  bars,  500  µm.    d,  
qPCR  analysis  reveals  increased  Klf2,  Klf4  and  Adamts4  expression  in  hindbrain  endothelial  
cells.  ***  P<0.001;;  **  P<0.01.    N=4.  Error  bars  indicate  SEM.    e,  ADAMTS-­cleaved  versican  
(DPEAAE)  and  KLF4  are  detected  in  nascent  (P6)  and  mature  (P11)  CCM  lesions  (arrows).    
Scale  bars,  50  µm.    f,  Elevated  levels  of  ADAMTS4  detected  by  immunoblotting  of  P11  Krit1ECKO  
hindbrain  lysate.  Results  are  representative  of  3  separate  experiments.  g,  Increased  Klf2  
expression  in  CCM  lesions  (arrows)  and  meningeal  vessels  of  Krit1ECKO  animals  detected  using  in  
situ  hybridization.  Scale  bars,  500  µm  (left)  and  100  µm  (right).  WM,  white  matter;;  GL,  granular  
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Figure  2.2  
  
Figure  2.  Endothelial  Rho  activity,  but  not  β-­catenin  or  SMAD3  signaling,  is  increased  
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during  CCM  formation.  a,  Immunostaining  for  the  endothelial  marker  PECAM  and  pMLC  in  the  
white  matter  (“WM”)  of  the  cerebellum  of  P6  control  and  Krit1ECKO  littermates  is  shown.  Scale  
bars,  50  µm.  b,  Anti-­GFP  immunostaining  to  detect  TCF/Lef:H2B-­GFP  Wnt/β-­catenin  reporter  
(“WntREP”)  activity.  Scale  bars,  50  µm.  c,  Immunoblotting  of  P6  brain  endothelial  cell  lysate  for  
GFP.    Results  are  representative  of  3  separate  experiments.  d,  qPCR  analysis  of  b-­catenin  target  
genes  in  hindbrain  endothelial  cells.  N=4-­5;;  P>0.05  for  comparison  of  all  values.  Error  bars  
indicate  SEM.  e,  Immunostaining  for  phospho-­SMAD3  (“pSMAD3”)  and  PECAM.  Scale  bars,  50  
µm.  f,  Total  SMAD3  and  pSMAD3  were  detected  by  immunoblotting  cerebellar  endothelial  cell  
lysate.  Results  are  representative  of  3  separate  experiments.    
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Figure  3.    Genetic  rescue  of  CCM  formation  and  increased  Rho  activity  with  loss  of  
MEKK3.    a,  Visual  detection  of  CCM  lesions  in  the  hindbrains  of  P11  Krit1fl/fl  animals  (top  left),  
Krit1ECKO  animals  (bottom  left),  and  MEKK3HetRSQ  animals  (right).    Scale  bars  indicate  1mm.    b,  
Composite  microCT  images  of  Krit1ECKO  and  MEKK3HetRSQ  hindbrains.  CCM  lesions  are  shown  in  
red.  c,  Quantitation  of  CCM  lesion  volumes.  N=5  or  6.    d,  qPCR  analysis  of  gene  expression  in  
cerebellar  endothelial  cells.  N=4.  e,  Postnatal  survival  of  Krit1ECKO  animals  with  and  without  
endothelial  loss  of  one  Map3k3  allele.    P=0.0009.    f,  qPCR  analysis  of  gene  expression  in  human  
umbilical  vein  endothelial  cells  treated  with  scrambled  (“Scr.”)  or  KRIT1  targeting  siRNAs,  alone  
and  in  the  presence  of  the  indicated  Rho  antagonists.  HF,  hydroxyfasudil.  N=3.  g,  Normalization  
of  Rho  activity  with  loss  of  MEKK3.  PECAM  and  pMLC  staining  of  white  matter  vessels  in  the  
indicated  P6  littermate  brains  is  shown.    Images  are  representative  of  5  independent  studies  for  
each  genotype.  Scale  bars,  50  µm.  ****  indicates  P<0.0001;;  ***  indicates  P<0.001;;  **  indicates  
P<0.01;;  *  indicates  P<0.05.  Error  bars  indicate  SEM.  
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Figure  2.4.  Genetic  rescue  of  CCM  formation  and  increased  Rho  activity  with  loss  of  KLF2  
and  KLF4.    a-­b,  Visual  appearance  of  CCM  lesions  in  Krit1ECKO,  Klf2HetRSQ,  Klf2HomoRSQ  and  
Klf4HetRSQ  animals  is  shown  above  and  composite  microCT  images  of  the  same  hindbrains  shown  
below.  Scale  bars,  1mm.  c-­d,  Volumetric  quantitation  of  CCM  lesions  in  Krit1ECKO  littermates  with  
and  without  endothelial  loss  of  one  or  two  Klf2  alleles  (c)  or  one  Klf4  allele  (d).  ***  indicates  
P<0.001;;  **  indicates  P<0.01.  N=5-­7.  e,  Rescue  of  increased  Rho  activity  by  loss  of  KLF2.    
PECAM  and  pMLC  staining  of  white  matter  (“WM”)  vessels  in  the  indicated  P6  littermate  brains  is  
shown.    Images  are  representative  of  4  independent  studies  for  each  genotype.  Scale  bars,  50  
µm.  
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Figure  2.5  
  
Figure  2.5.    Human  CCMs  exhibit  high  levels  of  endothelial  KLF2  and  KLF4  and  arise  due  
to  selective  loss  of  CCM2-­MEKK3  interaction.  a-­b,  Immunostaining  for  PECAM  and  KLF2  (a)  
or  KLF4  (b)  is  shown  for  cerebral  vessels  in  individuals  without  CCM  disease  (“control”,  left),  for  
CCM  lesions  arising  due  to  germline  mutations  in  KRIT1  or  PDCD10  (middle),  and  for  sporadic  
CCM  lesions  from  two  individuals  (right).    Arrows  indicate  nuclear  KLF2-­high  and  nuclear  KLF4-­
high  endothelial  cells  in  the  CCM  lesions.  The  red  asterisk  indicates  fluorescence  due  to  trapped  
intravascular  erythrocytes.  Scale  bars,  50  µm.  c,  Schematic  representation  of  the  CCM2  CCCT  
duplication  (“CCM2  CCCTdup”).    d,  CCM2  CCCTdup  does  not  bind  MEKK3.    The  indicated  
proteins  were  expressed  in  HEK293T  cells,  immunoprecipitated  using  anti-­HA  antibodies,  and  
immunoblotted  using  the  indicated  antibodies.    e,  CCM2  CCCT  dup  binds  KRIT1  and  PDCD10  
like  wild-­type  CCM2.    The  indicated  proteins  were  expressed  and  co-­immunoprecipitated  as  
described  in  (c).    The  results  shown  are  representative  of  at  least  3  separate  experiments.    
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Figure  2.6  
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Figure  2.6.  Histologic  characteristics  of  early  CCM  lesions  and  the  cerebellar  white  matter  
in  which  they  form.    a,  P7  and  P8  CCM  lesions  in  the  Krit1  model.    Hindbrains  from  Krit1ECKO  
mice  were  harvested  at  P7  and  P8  and  sections  stained  with  hematoxylin-­eosin  to  detect  vascular  
malformations.    Images  are  representative  of  4  independent  experiments.  Dotted  lines  indicate  
the  cerebellar  white  matter.    Arrows  indicate  CCM  lesions.  WM,  white  matter;;  GL,  granular  layer.  
b,  Versican  is  abundant  in  the  white  matter  of  the  P7  hindbrain,  the  site  of  primary  CCM  formation  
in  the  neonatal  mouse  model.    H-­E  staining  of  the  hindbrain  at  low  (top  left)  and  high  (bottom  left)  
magnification.    Antibody  staining  reveals  abundant  versican  protein  in  the  white  matter  of  the  
hindbrain  (center),  the  site  at  which  CCM  lesions  specifically  appear  at  this  timepoint  in  the  Krit1  
mouse  model,  and  less  abundant  versican  in  the  cortex.  DPEAAE  staining  reveals  a  pattern  of  
ADAMTS-­mediated  versican  degradation  that  is  the  inverse  of  intact  versican,  i.e.  higher  in  the  
cortex  and  lower  in  the  white  matter  (right).  Results  representative  of  three  independent  
experiments.  Scale  bars:  top,  500  µm;;  bottom,  100  µm.    Boxes  indicate  regions  shown  at  higher  
magnification  below.  Dotted  lines  indicate  the  cerebellar  white  matter.    WM,  white  matter;;  GL,  
granular  layer.  
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Figure  2.7  
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Figure  2.7.      Hes1  expression  rises  after  primary  CCM  lesion  formation  in  Krit1ECKO  
hindbrain  endothelial  cells  and  is  reversed  by  Map3k3  haploinsufficiency.    a,  qPCR  analysis  
of  Notch  target  genes  in  endothelial  cells  freshly  harvested  from  the  hindbrain  of  P6  or  P11  
Krit1ECKO  animals  compared  with  control,  tamoxifen-­treated  littermates.  **  indicates  P<0.01.    N=4.  
Error  bars  indicate  SEM.  b,  qPCR  analysis  of  gene  expression  in  endothelial  cells  freshly  
harvested  from  the  cerebellum  of  P11  Krit1fl/fl  and  Krit1ECKO  animals  with  and  without  endothelial  
loss  of  one  Map3k3  allele.  **  indicates  P<0.01.    N=4.  Error  bars  indicate  SEM.  
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Figure  2.8  
  
Figure  2.8.    Map3k3  haploinsufficiency  rescues  both  early  embryonic  lethality  due  to  
endothelial  loss  of  Krit1  and  postnatal  CCM  lesion  formation  due  to  endothelial  loss  of  
Ccm2.    a,  Partial  loss  of  MEKK3  rescues  early  lethality  associated  with  endothelial  deletion  of  
Krit1.    E10.5  littermate  embryos  are  shown.  Tie2-­Cre;;Krit1fl/fl  animals  lacking  endothelial  KRIT1  
die  by  E9.5  due  to  lack  of  patent  branchial  arch  arteries  (middle).  In  contrast,  Tie2-­
Cre;;Krit1fl/fl;;Map3k3fl/+  animals  develop  patent  arteries  and  survive  past  mid-­gestation  (right).    
Note  the  presence  of  pericardial  edema  due  to  a  persistent  cardiac  defect  in  the  Tie2-­
Cre;;Krit1fl/fl;;Map3k3fl/+  embryo.    Images  are  representative  of  3  independent  experiments.  b,  
Rescue  of  CCM  formation  in  the  Ccm2  model  with  loss  of  MEKK3.    VE-­cadherin  
CreERT2;;Ccm2fl/fl;;  Map3k3+/+  (“Ccm2ECKO”)  and  VE-­cadherin  CreERT2;;Ccm2fl/fl;;  Map3k3fl/+  
neonates  were  induced  with  tamoxifen  at  P1  and  lesion  formation  scored  by  visual  detection  in  
the  hindbrain  at  P11  as  done  for  Krit1ECKO  animals.  Images  are  representative  of  4  independent  
experiments.  
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Figure  2.9  
  
Figure  2.9.    Rescue  of  CCM  formation  in  Krit1ECKO  animals  with  homozygous  loss  of  Klf2.      
H-­E  sections  through  the  hindbrain  of  P11  VE-­cadherin  CreERT2;;Krit1fl/fl;;  Klf2fl/fl  and  control  VE-­
cadherin  CreERT2;;Krit1fl/fl  animals  are  shown.    No  true  CCM  lesions  were  observed  but  venous  
dilatation  was  evident  (arrow).  Images  are  representative  of  3  independent  experiments.  Dotted  
lines  indicate  the  cerebellar  white  matter.    WM,  white  matter;;  GL,  granular  layer.  
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Figure  2.10  
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Figure  2.10.  CCM2  binds  MEKK3  via  its  C-­terminal  helical  harmonin  domain.    a,  MEKK3  
binds  the  C-­terminal  domain  of  CCM2.    A  schematic  of  the  CCM2  protein  domains  is  shown  
above  and  the  series  of  N-­terminal  truncated  CCM2-­HA  proteins  used  to  map  the  CCM2-­MEKK3  
binding  region  shown  below.  MEKK3-­FLAG  and  the  indicated  N-­terminally  truncated  CCM2-­HA  
proteins  were  co-­expressed  in  HEK293T  cells  prior  to  immunoprecipitation  with  anti-­HA  
antibodies  and  immunoblotting  with  anti-­FLAG  antibodies  to  detect  associated  MEKK3  proteins  
(above).    The  immunoprecipitated  HA-­CCM2  was  detected  with  anti-­HA  antibodies  (below).  b,  
MEKK3-­FLAG  and  the  indicated  C-­terminally  truncated  CCM2-­HA  proteins  were  co-­
immunoprecipitated  to  map  the  CCM2-­MEKK3  binding  region.    c,  CCM2  CCCTdup  protein  is  
stably  expressed  in  cultured  endothelial  cells.  CCM2  CCCTdup-­HA  protein  was  expressed  in  
cultured  HUVECs  using  a  tetracycline-­inducible  lentiviral  vector  at  varying  doses  of  doxycycline.    
The  total  (i.e.  endogenous  CCM2  +  viral  CCM2  CCCTdup)  CCM2  mRNA  levels  were  measured  
using  qPCR  (shown  below)  and  CCM2  CCCTdup  protein  detected  using  anti-­HA  immunoblotting  
(shown  above).    GAPDH  immunoblots  are  shown  for  loading  control.    
	   49	  
Figure  2.11  
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Figure  2.11.  The  versican-­degrading  ADAMTS  proteases  are  regulated  by  KLF2  and  KLF4.    
a,  siRNA  knockdown  of  KLF2  or  KLF4  in  cultured  HUVECs  reduces  expression  of  ADAMTS4  
measured  using  qPCR.  b,  Adenoviral  expression  of  KLF2  drives  expression  of  the  versican-­
degrading  proteases  ADAMTS1,  ADAMTS4  and  ADAMTS9  in  addition  to  the  known  KLF2  target  
gene  eNOS.      KLF4  levels  are  reduced  in  KLF2-­overexpressing  HUVECs.    Results  are  shown  
relative  to  expression  following  exposure  to  control  adeno-­LacZ  virus.  c,  Adenoviral  expression  of  
KLF4  drives  expression  of  ADAMTS4  in  addition  to  the  known  KLF2/4  target  gene  eNOS.      KLF2  
levels  are  reduced  in  KLF4-­overexpressing  HUVECs.    Results  are  shown  relative  to  expression  
following  exposure  to  control  adeno-­LacZ  virus.    N=4-­5;;  ***P<0.001;;  **P<0.01;;*P<0.05.  Error  bars  
indicate  SEM.  
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Figure  2.12  
  
Figure  2.12.  The  MEK5  inhibitor  BIX02189  and  the  ERK5  inhibitor  XMD17-­109  reverse  the  
increase  in  KLF2  and  KLF4  expression  conferred  by  loss  of  KRIT1  in  cultured  endothelial  
cells.      HUVECs  were  treated  with  scrambled  (Scr.)  or  KRIT1-­targeted  siRNAs  with  and  without  
BIX02189  (10  µM)  and  XMD17-­109  (1  µM)  for  24  hours  and  the  levels  of  KLF2  and  KLF4  mRNA  
measured  using  qPCR.  ***  indicates  P<0.001;;  **  indicates  P<0.01.  N=3.  Error  bars  indicate  SEM.  
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CHAPTER  3:  Endothelial  TLR4  and  the  gut  microbiome  drive  cerebral  cavernous  
malformations  
  
The  following  text  and  figures  in  this  chapter  have  been  published  in  Nature,  2017.  
Abstract  
  
Cerebral  cavernous  malformations  (CCMs)  are  a  cause  of  stroke  and  seizure  for  which  
no  medical  therapies  exist.    CCMs  arise  from  loss  of  an  adaptor  complex  that  negatively  
regulates  MEKK3-­KLF2/4  signaling  in  brain  endothelial  cells,  but  upstream  activators  of  this  
disease  pathway  remain  unknown.    Here,  we  identify  endothelial  TLR4  and  the  gut  microbiome  
as  critical  stimulants  of  CCM  formation.    Activation  of  TLR4  by  gram  negative  bacteria  or  
lipopolysaccharide  accelerates  CCM  formation,  while  genetic  or  pharmacologic  blockade  of  TLR4  
signaling  prevents  CCM  formation  in  mice.    Polymorphisms  that  increase  expression  of  TLR4  or  
its  co-­receptor  CD14  are  associated  with  higher  CCM  lesion  burden  in  humans.  Germ-­free  mice  
are  protected  from  CCM  formation,  and  a  single  course  of  antibiotics  permanently  alters  CCM  
susceptibility  in  mice.  These  studies  identify  unexpected  roles  for  the  microbiome  and  innate  
immune  signaling  in  the  pathogenesis  of  a  cerebrovascular  disease,  as  well  as  novel  strategies  
for  its  treatment.    
3.1  Introduction  
  
Cerebral  cavernous  malformations  (CCMs)  are  relatively  common  vascular  
malformations  that  arise  predominantly  in  the  central  nervous  system,  causing  hemorrhagic  
stroke  and  seizure106.  CCMs  arise  from  loss  of  function  mutations  in  three  genes,  KRIT1,  CCM2,  
and  PDCD10,  that  encode  components  of  a  heterotrimeric,  intracellular  adaptor  protein  complex  
(the  “CCM  complex”)22,90.    The  clinical  course  of  familial  CCM  disease  is  highly  variable,  even  
among  individuals  who  share  identical  germline  mutations2,11,107,  suggesting  the  existence  of  
powerful  genetic  and/or  environmental  disease  modifiers.    Present  treatment  for  CCMs  consists  
solely  of  palliative  therapies  or  neurosurgical  resection.  
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Recent  studies  of  vertebrate  genetic  models  and  human  CCM  lesions  have  demonstrated  
that  loss  of  the  CCM  complex  results  in  vascular  lesion  formation  due  to  increased  MEKK3-­
KLF2/4  signaling  in  brain  endothelial  cells92,94,108,109,  and  that  the  CCM  complex  suppresses  
MEKK3-­KLF2/4  signaling  through  a  direct  interaction  between  CCM2  and  MEKK328,29.      Since  
effective  drugs  targeting  the  MEKK3-­KLF2/4  pathway  do  not  exist,  these  molecular  insights  have  
not  had  an  immediate  translational  impact.  However,  they  raise  a  key  mechanistic  question:  if  the  
role  of  the  CCM  complex  is  to  negatively  regulate  MEKK3-­KLF2/4  signaling,  what  activates  this  
pathway  in  brain  endothelial  cells?    Identification  of  upstream  activators  of  this  pathway  is  needed  
to  understand  the  pathogenesis  of  CCM  disease  and  reveal  viable  therapeutic  strategies.  
3.2  CCM  formation  is  driven  by  gram-­negative  bacteria  and  lipopolysaccharide    
  
   To  investigate  CCM  formation  in  mice,  we  generated  animals  in  which  endothelial  
specific  deletion  of  Krit1  or  Ccm2  was  induced  one  day  after  birth  (P1,  iECre;;Krit1fl/fl  &  
iECre;;Ccm2fl/fl).  In  this  model,  vascular  malformations  first  appear  in  the  cerebellar  white  matter  at  
P6,  with  numerous  mature  lesions  present  by  P10108,110.  These  mice  were  maintained  as  inbred  
breeding  colonies  and  initially  demonstrated  a  highly  penetrant  lesion  phenotype  (termed  
“susceptible”,  Fig.  3.1a  top).  However,  following  a  change  in  vivarium  at  the  University  of  
Pennsylvania,  we  noted  the  spontaneous  emergence  of  iECre;;Krit1fl/fl  &  iECre;;Ccm2fl/fl  sub-­
colonies  that  developed  barely  visible  hindbrain  lesions  at  P17  (termed  “resistant”,  Fig.  3.1a  
bottom).  Previous  studies  have  demonstrated  high  CCM  penetrance  on  a  C57BL/6J  
background110,  but  iECre;;Ccm2fl/fl  animals  back-­crossed  seven  generations  to  C57BL/6J  
remained  resistant  to  CCM  formation  (Fig.  3.7a).    Significantly,  among  a  large  population  of  CCM-­
resistant  animals,  we  detected  a  small  number  of  individual  pups  that  exhibited  robust  CCM  
formation  in  association  with  the  presence  of  intra-­abdominal,  gram  negative  bacterial  (GNB)  
abscesses  that  likely  developed  following  tamoxifen  injection  (Fig.  3.1b,  c  and  Fig.  3.7b).    This  
observation  suggested  that  gram  negative  infection  accelerates  CCM  pathogenesis.  
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   To  directly  test  the  role  of  gram  negative  infection,  gram  negative  abscesses  were  
induced  in  resistant  iECre;;Ccm2fl/fl  mice  at  P5  by  intra-­peritoneal  injection  of  live  Bacteroides  
fragilis  (B.  frag).    Following  B.  frag  injection,  9/16  resistant  iECre;;Ccm2fl/fl  animals  developed  large  
CCM  lesions  (termed  “Responders”,  Fig.  3.1d,  left),  but  7/16  animals  did  not  (termed  “Non-­
responders”,  Fig.  3.1d,  right).    Responders  to  B.  frag  injection  exhibited  splenic  abscesses  and  
higher  spleen  weights  compared  with  non-­responders  (Fig.  3.1e,  f),  suggesting  that  
hematogenous  spread  of  GNB  from  the  site  of  abscess  was  required  to  stimulate  CCM  formation  
in  resistant  iECre;;Ccm2fl/fl  animals.    Since  GNB  stimulate  mammalian  cellular  responses  in  large  
part  through  cell  membrane-­derived  lipopolysaccharide  (LPS),  we  tested  the  sufficiency  of  LPS  to  
drive  CCM  formation.    Injection  of  LPS  resulted  in  the  formation  of  massive  lesions  in  resistant  
iECre;;Ccm2fl/fl  animals  (Fig.  3.1g-­i),  but  had  no  effect  on  Ccm2fl/fl  littermates  (Fig.  3.7c,  d).    These  
findings  reveal  that  blood-­borne  GNB  and  LPS  are  strong  drivers  of  CCM  formation  in  mice.  
3.3  Endothelial  TLR4  function  and  brain  endothelial  CCM  complex  deficiency  underlie  
lesion  formation.  
	  
We  recently  demonstrated  that  loss  of  the  CCM  proteins  KRIT1  or  CCM2  results  in  
vascular  malformation  due  to  increased  MEKK3  signaling  in  endothelial  cells108.    LPS  activates  
intracellular  signals  through  the  innate  immune  receptor  TLR440,  and  MEKK3-­deficient  fibroblasts  
are  unable  to  activate  downstream  signaling  responses  to  LPS  in  vitro58.    We  therefore  
hypothesized  that  GNB  and  LPS  accelerate  CCM  formation  by  activating  TLR4-­MEKK3-­KLF2/4  
signaling  in  CCM  complex-­deficient  brain  endothelial  cells.    Analysis  of  susceptible  iECre;;Krit1fl/fl  
mice  revealed  that  CCM  lesions  arise  in  the  absence  of  an  immune  cell  infiltrate  at  P6  (Fig.  3.8),  
and  that  a  single  dose  of  LPS  at  P5  accelerated  CCM  formation  by  P6  (Fig.  3.2a).    Consistent  
with  a  brain  endothelial  cell  intrinsic  mechanism,  we  observed  synergistic  effects  of  CCM  
complex-­deficiency  and  LPS  injection  on  the  expression  of  CCM-­causing  genes  Klf2  and  Klf4,  
known  endothelial  TLR4  signaling  targets  IL-­1β  (Il1b)  and  E-­selectin  (Sele),  as  well  as  on  the  
level  of  phospho-­myosin  light  chain  (Fig.  3.2b  and  Fig.  3.7e).    
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To  directly  test  the  requirement  for  endothelial  TLR4  in  spontaneous  CCM  formation,  we  
bred  iECre;;Krit1fl/fl;;Tlr4fl/+  and  iECre;;Krit1fl/fl;;Tlr4fl/fl  mice  using  animals  from  the  susceptible  
iECre;;Krit1fl/fl  colony.    Loss  of  a  single  endothelial  Tlr4  allele  resulted  in  an  approximately  75%  
reduction  in  CCM  lesion  burden  at  P10,  while  loss  of  both  resulted  in  virtually  complete  
prevention  of  CCM  lesion  formation  (Fig.  3.2c,  d  and  Fig.  3.9a).  Cd14  encodes  a  soluble  TLR4  
co-­receptor  that  binds  LPS  and  facilitates  TLR4  signaling48,52.      Although  less  complete,  global  
loss  of  CD14  also  prevented  CCM  formation  in  susceptible  iECre;;Krit1fl/fl  mice  (Fig.  3.2e,  f  and  
Fig.  3.9b).  Lineage  tracing  studies  confirmed  that  iECre  (Cdh5(PAC)-­CreERT2)  transgene  activity  
was  restricted  to  endothelial  cells  (Fig.  3.10),  excluding  a  requirement  for  hematopoietic  cell  TLR4  
signaling  during  CCM  formation.  Finally,  to  exclude  a  role  for  the  CCM  complex  in  endothelial  
cells  outside  the  brain,  we  used  a  recently  generated  Slco1c1(BAC)-­CreERT2  transgene111  to  
further  restrict  deletion  of  Krit1  to  brain  endothelial  cells.  Slco1c1(BAC)-­CreERT2;;R26-­LSL-­RFP  
animals  exhibited  RFP+  endothelial  cells  in  the  brain  but  not  in  the  gut  or  liver  (Fig.  3.11a),  and  
Slco1c1(BAC)-­CreERT2;;Krit1fl/fl  (“iBrainECre  Krit1fl/fl”)  animals  developed  CCM  lesions  like  those  in  
iECre;;Krit1fl/fl  animals  (Fig.  3.11b,  c).    These  genetic  findings  identify  endothelial  TLR4  signaling  
as  a  critical  driver  of  CCM  formation  in  mice.  
3.4  Polymorphisms  that  increase  TLR4  and  CD14  expression  are  associated  with  
increased  CCM  lesion  formation  in  humans.  
	  
Human  and  mouse  studies  have  demonstrated  that  TLR4  signaling  positively  correlates  
with  receptor  expression  levels112,113,  suggesting  that  polymorphisms  associated  with  changes  in  
TLR4  expression  might  influence  the  natural  history  of  human  CCM  disease.    We  recently  
analyzed  830  genetic  variants  of  56  inflammatory  and  immune  related  genes  in  188  human  
patients  with  an  identical  nonsense  mutation  in  the  KRIT1  gene  (Q455X)  in  whom  CCM  lesion  
burden  was  measured  using  magnetic  resonance  imaging  (MRI)107.    Following  statistical  analysis,  
single  nucleotide  polymorphisms  (SNPs)  in  only  two  genes,  TLR4  (rs10759930,  chromosome  9,  
Fig.  3.3a)  and  CD14  (rs778587,  chromosome  5,  Fig.  3.3a),  were  found  to  be  significantly  
associated  with  increased  CCM  lesion  number.  Further  analysis  of  genes  in  TLR4-­MEKK3-­
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KLF2/4  signaling  pathways  identified  additional  SNPs  for  TLR4  (rs10759931)  and  CD14  
(rs778588)  in  linkage  disequilibrium  with  those  previously  identified  (Fig.  3.3a),  but  none  in  other  
pathway  genes  (Materials  and  Methods)  that  associated  with  altered  lesion  burden.    Significantly,  
the  TLR4  and  CD14  SNPs  associated  with  increased  CCM  lesion  number  are  in  the  5’  genomic  
region  of  each  gene  (Fig.  3.3a),  and  constitute  cis  expression  quantitative  trait  loci  (cis-­eQTLs)  
that  positively  regulate  whole-­blood  cell  expression  of  TLR4  and  CD14  in  a  dose-­dependent  
manner  corresponding  with  risk  allele  number  (Fig.  3.3b-­c  and114,115).  These  results  were  
independently  corroborated  by  a  similar  GTEx  Consortium  study  (Materials  and  Methods).  MRI  
analysis  revealed  additive  CCM  lesion  numbers  in  KRIT1  Q455X  patients  who  carried  one,  two  or  
three  TLR4  or  CD14  risk  alleles  (Fig.  3.3d-­f).  Carriers  of  TLR4  or  CD14  risk  alleles  were  
associated  with  72%  or  49%  more  lesions  compared  to  wildtype  individuals,  respectively  (Fig.  
3.3e  and  f).    These  findings  demonstrate  that  genetic  changes  associated  with  altered  TLR4  and  
CD14  expression  result  in  coordinate  changes  in  CCM  lesion  formation  in  both  humans  and  mice  
(Fig.  3.2c-­f),  supporting  the  hypothesis  that  TLR4/CD14  signaling  plays  a  central  and  conserved  
role  in  CCM  pathogenesis.  
3.5  The  bacterial  microbiome  is  a  primary  driver  of  CCM  formation  in  mice.  
	  
Although  endogenous  TLR4  ligands  have  been  identified116,  the  primary  known  TLR4  
ligand  is  GNB-­derived  LPS40,117.    The  findings  that  CCM  pathogenesis  requires  endothelial  TLR4  
and  CD14  (Fig.  3.2c-­f)  and  that  CCM  susceptibility  shifted  dramatically  with  a  change  in  vivarium  
(Fig.  3.1a)  suggested  that  GNB  in  the  microbiome  may  be  a  primary  source  of  TLR4  ligand  and  
an  important  regulator  of  CCM  disease.  To  directly  test  the  role  of  the  bacterial  microbiome  during  
CCM  formation,  we  delivered  susceptible  E19.5  iECre;;Krit1fl/fl  neonates  using  sterile  C-­section  
and  fostered  them  to  imported  conventional  or  germ-­free  Swiss  Webster  mothers  (Fig.  3.4a).  All  
fostered  iECre;;Krit1fl/fl  neonates  exhibited  robust  CCM  formation  at  P10  when  raised  by  
conventional  Swiss  Webster  mothers  (Fig.  3.4b,  c  and  Fig.  3.9c).  In  contrast,  7/8  fostered  
iECre;;Krit1fl/fl  neonates  raised  in  germ-­free  conditions  failed  to  develop  CCM  lesions,  indicating  
that  bacteria  are  required  for  CCM  pathogenesis  in  most  animals  (Fig.  3.4b-­c  and  Fig.  3.9c).  A  
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single  fostered  iECre;;Krit1fl/fl  neonate  developed  CCM  lesions  despite  reductions  in  gut  bacteria  
and  Krit1  mRNA  similar  to  fostered  iECre;;Krit1fl/fl  littermates  that  failed  to  develop  CCMs  (red  
boxes,  Fig.  3.4b-­e  and  Fig.  3.9c).  Prior  studies  have  demonstrated  that  MEKK3  is  required  for  
signaling  downstream  of  cytokines  IL-­1β58  and  TNFα118,  and  other  pattern-­recognition  receptors  
can  signal  in  endothelial  cells  through  the  same  effectors  utilized  by  TLR4119,120.  Thus,  the  
generation  of  lesions  in  a  germ-­free  iECre;;Krit1fl/fl  neonate  suggested  that  cytokines  or  immune  
receptors  other  than  TLR4  may  also  drive  CCM  formation  in  vivo.    To  directly  test  the  ability  of  
non-­TLR4  ligands  to  stimulate  CCM  formation,  we  administered  IL-­1β,  TNFα,  TLR3  ligand  
poly(I:C),  and  TLR2  ligand  peptidoglycan  (PGN)  to  resistant  iECre;;Ccm2fl/fl  neonates  and  
assessed  effects  on  CCM  formation.    IL-­1β  and  poly(I:C)  treatment  significantly  increased  CCM  
lesion  volume  although  no  difference  was  observed  with  TNFα  or  PGN  (Fig.  3.12).  These  findings  
identify  the  bacterial  biome  as  a  critical  driver  of  CCM  formation  in  vivo,  but  also  demonstrate  that  
cytokines  and  innate  immune  ligands  other  than  LPS  can  support  CCM  formation  in  vivo.  
3.6  CCM  susceptibility  is  associated  with  specific  gram-­negative  bacteria  in  the  gut  
microbiome.  
	  
Assessment  of  CCM  formation  in  iECre;;Krit1fl/fl  and  iECre;;Ccm2fl/fl  mice  at  P10  revealed  a  
remarkably  binary  phenotype  in  which  susceptible  mice  developed  numerous  lesions  while  
resistant  mice  developed  virtually  none  (Fig.  3.5a-­b  and  d-­e).    Lesion  volumes  were  
indistinguishable  among  susceptible  iECre;;Krit1fl/fl  and  iECre;;Ccm2fl/fl  animals  and  no  difference  in  
brain  endothelial  Tlr4  expression  was  detected  between  susceptible  and  resistant  animals  (Fig.  
3.7f),  supporting  a  dominant  role  of  non-­genetic  factors  such  as  the  gut  microbiome  in  
determining  CCM  susceptibility.    
To  identify  specific  bacteria  that  associate  with  CCM  susceptibility  or  resistance,  we  
performed  16S  rRNA  gene  sequencing  of  bacterial  DNA  extracted  from  the  feces  of  female  mice  
that  raised  susceptible  or  resistant  iECre;;Krit1fl/fl  and  iECre;;Ccm2fl/fl  animals  (Fig.  3.13a).    A  
PERMANOVA  test  of  unweighted  UniFrac  distances  revealed  clear  separation  of  susceptible  and  
resistant  bacterial  microbiome  communities,  regardless  of  whether  they  were  derived  from  
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iECre;;Krit1fl/fl  or  iECre;;Ccm2fl/fl  colonies  (p<0.0001,  R2=0.051  Fig.  5f).  Further  accounting  for  
relative  abundances  of  bacterial  species,  significant  separation  between  susceptible  and  resistant  
animals  was  also  observed  using  weighted  UniFrac  analysis  (p=0.0016,  R2=0.091,  Fig.  3.5g).    
Fitting  generalized,  linear  mixed  effects  models  for  commonly  present  bacterial  taxa  identified  one  
major  group  that  differed  significantly  between  the  gut  biomes  of  susceptible  and  resistant  
animals:  gram  negative  Bacteroidetes  s24-­7  (s24-­7)  was  significantly  more  abundant  in  
susceptible  animals  irrespective  of  genotype  (Fig.  3.5h  and  Fig.  3.13b-­c).  Significantly,  16S  
sequencing  of  gut  bacteria  from  conventional  Swiss-­Webster  foster  mothers  revealed  high  levels  
of  s24-­7,  explaining  susceptibility  to  CCM  formation  by  C-­section/fostered  iECre;;Krit1fl/fl  neonates  
(Fig.  3.4  and  Fig.  3.5c-­e  and  h).    These  findings  support  a  key  role  for  the  gut  microbiome  in  CCM  
disease  pathogenesis,  and  suggest  that  CCM  susceptibility  can  be  significantly  affected  by  levels  
of  specific  GNB  in  the  gut  microbiome.  
3.7  CCM  formation  can  be  blocked  by  TLR4  antagonists  or  altering  the  microbiome.  
	  
Our  studies  do  not  exclude  a  role  for  TLR4  signaling  in  non-­brain  endothelial  cells.  
However,  they  are  most  consistent  with  a  disease  model  in  which  brain  endothelial  TLR4/CD14  
receptors  stimulate  MEKK3-­KLF2/4  signaling  in  response  to  GNB  or  GNB-­derived  LPS  that  
translocate  from  the  gut  lumen  to  circulating  blood  (Fig.  3.6a)—a  process  significantly  influenced  
by  the  composition  of  the  gut  microbiome121-­124.    This  model  predicts  two  novel  approaches  to  
treat  CCM  disease:  TLR4  blockade  and  deliberate  microbiome  manipulation.    
Tak242  (resatorvid)  is  a  small  molecule  TLR4  antagonist  that  binds  the  intracellular  
domain  of  TLR4  and  blocks  signal  transduction125.  Treatment  of  susceptible  iECre;;Krit1fl/fl  mice  
with  Tak242  demonstrated  an  approximately  80%  reduction  in  CCM  lesion  volume  (Fig.  3.6b-­d).      
LPS-­RS  is  a  hypo-­acetylated  LPS  derived  from  Rhodobacter  sphaeroides  that  competitively  
antagonizes  TLR4126.  Treatment  of  susceptible  iECre;;Krit1fl/fl  mice  with  LPS-­RS  conferred  a  >90%  
reduction  in  CCM  lesion  volume  (Fig.  3.14).    These  studies  confirm  the  essential  role  of  TLR4  
signaling  in  CCM  pathogenesis  and  suggest  that  TLR4  antagonists  may  be  effective  therapies.  
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To  test  the  effect  of  deliberate  microbiome  manipulation  on  CCM  formation,  we  designed  
an  intergenerational  study  utilizing  a  single  course  of  antibiotics  to  reset  the  microbiome  (Fig.  
3.6e).  Male-­female  pairs  of  susceptible  iECre;;Krit1fl/fl  mice  were  crossed  and  baseline  CCM  
formation  was  measured  in  the  offspring  at  P10  (Fig.  3.6f  ‘Generation  1  –  ABX  Naïve’).    Next,  the  
same  male-­female  pairs  were  mated  a  second  time  and  broad-­spectrum  antibiotics  administered  
maternally  from  E14.5  to  P10  prior  to  lesion  assessment  (Fig.  3.6g  ‘Generation  2  –  Maternal  
ABX’).    Finally,  4-­6  weeks  after  withdrawal  of  antibiotics,  the  same  male-­female  pair  delivered  a  
third  litter  and  lesions  were  assessed  at  P10  (Fig.  3.6h  ‘Generation  3  –  Post  ABX’).    As  expected,  
Generation  1  susceptible  iECre;;Krit1fl/fl  mice  developed  numerous  lesions  (Fig.  3.6f,  j  and  Fig.  
3.9d  ).    Consistent  with  our  findings  using  germ-­free  animals,  Generation  2  maternal  antibiotic  
treatment  reduced  CCM  formation  by  >95%  (Fig.  3.6g,  j),  in  association  with  a  96%  reduction  in  
total  gut  bacterial  load  (Fig.  3.6i).  Remarkably,  Generation  3  iECre;;Krit1fl/fl  offspring  from  the  
same  mating  pair  failed  to  develop  CCMs  (Fig.  3.6h,  j),  despite  bacterial  load  returning  to  pre-­
antibiotic  levels  (Fig.  3.6i),  except  for  a  single  Generation  3  animal  that  developed  an  intra-­
abdominal  abscess  with  pronounced  splenomegaly  (Fig.  3.6j,  star,  Fig.  3.15a).  Maternal  
treatment  with  vancomycin  alone,  a  broad-­spectrum  antibiotic  specific  for  gram  positive  bacteria,  
had  no  effect  on  CCM  formation,  consistent  with  a  causal  role  for  GNB  (Fig.  3.15b-­h).  
Measurement  of  s24-­7  levels  in  the  intestines  of  Generation  1,  2  and  3  neonates  harvested  for  
analysis  of  lesion  volume  revealed  a  significant,  sustained  reduction  in  Generation  3  relative  to  
Generation  1  (Fig.  3.6k-­l),  consistent  with  the  observation  that  resistant  Krit1fl/fl  and  Ccm2fl/fl  
mothers  have  lower  s24-­7  levels  than  susceptible  mothers  (Fig.  3.5h).    Conversely,  sterile  C-­
section/fostering  of  resistant  iECre;;Krit1fl/fl  and  iECre;;Ccm2fl/fl  pups  to  conventional  Swiss-­
Webster  foster  mothers  with  high  levels  of  s24-­7  (Fig.  3.5h)  restored  CCM  susceptibility  (Fig.  
3.16).  These  findings  provide  further  evidence  that  qualitative  changes  in  the  bacterial  
microbiome  can  alter  disease  course.    
3.8  Discussion  
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Designing  rational  therapies  for  CCM  disease  is  complicated  by  the  fact  that  many  of  the  
pathogenic  events  take  place  within  brain  endothelial  cells  of  the  central  nervous  system  (CNS),  
where  drug  delivery  is  blocked  by  the  blood-­brain  barrier  (BBB)127.  The  finding  that  LPS  
accelerates  CCM  formation  (Fig.  3.2a-­e)  although  it  is  unable  to  cross  the  BBB128  suggests  that  
CCM  formation  is  driven  by  activation  of  endothelial  TLR4  receptors  on  the  luminal,  blood  side  of  
the  BBB  (Fig.  3.6a).  Tak242  or  LPS-­RS  effectively  reduce  lesion  formation,  confirming  endothelial  
TLR4  as  a  “druggable”  target  for  CCM  disease  (Fig.  3.6b-­d  and  Fig.  3.14).  Existing  TLR4  blocking  
agents  developed  for  sepsis  treatment129  could  potentially  be  repurposed  as  therapies  for  severe  
human  CCM  disease.      However,  such  application  will  first  need  to  address  the  requirement  for  
chronic  therapy,  the  potential  risk  of  lethal  sepsis,  and  whether  anti-­TLR4  therapy  will  affect  
existing  as  well  as  nascent  lesions.    
Manipulation  of  gut  microbiome-­host  interactions  is  a  more  exciting  potential  strategy  to  
treat  a  life-­long  disease  such  as  CCM.  The  microbiome  has  been  associated  with  many  human  
diseases130,  but  specific  molecular  mechanisms  by  which  it  contributes  to  disease  pathogenesis  
have  been  difficult  to  define.  Our  studies  support  a  central  role  for  the  gut  microbiome  and  
endothelial  responses  to  GNB  in  the  pathogenesis  of  CCMs.  We  find  that  the  bacterial  
microbiome  is  the  primary  source  of  TLR4  ligand  required  to  stimulate  CCM  formation  in  mice,  
and  that  small  qualitative  differences  in  the  gut  microbiome  may  have  dramatic  effects  on  the  
course  of  CCM  disease  in  this  animal  model.    Although  s24-­7  is  not  found  in  humans,  the  
association  of  CCM  disease  susceptibility  with  this  GNB  is  particularly  interesting  because  it  is  
associated  with  disruption  of  the  gut  epithelial  barrier131.  Thus,  a  key  step  in  CCM  pathogenesis  is  
predicted  to  be  translocation  of  bacteria  or  bacterial  LPS  from  the  gut  lumen  into  circulation  (Fig.  
3.6a).  Whether  similar  inflammatory/colitogenic  microbiomes  also  accelerate  human  CCM  
disease  remains  an  important  question.  The  clinical  course  of  CCM  disease  is  exceptionally  
variable,  even  among  individuals  with  familial  CCM  disease  due  to  a  common  KRIT1  
mutation11,107.    Genetic  polymorphisms  that  alter  TLR4  and  CD14  expression  account  for  some  of  
this  heterogeneity  (Fig.  3.3),  but  most  of  the  clinical  variability  remains  unexplained  and  may  
reflect  the  effect  of  individual  microbiomes.    Future  studies  that  simultaneously  define  the  
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genomes  and  microbiomes  of  CCM  patients  will  be  required  to  test  this  intriguing  hypothesis  and  
determine  whether  the  microbiome  is  a  viable  therapeutic  target  for  this  disease.  
3.9  Materials  and  Methods  
	  
University  of  Pennsylvania  (Philadelphia)  Mice  
The  Cdh5(PAC)-­CreERT2  transgenic  mice  (iECre)  were  a  generous  gift  from  Ralf  H.  
Adams102.  Krit1fl/fl  and  Ccm2fl/fl  animals  have  been  previously  described15,18.  Tlr4fl/fl,  Cd14-­/-­,  Ai14  
(R26-­LSL-­RFP),  and  R26-­CreERT2  animals132-­135  were  obtained  from  the  Jackson  Laboratories.  
The  Slco1c1(BAC)-­CreERT2  transgenic  mice  (iBrainECre)  have  been  previously  described111.  All  
experimental  animals  were  maintained  on  a  mixed  129/SvJ,  C57BL/6J,  DBA/2J  genetic  
background  unless  specifically  described.  C57BL/6J  and  timed  pregnant  Swiss  Webster  mice  
were  purchased  from  Charles  River  Laboratories.  Germ-­free  Swiss  Webster  mice  were  
purchased  from  Taconic.  Breeding  pairs  between  two  and  ten  months  of  age  were  used  to  
generate  the  neonatal  CCM  mouse  model  pups.  Mice  were  housed  in  a  specific  pathogen-­free  
facility  where  cages  were  changed  on  a  weekly  basis;;  ventilated  cages,  bedding,  food,  and  
acidified  water  (pH  2.5-­3.0)  were  autoclaved  prior  to  use,  ambient  temperature  maintained  at  
23°C,  and  5%  Clidox-­STM  was  utilized  as  a  disinfectant.  Experimental  breeding  cages  were  
randomly  housed  on  three  different  racks  in  the  vivarium,  and  all  cages  were  kept  on  automatic  
12-­hour  light/dark  cycles.  The  University  of  Pennsylvania  Institutional  Animal  Care  and  Use  
Committee  (IACUC)  approved  all  animal  protocols,  and  all  procedures  were  performed  in  
accordance  with  these  protocols.    
Centenary  Institute  (Australia)  Mice  
A  portion  of  the  resistant  iECre;;Ccm2fl/fl  colony  was  exported  to  the  Centenary  Institute,  
Sydney,  Australia  where  the  mice  were  permanently  maintained  as  an  inbred  colony  in  a  
quarantine  facility.  After  several  generations,  this  colony  uniformly  converted  to  lesion  
susceptibility.  Cages  were  changed  on  a  weekly  basis;;  ventilated  cages,  bedding,  food,  and  
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acidified  water  (pH  2.5-­3.0)  were  autoclaved  prior  to  use.  Ambient  temperature  was  maintained  
between  22-­26°C,  and  80%  ethanol  and  F10SCTM  (1:125  dilution  of  the  concentrate,  a  quaternary  
ammonium  compound)  were  used  as  disinfectants.  Experimental  breeding  cages  were  randomly  
distributed  throughout  the  vivarium,  and  all  cages  were  kept  on  12-­hour  light/dark  cycles.  The  
Sydney  Local  Health  District  Animal  Welfare  Committee  approved  all  animal  ethics  and  protocols.  
All  experiments  were  conducted  under  the  guidelines/regulations  of  Centenary  Institute  and  the  
University  of  Sydney.  
Gnotobiotic  animal  husbandry  
   Germ  free  Swiss  Webster  mice  were  purchased  from  Taconic  and  directly  transferred  
into  sterile  isolators  (Class  Biologically  Clean  Ltd.)  under  the  care  of  the  Penn  Gnotobiotic  Mouse  
Facility.  Food,  bedding,  and  water  (non-­acidified)  were  autoclaved  prior  to  transfer  into  the  sterile  
isolators.  Ventilated  cages  were  changed  weekly,  and  all  cages  in  the  vivarium  were  kept  under  
12-­hour  light/dark  cycles.  Microbiology  testing  (aerobic  and  anaerobic  culture,  16S  qPCR)  was  
performed  every  ten  days  and  fecal  samples  were  sent  to  Charles  Rivers  Laboratories  for  
pathology  testing  on  a  quarterly  basis.  Further  details  regarding  the  sterile  C-­section  fostering  can  
be  found  below.  The  University  of  Pennsylvania  Institutional  Animal  Care  and  Use  Committee  
(IACUC)  approved  all  animal  protocols,  and  all  procedures  were  performed  in  accordance  with  
these  protocols.  
Induction  of  the  neonatal  CCM  mouse  model  
For  all  neonatal  CCM  mouse  model  experiments,  at  one-­day  post-­birth  (P1),  pups  were  
intragastrically  injected  by  30-­gauge  needle  with  40  µg  of  4-­hydroxytamoxifen  (4OHT,  Sigma  
Aldrich,  H7904)  dissolved  in  a  9%  ethanol/corn  oil  (volume/volume)  vehicle  (50  µL  total  volume  
per  injection).  This  solution  was  freshly  prepared  from  pre-­measured,  4OHT  powder  for  every  
injection.  Prior  to  injection,  the  pup  skin  was  sanitized  using  ethanol  wipes.  The  P1  time  point  was  
defined  by  checking  experimental  breeding  pairs  every  evening  for  new  litters.  The  following  
morning  (P1),  pups  were  injected  with  4OHT.  All  experimental  pups  were  subjected  to  this  
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induction  regimen.  For  the  Tlr4  rescue  experiment  (Fig.  2),  and  all  lineage  tracing  experiments,  
an  additional  dose  of  40  µg  4OHT  was  intragastrically  delivered  at  P2  (P1+2,  two  total  doses).  
Pups  were  then  harvested  as  previously  described108  at  the  specified  time  points.    
Histology  
Tissue  samples  were  fixed  in  4%  formaldehyde  overnight,  dehydrated  in  100%  ethanol,  
and  embedded  in  paraffin.  5  µm  thick  sections  were  used  for  hematoxylin  &  eosin  and  
immunohistochemistry  staining.    The  following  antibodies  were  used  for  immunostaining:  rat  anti-­
PECAM  (1:20,  Histo  Bio  Tech  DIA-­310),  rabbit  anti-­pMLC2  (1:200,  Cell  Signaling  3674S),  goat  
anti-­KLF4  (1:100,  R&D  AF3158),  and  rabbit  anti-­RFP  (1:50,  Rockland  600-­401-­379).  Littermate  
control  and  experimental  animal  sections  were  placed  on  the  same  slide  and  immunostained  at  
the  same  time  under  identical  conditions.  Images  were  taken  at  the  same  time  using  the  same  
exposure  times  and  color  channels,  and  were  subsequently  overlaid  using  ImageJ.  
Gram  staining  
Intra-­abdominal  abscesses  were  dissected  and  triturated  in  500  µL  of  SOC  medium.  
Drops  of  the  mixture  were  placed  on  a  microscope  slide,  briefly  exposed  to  heat,  and  gram  
staining  was  performed  using  a  kit  from  Sigma  Aldrich  (77730)  following  the  manufacturer’s  
protocol.  
Whole-­mount  retinal  endothelium  staining  
Eyes  from  euthanized  P17  mice  were  removed  and  fixed  overnight  in  cold  4%  PFA/PBS  
solution.  The  following  day,  retinas  were  dissected,  cut  into  petals,  and  stained  with  isolectin-­B4  
conjugated  to  Alexa488  fluorophore  (Thermo  Fisher  I21411)  as  previously  described136.  The  
retinas  were  then  whole-­mounted  on  microscopy  slides  in  a  flat,  four-­petal  shape  for  fluorescence  
imaging.    
Bacteroides  fragilis  (B.  frag)  abscess  model  
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B.  frag  was  purchased  directly  from  the  ATCC  (strain  25285)  and  grown  in  chopped  meat  
glucose  (CMG)  broth  (Anaerobe  Systems  AS-­813)  under  anaerobic  conditions  at  37°C.  
Autoclaved,  degassed  cecal  contents  (ACC)  were  generated  by  harvesting  cecal  contents  from  
the  colons  of  euthanized  adult  mice  between  2-­8  months  of  age.  Cecal  contents  were  then  
autoclaved  and  pulverized  in  an  equal  volume  of  CMG  broth.  This  slurry  was  filtered  through  a  70  
µm  nylon  strainer  and  degassed  overnight  in  the  anaerobic  chamber.  One  mL  of  CMG  broth  was  
inoculated  with  B.  frag  and  grown  overnight  to  an  optical  density  between  0.8  and  1.0.  An  equal  
volume  of  ACC  was  mixed  with  the  overnight  bacterial  culture.  100  µL  of  this  B.  frag/ACC  mixture  
was  injected  intraperitoneally  into  five-­day  old  pups  with  a  31-­gauge  needle.  Control  littermates  
were  simultaneously  injected  intraperitoneally  with  100  µL  of  ACC  alone.  Pups  were  harvested  at  
P17.  Spleen  weight  was  measured  immediately  after  dissection,  and  all  tissue  was  subsequently  
processed  as  described  above.  
Intravenous  lipopolysaccharide  (LPS),  peptidoglycan  (PGN),  polyinosinic:polycytidylic  acid  
(poly(I:C)),  interleukin-­1  beta  (IL-­1β),  and  tumor  necrosis  factor-­alpha  (TNFα)  injections  
Lipopolysaccharide  from  E.  coli  O127:B8  was  purchased  from  Sigma  (L3129)  and  
administered  to  the  low  lesion  penetrance,  resistant  iECre;;Ccm2fl/fl  neonatal  CCM  disease  model.  
At  P5,  a  3  µg  dose  of  LPS  dissolved  in  sterile  PBS  was  administered  retro-­orbitally  (RO)  in  a  total  
30  µL  volume  by  31-­gauge  needle.  At  P10,  a  5  µg  dose  of  LPS  was  administered  RO  in  a  total  50  
µL  volume  by  31-­gauge  needle.  Control  animals  were  identically  injected  with  PBS  alone.  Pups  
were  euthanized  and  brains  dissected  at  specified  time  points.  PGN  from  Bacillus  subtilis  (a  
gram-­positive  gut  commensal)  was  purchased  from  Invivogen  (tlrl-­pgnb3)  and  administered  to  the  
resistant  iECre;;Ccm2fl/fl  neonatal  CCM  disease  model  under  identical  conditions  as  the  LPS  
experiments.  Poly(I:C)  was  purchased  from  Invivogen  (tlrl-­picw)  and  administered  to  the  resistant  
iECre;;Ccm2fl/fl  neonatal  CCM  disease  model  under  identical  conditions  as  the  LPS  experiments.  
Mouse  IL-­1β  was  purchased  from  Genscript  (Z02988)  and  administered  to  the  resistant  
iECre;;Ccm2fl/fl  neonatal  CCM  disease  model.  At  P5,  a  5  ng  dose  of  IL-­1β  dissolved  in  sterile  PBS  
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was  administered  RO  in  a  total  30  µL  volume  by  31-­gauge  needle.  At  P10,  an  8  ng  dose  of  IL-­1β  
was  administered  RO  in  a  total  50  µL  volume  by  31-­gauge  needle.  Control  animals  were  
identically  injected  with  PBS  alone.  Pups  were  euthanized  and  brains  dissected  at  specified  time  
points.  Mouse  TNFα  was  purchased  from  Genscript  (Z02918)  and  administered  to  the  resistant  
iECre;;Ccm2fl/fl  neonatal  CCM  disease  model  under  identical  conditions  as  the  IL-­1β  experiments.  
Contrast-­enhanced,  X-­ray  micro-­computed  tomography  (microCT)  
For  all  experiments  utilizing  microCT  quantification  of  CCM  lesion  volume,  brains  were  
harvested  and  immediately  placed  in  4%  PFA/PBS  fixative.  Brains  remained  in  fixative  until  
staining  with  non-­destructive,  iodine  contrast  and  subsequent  microCT  imaging  performed  as  
previously  described137.  Importantly,  all  tissue  processing,  imaging,  and  volume  quantification  
were  done  in  a  blinded  manner  by  investigators  at  The  University  of  Chicago  without  any  
knowledge  of  experimental  details.    
As  previously  done,  we  blinded  samples  at  three  distinct  points  in  the  analysis.    First,  
neonatal  CCM  model  pups  were  injected  with  4OHT  without  knowledge  of  genotypes.  Second,  
hindbrains  from  genotyped  animals  were  given  randomized,  de-­identified  labels  to  provide  for  
blinded  microCT  scanning  by  an  independent  operator.  Third,  randomized  microCT  image  stacks  
were  analyzed  in  a  blinded  manner  by  individuals  not  involved  in  any  prior  experimental  steps.  
Immune  cell  isolation  from  neonatal  brain  
Mice  were  anesthetized  with  AvertinTM  and  underwent  intra-­cardic  perfusion  with  10  mL  
of  cold  PBS.  The  brain  was  separated  from  the  brainstem,  and  the  cerebellum  was  separated  
from  the  remaining  brain  and  processed  in  parallel.    The  tissue  was  minced  with  scissors,  placed  
in  digestion  buffer  (RPMI,  20mM  HEPES,  10%  FCS,  1mM  CaCl2,  1mM  MgCl2,  0.05mg/ml  
Liberase  TM  (Sigma),  0.02mg/ml  DNase  I  (Sigma)),  and  incubated  for  40  min  at  37  °C  with  
shaking  at  200  rpm.  The  mixture  was  passed  through  a  100  μm  strainer  and  washed  with  FACS  
Buffer  (PBS,  1%  FBS).    Cells  were  resuspended  in  4  mL  of  40%  Percoll  (GE  Healthcare)  and  
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overlaid  on  4  mL  of  67%  Percoll.  Gradients  were  centrifuged  at  400  xg  for  20  min  at  4  °C  and  
cells  at  the  interface  were  collected,  washed  with  10  mL  of  FACS  Buffer,  and  stained  for  flow  
cytometric  analysis.    
Hematopoietic  cell  isolation  from  neonatal  whole  blood,  spleen  and  subsequent  FACs  analysis  
   Neonatal  P10  mice  were  anesthetized  with  AvertinTM  and  underwent  intracardiac  
puncture/blood  draw  using  a  27  gauge  needle/syringe  coated  with  0.5  M  EDTA,  pH  8.0  
immediately  prior  to  use.  Cells  were  pelleted  by  centrifugation  at  300  xg  for  5  minutes  at  4°C.  
Serum  was  removed  and  RBCs  were  lysed  using  ACK  lysis  buffer.  Spleens  were  dissected  in  
parallel,  hand-­homogenized  using  a  mini-­pestle  and  RBCs  were  lysed  using  ACK  lysis  buffer.  
Cells  from  both  sets  of  tissues  were  passed  through  a  70  µm  cell-­strainer,  pelleted,  and  
resuspended  in  FACS  buffer  (PBS,  2%  FBS,  0.1%  NaN3)  for  immunostaining  and  subsequent  
FACS  analysis.  
Immune  cell  staining  and  flow  cytometry  analysis  
Cells  were  isolated  from  the  indicated  tissues.  Single-­cell  suspensions  were  stained  with  
CD16/32  and  with  indicated  fluorochrome-­conjugated  antibodies.  Live/Dead  Fixable  Violet  Cell  
Stain  Kit  (Invitrogen)  was  used  to  exclude  non-­viable  cells.  Multi-­laser,  flow  cytometry  analysis  
procedures  were  done  at  the  University  of  Pennsylvania  Flow  Cytometry  and  Cell  Sorting  Facility  
using  BD  LSRII  cell  analyzers  running  FACSDiva  software  (BD  Biosciences).  Two-­laser,  flow  
cytometry  analyses  were  done  at  the  University  of  Pennsylvania  iPS  Cell  Core  using  BD  Accuri  
C6  instruments.  FlowJo  software  (v.10  TreeStar)  was  used  for  data  analysis  and  graphics  
rendering.  All  fluorochrome-­conjugated  antibodies  used  are  listed  as  follows  (Clone,  Company,  
Catalog  Number):  CD11b  (M1/70,  Biolegend,  101255);;  CD11c  (N418,  Biolegend,  117318);;  
CD16/32  (93,  Biolegend,  101319);;  CD16/32  (93,  eBiosciences,  56D0161D80);;  CD19  (6D5,  
Biolegend,  115510);;  CD3ε  (145D2C11,  Biolegend,  100304);;  CD4  (GK1.5,  Biolegend,  100406);;  
CD45  (30-­F11,  Biolegend,  103121  or  103151),  CD8a  (53D6.7,  Biolegend,  100725);;  Foxp3  (FJK-­
16s,  eBiosciences,  50-­5773-­82);;  Ly-­6G  (1A8,  Biolegend,  127624);;  Live/Dead  (N/A,  Thermofisher,  
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LD34966);;  NK1.1  (PK136,  Biolegend,  108745);;  RORγt  (B2D,  eBiosciences,  12-­6981-­82);;  Siglec-­
F  (E50D2440,  BD,  562757);;  TCRγδ  (UC7-­13D5,  Biolegend,  107504)  
Isolation  of  cerebellar  endothelial  cells,  lung  endothelial  cells,  and  gene  expression  analysis  
At  the  specified  time  points,  cerebellar  endothelial  cells  were  isolated  through  enzymatic  
digestion  followed  by  separation  using  magnetic-­activated  cell  sorting  by  anti-­CD31  conjugated  
magnetic  beads  (MACS  MS  system,  Miltenyl  Biotec),  as  previously  described108.  Lung  endothelial  
cells  were  isolated  through  enzymatic  digestion  as  previously  described  followed  by  separation  
using  anti-­CD31  conjugated  magnetic  beads  and  the  MACS  MS  system138.  Isolated  endothelial  
cells  were  pelleted  and  total  RNA  was  extracted  using  the  RNeasy  Micro  kit  (Qiagen  74004).  For  
qPCR  analysis,  cDNA  was  synthesized  from  300  ng  to  500  ng  total  RNA  using  the  SuperScriptTM  
VILO  cDNA  Synthesis  Kit  and  Master  Mix  (Thermo  Fisher  11755050).  Real-­time  PCR  was  
performed  with  Power  SYBR  Green  PCR  Master  Mix  (Thermo  Fisher  4368577)  using  the  primers  
listed:  
mGapdh  Forward:  5’-­  AAATGGTGAAGGTCGGTGTGAACG  -­3’  
mGapdh  Reverse:  5’-­  ATCTCCACTTTGCCACTGC  -­3’  
mKlf2  Forward:  5’-­  CGCCTCGGGTTCATTTC  -­3’  
mKlf2  Reverse:  5’-­  AGCCTATCTTGCCGTCCTTT  -­3’  
mKlf4  Forward:  5’-­  GTGCCCCGACTAACCGTTG  -­3’  
mKlf4  Reverse:  5’-­  GTCGTTGAACTCCTCGGTCT  -­3’  
mKrit1  Forward:  5’-­  CCGACCTTCTCCCCTTGAAC  -­3’  
mKrit1  Reverse:  5’-­  TCTTCCACAACGCTGCTCAT  -­3’  
mIl1b  Forward:  5’-­  GCAACTGTTCCTGAACTCAACT  -­3’  
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mIl1b  Reverse:  5’-­  ATCTTTTGGGGTCCGTCAACT  -­3’  
mSele  Forward:  5’-­  ATGCCTCGCGCTTTCTCTC  -­3’  
mSele  Reverse:  5’-­  GTAGTCCCGCTGACAGTATGC  -­3’  
mTlr4  Forward:  5’-­  ACTGGGGACAATTCACTAGAGC  -­3’    
mTlr4  Reverse:  5’-­  GAGGCCAATTTTGTCTCCACA  -­3’  
Identification  of  human  CCM  associated  single  nucleotide  polymorphisms  
As  part  of  the  Brain  Vascular  Malformation  Consortium  (BVMC)  CCM  study  (Project  1),  a  
large  cohort  of  familial  CCM  individuals  with  identical  KRIT1  Q455X  mutations  were  enrolled  
between  2009  –  2014  at  the  University  of  New  Mexico.  All  study  protocols  were  approved  by  the  
Institutional  Review  Boards  at  the  University  of  New  Mexico  and  University  of  California  San  
Francisco  (UCSF)  and  all  procedures  were  done  in  accordance  with  these  protocols.  Prior  to  
participation  in  the  study,  written  informed  consent  was  obtained  from  every  patient  and  properly  
documented  by  UNM  investigators.  
  At  study  enrollment,  participants  received  a  neurological  examination  (LM)  and  3T  MRI  
imaging  using  a  volume  T1  acquisition  (MPRAGE,  1-­mm  slice  reconstruction)  and  axial  TSE  T2,  
T2  gradient  recall,  susceptibility-­weighted,  and  FLAIR  sequences.  Lesion  counting  by  the  
neuroradiologist  (BH)  was  based  on  concurrent  evaluation  of  axial  susceptibility-­weighted  
imaging  with  1.5-­mm  reconstructed  images  and  axial  T2  gradient  echo  3-­mm  images.    
   Participants  also  provided  blood  or  saliva  samples  for  genetic  studies.  Genomic  DNA  was  
extracted  using  standard  protocols.  De-­identified  samples  were  normalized,  plated  on  96-­well  
plates,  and  genotyped  at  the  UCSF  Genomics  Core  Facility  using  the  Affymetrix  Axiom  Genome-­
wide  LAT1  Human  Array.  Affymetrix  Genotyping  Console  (GTC)  4.1  Software  package  was  used  
to  generate  quality  control  metrics  and  genotype  calls.  All  samples  had  genotyping  call  rates  of  
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≥97%  and  were  further  checked  for  sample  mix-­ups  (sex  check,  Mendelian  errors  and  cryptic  
relatedness),  resulting  in  188  samples  for  genetic  analysis.        
   21  candidate  genes  were  further  examined  in  the  TLR4  and  MEKK3-­KLF2/4  signaling  
pathways  (TLR4,  CD14,  MD-­2,  LBP,  MYD88,  TICAM1,  TIRAP,  TRAF1-­6,  MAP3K3,  MEK5,  
ERK5,  MEF2C,  KLF2,  KLF4,  ADAMTS4,  ADAMTS5)  including  467  SNPs  within  20kb  upstream  
or  downstream  of  each  gene  locus  using  UCSC  Genome  Browser  coordinates  (GRCh37/hg19).    
Because  total  lesion  counts  are  highly  right  skewed,  raw  counts  were  log-­transformed  and  
analysis  was  performed  on  residuals  (adjusted  for  age  at  enrollment  and  sex).  To  identify  
genotypes  associated  with  log-­transformed  residual  counts,  linear  regression  analysis  was  
implemented  using  QFAM  family-­based  association  tests  for  quantitative  traits  (PLINK  v1.07  
software),  with  stringent  multiple  testing  correction  (Bonferroni  correction  for  the  number  of  SNPs  
tested  within  each  gene)  given  that  some  SNPs  on  the  Affymetrix  array  were  in  linkage  
disequilibrium  with  each  other,  i.e.,  statistically  correlated  with  r2>0.8.    
Characterization  of  human  cis-­eQTLs  
The  Fehrmann  dataset  used  for  eQTL  lookups  consisted  of  peripheral  blood  samples  
from  the  United  Kingdom  and  Netherlands139,140.  Samples  were  genotyped  with  Illumina  
HumanHap300,  HumanHap370  or  610  Quad  platforms.  Genotypes  were  input  by  Impute  v2141  
using  the  GIANT  1000G  p1v3  integrated  call  set  for  all  ancestries  as  a  reference142.  Gene  
expression  levels  were  measured  by  Illumina  HT12v3  arrays.  Gene  expression  pre-­processing  
involved  quantile  normalization,  log2  transformation,  probe  centering  and  scaling,  population  
stratification  correction  (first  4  genetic  multidimensional  scaling  components  were  removed  from  
gene  expression  data)  and  correction  for  unknown  confounders  (first  20  gene  expression  
principal  components  not  associated  with  genetic  variants  were  removed  from  gene  expression  
data).  Identification  of  potential  sample  mix-­ups  was  conducted  by  MixupMapper114  and  finally  
1,227  samples  remained.  All  pre-­processing  steps  were  performed  with  the  QTL  mapping  
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pipeline  v1.2.4D  (https://molgenis26.target.rug.nl/downloads/eqtl-­mapping-­pipeline-­1.2.4D-­
SNAPSHOT-­dist.tar.gz).  
These  results  are  corroborated  by  an  independently  conducted  GTEX  Consortium  study  
(http://www.gtexportal.org/home/snp/rs10759930  and  
http://www.gtexportal.org/home/snp/rs778587).    
Tak242  and  LPS-­RS  administration  
Tak242  was  purchased  from  EMD  Millipore  (614316)  and  administered  to  the  neonatal  
CCM  disease  model.  Five,  seven,  and  nine  days  after  birth,  a  60  µg  dose  of  Tak242  was  
dissolved  in  DMSO/sterile  intralipid  (Sigma,  I141)  vehicle  and  administered  RO  in  a  total  volume  
of  30  µL.  Control  animals  were  identically  injected  with  sterile  DMSO/intralipid  vehicle  alone.  
Pups  were  euthanized  and  brains  dissected  10  days  after  birth.    
LPS-­RS  ultrapure  was  purchased  from  Invivogen  (tlrl-­prslps)  and  administered  to  the  
neonatal  CCM  disease  model.  Starting  at  P5,  a  20  µg  dose  dissolved  in  sterile  PBS  was  
administered  RO  in  a  total  volume  of  30  µL  every  24  hours.  Control  animals  were  identically  
injected  with  sterile  PBS  alone.  Pups  were  euthanized  and  brains  dissected  10  days  after  birth.  
Transgenerational  antibiotic  administration  
Experimental  breeding  pairs  of  mice,  yielding  susceptible  neonatal  CCM  pups,  were  
identified  by  induction  of  a  neonatal  CCM  litter  and  evaluation  of  lesion  burden.  These  breeding  
pairs  then  underwent  timed  matings  and  at  E14.5,  both  male  and  female  adult  mice  were  subject  
to  antibiotic-­laced  drinking  water  mixed  with  40  g/L  of  sucralose  and  red  food  coloring.  Antibiotic  
water  was  replaced  daily.  The  following  antibiotics  were  mixed  with  0.22  µm-­filtered  water:  
penicillin  (500  mg/L),  neomycin  (500  mg/L),  streptomycin  (500  mg/L),  metronidazole  (1  g/L),  and  
vancomycin  (1g/L).  Antibiotics  were  purchased  from  the  Hospital  of  the  University  of  
Pennsylvania  pharmacy.  The  neonatal  CCM  model  was  induced  as  described  above.  At  P10,  
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pups  were  euthanized  and  antibiotic  water  switched  for  normal  drinking  water.  Experimental  
breeding  pairs  were  then  mated  to  obtain  third  generation,  post-­antibiotic  pups.  
Vancomycin  mono-­antibiotic  administration  
   Co-­housed,  susceptible  Krit1fl/fl  females  underwent  evening-­morning  timed  matings  with  a  
single  susceptible  iECre;;Krit1fl/fl  male.  Upon  detection  of  a  plug  in  the  morning,  the  females  were  
subsequently  separated  into  singly-­housed  cages.  At  E14.5,  female  mice  were  subject  to  either  
vancomycin  (1  g/L)-­laced  or  untreated  (vehicle)  sterile-­filtered  drinking  water,  changed  daily.  The  
drinking  water  was  further  mixed  with  40  g/L  sucralose  and  red  food  coloring.  Pups  were  
harvested  at  P11.  
Bacterial  DNA  extraction  from  neonatal  mouse  guts  and  bacterial  rDNA  qPCR  
The  entire  neonatal  gut  was  dissected,  snap-­frozen  on  dry  ice,  and  stored  at  -­80°C.  The  
QIAamp  DNA  Stool  Mini  Kit  (Qiagen  51504  or  51604)  was  used  to  extract  bacterial  DNA  from  the  
neonatal  gut.  Prior  to  commencing  the  standard  Qiagen  protocol,  the  frozen  gut  was  mixed  in  the  
included  stool  lysis  buffer  and  homogenized  with  a  5  mm  stainless  steel  bead  in  a  TissueLyser  LT  
(Qiagen  69980)  at  50  hz  for  10  minutes  at  4°C.  Concentration  of  the  extracted  DNA  was  
equalized  and  16  ng  of  DNA  was  used  per  qPCR  reaction  with  universal  bacterial  16S  rRNA  gene  
primers67,  two  different  sets  of  previously  characterized  Bacteroidetes  s24-­7  primers143,144,  and  
Firmicutes  primers145.  
Universal  16S  rRNA  Forward:  5’-­  ACTGAGAYACGGYCCA  -­3’  
Universal  16S  rRNA  Reverse:  5’-­  TTACCGCGGCTGCTGGC  -­3’  
Bacteroidetes  s24-­7  rRNA  set  1  Forward:  5’-­  GGAGAGTACCCGGAGAAAAAGC  -­3’  
Bacteroidetes  s24-­7  rRNA  set  1  Reverse:  5’-­  TTCCGCATACTTCTCGCCCA  -­3’  
Bacteroidetes  s24-­7  rRNA  set  2  Forward:  5’-­  CCAGCAGCCGCGGTAATA  -­3’  
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Bacteroidetes  s24-­7  rRNA  set  2  Reverse:  5’-­  CGCATTCCGCATACTTCTC  -­3’  
Firmicutes  rRNA  Forward:  5’-­  TGAAACTYAAAGGAATTGACG  -­3’  
Firmicutes  rRNA  Reverse:  5’-­  ACCATGCACCACCTGTC  -­3’  
Sterile  C-­section  and  fostering  to  conventional  Swiss  Webster  recipient  females  
Evening-­morning  timed  matings  to  generate  donor  susceptible  or  resistant  females  
yielding  iECre;;Krit1fl/fl  or  iECre;;Ccm2fl/fl  pups  were  performed  and  timed  pregnant  Swiss  Webster  
females  (Charles  River  024)  were  ordered  to  serve  as  foster  mothers.  To  prevent  delivery  of  the  
pups,  at  E16.5,  donor  females  were  injected  subcutaneously  with  100  µL  of  a  15  µg/mL  solution  
of  medroxyprogesterone  (Sigma  Aldrich,  M1629)  dissolved  in  DMSO.  The  morning  of  E19.5,  the  
donor  mother  was  euthanized  by  cervical  dislocation  and  submerged  in  a  warm  sterile  solution  of  
1%  VirkonSTM/PBS  (weight/volume)  for  one  minute.  The  uterus  was  then  dissected  in  a  sterile  
laminar  flow  hood,  submerged  in  a  warm  sterile  solution  of  1%  VirkonSTM/PBS  for  one  minute  and  
quickly  rinsed  with  warm  sterile  PBS.  Pups  were  then  removed  from  the  uterus  and  fostered  to  
the  Swiss  Webster  recipient  female.  The  following  morning,  induction  of  the  neonatal  CCM  model  
was  performed  as  described  above.      
Sterile  C-­section  and  fostering  to  germ-­free  Swiss  Webster  recipient  females  
   Timed  matings  were  performed  using  germ-­free  Swiss  Webster  mice  housed  in  sterile  
isolators  under  care  of  the  University  of  Pennsylvania  Gnotobiotic  Mouse  Facility.  Simultaneous  
evening-­morning  timed  matings  were  also  performed  using  co-­housed,  susceptible  Krit1fl/fl  
females  and  iECre;;Krit1fl/fl  males  previously  characterized  to  yield  CCM-­susceptible  pups.  
Medroxyprogesterone  was  administered  to  donor  females  and  the  sterile  C-­section  was  
performed  at  E19.5  as  described  in  the  previous  section.  The  intact  uterus  was  passed  through  a  
J-­tube  filled  with  warm  1%  VirkonSTM/PBS  that  was  hermetically  sealed  to  the  sterile  isolator.  
Pups  were  dissected  from  the  uterus  inside  the  sterile  isolator  and  fostered  to  the  recipient  germ-­
free  Swiss  Webster  mother.  Approximately  one  week  later,  fecal  samples  were  collected  for  
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microbiology  testing.  Germ-­free  status  was  further  confirmed  by  16S  qPCR  of  bacterial  DNA  
isolated  from  maternal  feces  and  neonatal  guts.  
Collection  of  maternal  CCM  mouse  feces  
Fresh  fecal  pellets  were  collected  from  experimental  females  yielding  susceptible  or  
resistant  pups  one  day  after  harvesting  the  pups  to  determine  phenotypic  severity.  Collection  was  
performed  between  four  and  six  PM,  pellets  were  immediately  snap-­frozen  on  dry  ice,  and  stored  
at  -­80°C.  
Extraction  and  library  preparation  of  bacterial  DNA  for  16S  rRNA  gene  sequencing  
DNA  was  extracted  from  stool  samples  using  the  Power  Soil  htp  kit  (Mo  Bio  Laboratories,  
Carlsbad,  CA,  USA)  following  the  manufacturer's  protocol.    Library  preparation  was  performed  by  
utilizing  previously  described  barcoded  primers  targeting  the  V1  V2  region  of  the  16S  rRNA  
gene146.    PCR  reactions  were  performed  in  quadruplicate  using  AccuPrime  Taq  DNA  Polymerase  
High  Fidelity  (Invitrogen,  Carlsbad,  CA,  USA).    Each  PCR  reaction  consisted  of  0.4  µM  primers,  
1x  AccuPrime  Buffer  II,  1  U  Taq,  and  25  ng  DNA.    PCRs  were  run  using  the  following  parameters:  
95°C  for  5  min;;  20  cycles  of  95°C  for  30  sec,  56°C  for  30  sec,  and  72°C  for  90  sec;;  and  72°C  for  
8  min.  Quadruplicate  PCR  reactions  were  pooled  and  products  were  purified  using  AMPureXP  
beads  (Beckman-­Coulter,  Brea,  CA,  USA).    Equimolar  amounts  from  each  sample  were  pooled  to  
produce  the  final  library.  Positive  and  negative  controls  were  carried  through  the  amplification,  
purification,  and  pooling  procedures.    Negative  controls  were  used  to  assess  reagent  
contamination  and  consisted  of  extraction  blanks  and  DNA-­free  water.    Positive  controls  were  
used  to  assess  amplification  and  sequencing  quality  and  consisted  of  gBlock  DNA  (Integrated  
DNA  Technologies,  Coralville,  Iowa,  USA)  containing  non-­  bacterial  16S  rRNA  gene  sequences  
flanked  by  bacterial  V1  and  V2  primer  binding  sites.  Paired-­end  2x250bp  sequence  reads  were  
obtained  from  the  MiSeq  (Illumina,  San  Diego,  CA,  USA)  using  the  500  cycle  v2  kit  (Illumina,  San  
Diego,  CA,  USA).    
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Analysis  of  16S  sequencing  
Sequence  data  were  processed  using  QIIME  version  1.9.1147.  Read  pairs  were  joined  to  
form  a  complete  V1V2  amplicon  sequence.  Resulting  sequences  were  quality  filtered  and  
demultiplexed.  Operational  Taxonomic  Units  (OTUs)  were  selected  by  clustering  reads  at  97%  
sequence  similarity148.  Taxonomy  was  assigned  to  each  OTU  with  a  90%  sequence  similarity  
threshold  using  the  Greengenes  reference  database149.  A  phylogenetic  tree  was  inferred  from  the  
OTU  data  using  FastTree150.  The  phylogenetic  tree  was  then  used  to  calculate  weighted  and  
unweighted  UniFrac  distances  between  each  pair  of  samples  in  the  study151,152.    Microbiome  
compositional  differences  were  visualized  using  Principle  Coordinates  Analysis  (PCoA).  
Community-­level  differences  between  mice  genetic  background  as  well  as  disease  susceptibility  
groups  were  assessed  using  a  PERMANOVA  test153  of  weighted  and  unweighted  UniFrac  
distances.    To  assess  significance  in  the  PERMANOVA  test,  each  cage  was  randomly  re-­
assigned  to  groups  9999  times.  Differential  abundance  was  assessed  for  taxa  present  in  at  least  
80%  of  the  samples,  using  generalized  linear  mixed  effects  models.    For  tests  of  taxon  
abundance,  the  cage  was  modeled  as  a  random  effect,  as  previous  research  has  established  that  
the  fecal  microbiota  of  mice  are  correlated  within  cages154.    The  p-­values  were  corrected  for  
multiple  testing  using  Benjamini-­Hochberg  method.  
Statistics  
Sample  sizes  were  estimated  based  on  our  previous  experience  with  the  neonatal  CCM  
model  and  lesion  volume  quantitation  by  microCT108.  Using  forty  historically  collected,  susceptible  
iECre;;Krit1fl/fl    and  iECre;;Ccm2fl/fl  P10  brains,  we  calculated  a  sample  standard  deviation  of  0.250  
mm3.  Between  iECre;;Krit1fl/fl  and  iECre;;Ccm2fl/fl  genotypes,  an  F-­test  to  compare  variances  
confirmed  no  significant  difference  (p=0.340).    Thus,  for  a  two-­group  comparison  of  lesion  
volumes,  each  sample  group  requires  seven  animals  for  a  desired  statistical  power  of  95%  (β=  
0.05),  and  a  conventional  significance  threshold  of  5%  (α=  0.05)  assuming  an  effect  size  of  50%  
(0.5)  and  equal  standard  deviations  between  sample  groups.  These  predictive  calculations  were  
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corroborated  by  our  recent  publication  in  which  larger  effect  sizes  (>90%)  were  found  to  be  
statistically  significant  with  four  to  five  samples  per  group108.  All  experimental  and  control  animals  
were  littermates,  and  none  were  excluded  from  analysis  at  the  time  of  harvest.  Experimental  
animals  were  lost  or  excluded  at  two  pre-­defined  points:  (i)  failure  to  properly  inject  4OHT  and  
observation  of  significant  leakage;;  (ii)  death  prior  to  P10  because  of  injection  or  chaos.  Given  the  
early  time  points,  no  attempt  was  made  to  distinguish  or  segregate  results  based  on  neonatal  
genders.  P-­values  were  calculated  as  indicated  in  figure  legends  using  an  unpaired,  two-­tailed  
Student’s  t-­test;;  one-­way  ANOVA  with  multiple  comparison  corrections  (Holm-­Sidak  or  
Bonferroni);;  PERMANOVA;;  or  linear  mixed  effects  modeling.    As  indicated  in  the  figure  legends,  
the  standard  error  of  the  mean  (s.e.m.),  95%  confidence  interval,  or  boxplot  is  shown.  
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Figure  3.1  
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Figure  3.1.    CCM  formation  is  stimulated  by  gram  negative  bacterial  infection  and  
intravenous  LPS  injection.    a,  Lesion  formation  in  susceptible  and  resistant  iECre;;Ccm2fl/fl  mice  
at  P17.  Dotted  lines  trace  cerebellar  white  matter.  Asterisks;;  CCM  lesions  Scale  bars,  1  mm  (left)  
and  100  µm  (right).  b,  Hindbrains  of  resistant  iECre;;Ccm2fl/fl  littermates  without  (top)  and  with  
(bottom)  spontaneous  abdominal  gram-­negative  abscess.  Scale  bars,  1  mm.  Arrows;;  CCM  
lesions.  c,  The  bacterial  abscess  (“absc”)  identified  in  (b)  contains  gram  negative  bacteria  
(arrows).  Scale  bars,  4  mm  (top)  and  10µm  (bottom).  d,  CCM  formation  in  resistant  iECre;;Ccm2fl/fl  
littermates  following  injection  with  a  live  B.  fragilis/autoclaved  cecal  contents  mixture  (B.  fragilis)  
or  ACC  alone  (ACC  vehicle).  Scale  bars,  1  mm.  e-­f,  Resistant  iECre;;Ccm2fl/fl  responders  exhibit  
splenic  abscesses  and  increased  spleen  weight  compared  with  non-­responders.  g,  CCM  
formation  in  resistant  iECre;;Ccm2fl/fl  mice  following  vehicle  or  LPS  treatment.  Scale  bars,  1  mm.    
h-­i,  Quantitation  of  lesion  and  total  brain  volumes.  Error  bars  shown  as  s.e.m.  and  significance  
determined  by  one-­way  ANOVA  with  Holm-­Sidak  correction  for  multiple  comparisons  or  unpaired,  
two-­tailed  t-­test.    ****  indicates  p<0.0001;;  ***indicates  p<0.001;;  n.s.  indicates  p>0.05.  
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Figure  3.2  
  
	   79	  
Figure  3.2.    CCM  lesion  formation  requires  endothelial  TLR4/CD14  signaling.    a,  Injection  of  
LPS  at  P5  drives  CCM  formation  by  P6  in  susceptible  iECre;;Krit1fl/fl  littermates.  Scale  bars,  1mm  
(white)  and  50  µm  (yellow).  Arrows  and  arrowheads;;  CCM  lesions.  Dotted  lines;;  cerebellar  white  
matter.  b,  Gene  expression  in  cerebellar  endothelial  cells  isolated  from  the  indicated  littermates  at  
P6.    N≥3  per  group.  c-­f,  Genetic  rescue  of  CCM  formation  with  endothelial  loss  of  TLR4  or  global  
loss  of  CD14.  Visual  appearance  of  CCM  lesions  (above),  corresponding  microCT  images  
(below),  and  lesion  volume  quantitation.  Scale  bars,  1mm.  Error  bars  shown  as  s.e.m  and  
significance  determined  by  one-­way  ANOVA  with  Holm-­Sidak  correction  for  multiple  
comparisons.  ****indicates  p<0.0001;;  ***indicates  p<0.001;;  **indicates  p<0.01;;  n.s.  indicates  
p>0.05.  
	   80	  
Figure  3.3  
  
	   81	  
Figure  3.3.  Increased  TLR4  or  CD14  expression  is  associated  with  higher  lesion  number  in  
familial  CCM  patients.    a,  SNPs  in  the  5’  genomic  regions  of  TLR4  and  CD14  associated  with  
increased  lesion  numbers  in  familial  CCM  patients  are  shown  relative  to  the  transcriptional  start  
site  (TSS).    b-­c,  Normalized  microarray  measurement  of  TLR4  and  CD14  expression  in  whole  
blood  cells  from  individuals  in  the  general  population  with  the  indicated  TLR4  rs10759930  and  
CD14  rs778587  genotypes.  d,  Representative  MRI  images  of  KRIT1  Q455X  patients  with  raw  
lesion  count  and  TLR4/CD14  SNP  genotypes  (RA;;  risk  allele).  e-­f,  Sex  and  age  adjusted  
log(lesion  burden)  in  KRIT1  Q455X  patients  with  indicated  genotypes.  Error  bars  shown  as  95%  
confidence  intervals  and  significance  determined  by  one-­way  ANOVA  with  Holm-­Sidak  correction  
for  multiple  comparisons.  ****indicates  p<0.0001;;  ***indicates  p<0.001;;  **indicates  p<0.01;;  
*indicates  p<0.05.  
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Figure  3.4  
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Figure  3.4.    CCMs  fail  to  form  in  most  germ-­free  mice.    a,  Experimental  design  in  which  
offspring  of  susceptible  Krit1fl/fl  females  were  fostered  to  conventional  or  germ-­free  Swiss-­
Webster  mothers.  b,  Hindbrains  from  P10  offspring  fostered  in  conventional  (4/8  shown,  top)  or  
germ-­free  conditions  (8/8  shown,  bottom).  c,  Lesion  volume  quantitation  of  iECre;;Krit1fl/fl  
hindbrains  following  C-­section/fostering  in  conventional  or  germ-­free  conditions.  d,  Relative  
quantitation  of  neonatal  gut  bacterial  load  measured  by  qPCR  of  bacterial  16S  rRNA  gene  copies.  
e,  Relative  quantitation  of  Krit1  mRNA  in  lung  endothelial  cells  (LEC)  measured  by  qPCR.  Red  
boxes  indicate  values  for  the  single  germ-­free  animal  with  significant  lesions.  Scale  bars,  1  mm.  
Error  bars  shown  as  s.e.m.  and  significance  determined  by  unpaired,  two-­tailed  Student’s  t-­test.  
****indicates  p<0.0001;;  n.s.  indicates  p>0.05.  
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Figure  3.5  
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Figure  3.5.    CCM  susceptibility  is  associated  with  increased  levels  of  gram  negative  
Bacteroidetes  s24-­7.  a-­c,  Visual  and  microCT  images  of  hindbrains  from  susceptible  (top)  and  
resistant  (bottom)  iECre;;Krit1fl/fl  and  iECre;;Ccm2fl/fl  animals  and  susceptible  iECre;;Krit1fl/fl  animals  
fostered  to  conventional  Swiss-­Webster  (SW)  mothers.  Scale  bars,  1  mm.    d-­e,  Quantitation  of  
lesion  and  brain  volumes.  Error  bars  shown  as  s.e.m.  and  significance  determined  by  one-­way  
ANOVA  with  Holm-­Sidak  correction  for  multiple  comparisons.  f-­g,  Principle  Coordinates  Analysis  
(PCoA)  of  unweighted  and  weighted  UniFrac  bacterial  composition  distances  from  the  feces  of  
susceptible  and  resistant  Krit1fl/fl  and  Ccm2fl/fl  mothers.    P-­values  compare  bacterial  compositions  
in  all  resistant  to  all  susceptible  animals  using  PERMANOVA.  h,  Relative  abundance  boxplot  of  
Bacteroidetes  s24-­7  in  susceptible  or  resistant  Krit1fl/fl  or  Ccm2fl/fl  mothers  and  conventional  SW  
foster  mothers.  Significance  determined  by  linear  mixed  effects  model  with  Benjamini-­Hochberg  
correction  for  multiple  comparisons.  ****indicates  p<0.0001;;  ***indicates  p<0.001;;  n.s.  indicates  
p>0.05.  Note:  Conventional  SW  data  from  Figs.  4  and  5  are  the  same  experiment.  
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Figure  3.6  
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Figure  3.6.  Preventing  CCM  formation  by  TLR4  antagonism  and  microbiome  manipulation.  
a,  Model  of  pathogenesis  in  which  gram-­negative  bacteria  (GNB)  in  the  gut  are  the  source  of  LPS  
that  enters  circulating  blood,  activating  luminal,  brain  endothelial  TLR4  receptors.  LPS-­TLR4  
stimulation  drives  MEKK3-­KLF2/4  signaling  to  induce  CCMs.  b,  Visual  and  microCT  images  of  
hindbrains  from  vehicle  or  Tak242  injected  animals.  c-­d,  Lesion  and  brain  volume  quantitation.  e,  
Intergenerational  experiment  in  which  susceptible  iECre;;Krit1fl/fl  mating  pairs  were  used  to  test  the  
acute  and  chronic  effects  of  antibiotic  treatment  on  CCM  formation.  f-­h,  Visual  and  corresponding  
microCT  images  of  hindbrains  from  offspring  of  three  generations  from  one  mating  pair,  
representative  of  three  pairs.  i,  Relative  quantitation  of  neonatal  gut  bacterial  load  measured  by  
qPCR  of  the  bacterial  16S  rRNA  gene.  N=4  per  group.  j,  Lesion  volume  quantitation.  k-­l,  Relative  
quantitation  of  Bacteroidetes  s24-­7  (s24-­7)  load  in  the  neonatal  gut  measured  by  qPCR  of  the  
s24-­7  rRNA  gene  (two  distinct  primer  sets).  N≥8  per  group.  All  scale  bars,  1  mm.  Error  bars  
shown  as  s.e.m.  or  boxplot  and  significance  determined  by  one-­way  ANOVA  with  Holm-­Sidak  
correction  for  multiple  comparisons.  ****indicates  p<0.0001;;  ***indicates  p<0.001;;  **indicates  
p<0.01;;  *indicates  p<0.05;;  n.s.  indicates  p>0.05.  
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Figure  3.7  
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Figure  3.7.  CCM  formation  in  resistant  iECre;;Ccm2fl/fl  animals  is  stimulated  by  abscess  
formation  and  LPS.  a,  Resistance  to  CCM  formation  is  maintained  in  a  C57BL/6J  strain  
background.  iECre;;Ccm2fl/fl  animals  were  back-­crossed  7  generations  onto  a  C57BL/6J  
background  and  gene  deletion  induced  at  P1  with  visual  hindbrain  assessment  at  P10.  N=7.  
Scale  bars,  1  mm.  b,  Retinal  CCM  formation  is  stimulated  by  gram  negative  bacterial  infection.  
Retinas  of  P17  resistant  iECre;;Ccm2fl/fl  littermates  are  shown.    The  sample  shown  below  is  from  
the  animal  that  developed  the  spontaneous  gram-­negative  abscess  shown  in  Fig.  1c.  Scale  bars,  
500  µm.  c-­d,  Administration  of  LPS  does  not  drive  CCM  formation  in  Cre-­negative  neonatal  mice.    
LPS  was  administered  intravenously  to  Ccm2fl/fl  and  iECre;;Ccm2fl/fl  littermates  as  shown  in  Figure  
1g,  and  hindbrains  assessed  at  P17  visually  (c)  and  histologically  (H&E  staining,  d).  N≥3  per  
group.  Scale  bars,  1  mm  (c)  and  100  µm  (d).  e,  LPS  induces  myosin  light  chain  activation  in  
CCM-­deficient  brain  endothelial  cells.  Phospho-­myosin  light  chain  (pMLC)  and  PECAM  staining  
of  hindbrains  from  P5  LPS-­  or  vehicle-­injected  resistant  iECre;;Ccm2fl/fl  littermates.  Dotted  lines  
trace  the  purkinje  cell  layer.  N≥4  per  group.  Scale  bars,  50  µm.    f,  Tlr4  expression  does  not  differ  
between  CCM  susceptible  and  resistant  animals.  Tlr4  expression  was  measured  using  qPCR  in  
cerebellar  endothelial  cells  isolated  from  the  indicated  animals  at  P10.  Error  bars  shown  as  s.e.m.  
and  significance  determined  by  unpaired,  two-­tailed  Student’s  t-­test.  n.s.  indicates  p>0.05.  
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Figure  3.8  
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Figure  3.8.    Analysis  of  immune  cells  in  P6  and  P11  Krit1fl/fl  and  iECre;;Krit1fl/fl  brains.    a,  
Gating  strategy  for  B  cells,  NK  cells,  γδ  T  cells,  CD4  T  cells,  CD8  T  cells,  eosinophils,  neutrophils  
and  monocytes/macrophages  from  cerebrum  and  cerebellum  is  shown.  Cellular  surface  markers  
used  were  as  follows:  Neutrophils  (CD45+,  CD11b+,  Ly6-­G+),  Eosinophils  (CD45+,  CD11b+,  
CD11c-­,  Ly6G-­,  Siglec-­F+,  SSChi),  Monocyte/Macrophage  (CD45+,  CD11b+,  CD11c-­,  Ly6G-­,  
Siglec-­F-­,  SSClo),  NK  cells  (CD45+,  CD11b-­,  CD19-­,  NK1.1+),  B  cells  (CD45+,  CD11b-­,  NK1.1-­,  
CD19+),  γδ  T  cell  (CD45+,  CD11b-­,  NK1.1-­,  CD19-­,  CD3+,  TCRγδ+),  CD4  T  cell  (CD45+,  CD11b-­,  
NK1.1-­,  CD19-­,  CD3+,  TCRγδ-­,  CD8-­,  CD4+),  CD8  T  cell  (CD45+,  CD11b-­,  NK1.1-­,  CD19-­,  CD3+,  
TCRγδ-­,  CD4-­,  CD8+).    b,  The  number  of  B  cells,  NK  cells,  γδ  T  cells,  CD4  T  cells,  CD8  T  cells,  
eosinophils,  neutrophils,  and  monocytes/macrophages  isolated  from  P6  cerebrum  (top)  and  
cerebellum  (bottom)  is  shown  for  susceptible  Krit1fl/fl  and  iECre;;Krit1fl/fl  littermates.    N≥6  per  
group.    No  significant  differences  were  detected.    c,  The  number  of  B  cells,  NK  cells,  γδ  T  cells,  
CD4  T  cells,  CD8  T  cells,  eosinophils,  neutrophils,  and  monocytes/macrophages  isolated  from  
P11  cerebrum  (top)  and  cerebellum  (bottom)  is  shown  for  susceptible  Krit1fl/fl  and  iECre;;Krit1fl/fl  
littermates.  N≥6  per  group.  d-­e,  Frequency  of  RORγt+  CD4  T  cells  isolated  from  P6  and  P11  
cerebellum.    N≥6  per  group.  Error  bars  of  all  graphs  shown  as  s.e.m.  and  significance  determined  
by  unpaired,  two-­tailed  Student’s  t-­test.  *indicates  p<0.05.    Note  that  there  is  significant  immune  
cell  presence  in  the  cerebellum  of  susceptible  iECre;;Krit1fl/fl  animals  at  P11  but  not  at  P6.  
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Figure  3.9.    Changes  in  the  volume  of  CCM  lesions  are  not  accompanied  by  changes  in  
total  brain  volume.    The  indicated  total  brain  volumes  were  measured  using  microCT  imaging.  
a-­b,  Brain  volumes  corresponding  to  the  genetic  rescue  experiments  shown  in  Fig.  2c-­f,  
respectively.  c,  Brain  volumes  corresponding  to  the  C-­section/germ  free  fostering  experiment  
shown  in  Fig.  4b-­c.  d,  Brain  volumes  corresponding  to  the  intergenerational  antibiotic  experiment  
shown  in  Fig.  6f-­h  and  j.  n.s.  indicates  p>0.05.    
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Figure  3.10  
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Figure  3.10.    Lineage  tracing  of  the  Cdh5(PAC)-­CreERT2  (iECre)  transgene  in  neonatal  mice.    
a-­c,  R26-­LSL-­RFP,  R26-­CreERT2;;R26-­LSL-­RFP,  and  Cdh5(PAC)-­CreERT2;;R26-­LSL-­RFP  neonates  
were  induced  with  doses  of  tamoxifen  on  P1+2  (two  total  doses)  and  CD45+;;RFP+  hematopoietic  
cell  numbers  in  the  spleen  and  peripheral  blood  assessed  at  P10.  N≥5  per  group.  Error  bars  
shown  as  s.e.m.  and  significance  determined  by  one-­way  ANOVA  with  Holm-­Sidak  correction  for  
multiple  comparisons.  ***indicates  p<0.001;;  n.s.  indicates  p>0.05.  Note  that  the  number  of  
labeled  hematopoietic  cells  in  Cdh5(PAC)-­CreERT2;;R26-­LSL-­RFP  animals  is  indistinguishable  
from  R26-­LSL-­RFP  negative  control  animals,  while    >90%  of  CD45+  cells  were  RFP+  in  R26-­
CreERT2;;R26-­LSL-­RFP  positive  control  animals.  d,  Anti-­RFP  and  anti-­PECAM  immunostaining  of  
P10  hindbrains  from  Krit1fl/fl;;R26-­LSL-­RFP  negative  control  and  iECre;;Krit1fl/fl;;R26-­LSL-­RFP  was  
performed  to  identify  Cre+  descendants  at  the  site  of  CCM  formation.    Note  that  all  RFP+  cells  in  
iECre;;Krit1fl/fl;;R26-­LSL-­RFP  animals  are  PECAM+,  consistent  with  endothelial-­specific  Cre  
activity.    Asterisk  indicates  CCM  lesion.  Results  are  representative  of  ≥  3  per  group.  Scale  bars,  
100  µm.    
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Figure  3.11  
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Figure  3.11.  The  Slco1c1(BAC)-­CreERT2  (iBrainECre)  transgene  expresses  selectively  in  
brain  endothelial  cells  and  iBrainECre-­driven  deletion  of  Krit1  confers  CCM  formation  in  
neonatal  mice.    a,  R26-­LSL-­RFP,  Cdh5(PAC)-­CreERT2;;R26-­LSL-­RFP  and  Slco1c1(BAC)-­
CreERT2;;R26-­LSL-­RFP  neonates  were  induced  with  tamoxifen  injection  on  P1+2  (two  total  doses).  
Immunostaining  for  RFP  and  PECAM  was  performed  at  P10  in  the  indicated  tissues.  Results  are  
representative  of  at  least  three  animals  per  group  and  three  independent  experiments.  Scale  
bars,  100  µm.  Note  the  presence  of  RFP+  PECAM+  cells  in  the  brain,  small  intestine,  cecum,  
colon  and  liver  of  Cdh5(PAC)-­CreERT2;;R26-­LSL-­RFP  animals,  but  only  in  the  brain  of  
Slco1c1(BAC)-­CreERT2;;R26-­LSL-­RFP  animals.  b,  Visual  (top)  and  corresponding  microCT  
(bottom)  images  of  brains  from  susceptible  iBrainECre;;Krit1fl/+  and  iBrainECre;;Krit1fl/fl  P10  
animals.  Arrow  indicates  CCM  lesions  in  the  cerebrum.  Scale  bars,  1  mm.  c,  H&E  staining  of  
cerebellum  (hindbrain)  from  the  indicated  animals  (left).  H&E  staining  of  cerebrum  (forebrain)  
from  the  indicated  animals  (middle).  KLF4  and  PECAM  immunostaining  from  the  indicated  
animals  (right).  Scale  bars,  50  µm.  Asterisks  denote  CCM  lesions.  N≥5  per  group.  
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Figure  3.12  
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Figure  3.12.    CCM  formation  can  be  stimulated  by  IL-­1β  or  poly(I:C)  treatment.    a,  Schematic  
of  the  experimental  design  in  which  littermates  receive  a  retro-­orbital  injection  of  the  indicated  
cytokine  or  TLR  ligand  at  P5  and  P10  prior  to  tissue  harvest  and  analysis  at  P17.    b-­m,  Visual  
images  and  volumetric  quantitation  of  CCM  lesions  in  the  hindbrains  of  P17  iECre;;Ccm2fl/fl  
littermates  injected  with  the  indicated  cytokines,  TLR  ligands,  or  vehicle  control  are  shown.  Error  
bars  shown  as  s.e.m.  and  significance  determined  by  unpaired,  two-­tailed  Student’s  t-­test.  
*indicates  p<0.05;;  n.s.  indicates  p>0.05.    Scale  bars,  1  mm.  
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Figure  3.13.    16s  rRNA  sequencing  results  from  susceptible  and  resistant  Krit1fl/fl  and  
Ccm2fl/fl  dams.    a,  Heat  map  showing  relative  abundance  of  bacterial  taxa  (right)  identified  in  
susceptible  (blue)  and  resistant  (salmon)  Krit1  (ccm1,  purple)  and  Ccm2  (ccm2,  green)  animals  
(top).    b,  Box  plots  of  bacterial  taxa  that  demonstrated  significant  differential  abundance  in  
susceptible  versus  resistant  animals  and  the  relative  abundance  of  those  taxa.  c,  Boxplot  of  the  
Firmicutes  [Ruminococcus]  taxon  that  displayed  significant  differential  abundance  between  Krit1  
and  Ccm2  genotypes.  Note  that  the  relative  abundance  of  Bacteroidetes  s24-­7  is  anywhere  from  
10  to  10,000-­fold  greater  than  any  other  taxon.  Significance  (p<0.05)  for  b  and  c  determined  by  
linear  mixed  effects  modeling  with  Benjamini-­Hochberg  correction  for  multiple  comparisons.  
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Figure  3.14  
	  
Figure  3.14.  Blockade  of  CCM  formation  by  the  TLR4  antagonist  LPS-­RS.  a,  Schematic  of  
the  experimental  design  in  which  iECre;;Krit1fl/fl  littermates  receive  retro-­orbital  injections  of  the  
TLR4  antagonist  LPS-­RS.    b,  Visual  (left)  and  microCT  (right)  images  of  hindbrains  from  vehicle  
or  LPS-­RS  injected  animals.  c-­d,  Quantitation  of  CCM  lesion  and  brain  volume  in  iECre;;Krit1fl/fl  
littermates  treated  with  vehicle  or  LPS-­RS.  Error  bars  shown  as  s.e.m.  and  significance  
determined  by  unpaired,  two-­tailed  Student’s  t-­test.  **indicates  p<0.01;;  n.s.  indicates  p>0.05.  All  
scale  bars,  1  mm.  
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Figure  3.15.  CCM  formation  is  stimulated  by  spontaneous  abscess  formation  and  not  
blocked  by  vancomycin.    a,  P10  hindbrains  from  Generation  3/Post  ABX  iECre;;Krit1fl/fl  
littermates  in  the  longitudinal  antibiotic  experiment  described  in  Fig  6e-­l.  The  animal  with  a  large  
CCM  lesion  burden  on  the  far  right  was  found  to  have  an  abdominal  abscess  (circle,  “absc”)  and  
splenomegaly  (arrow,  lower  right).  Scale  bar,  1  mm.  b,  Schematic  of  the  experimental  design  in  
which  cohoused,  lesion  susceptible  iECre;;Krit1fl/fl  mating  pairs  were  used  to  test  the  acute  effect  
of  vancomycin  treatment  on  CCM  formation.  Offspring  were  studied  after  receiving  maternal  
vehicle  or  vancomycin  administered  from  E14.5  to  P11.  c-­d,  Visual  images  of  hindbrains  from  
representative  offspring  following  vehicle  or  vancomycin  antibiotic  treatment.  Scale  bars,  1  mm.    
e-­f,  Volumetric  quantitation  of  CCM  lesions  and  brain  volumes  in  iECre;;Krit1fl/fl  littermates  treated  
with  vehicle  or  vancomycin.  g-­h,  Relative  quantitation  of  total  neonatal  gut  bacterial  load  
measured  by  qPCR  of  bacterial  universal  16S  or  Firmicutes-­specific  rRNA  gene  copies.  N≥6  per  
group.  Error  bars  of  all  graphs  shown  as  s.e.m.  and  significance  determined  by  unpaired,  two-­
tailed  Student’s  t-­test.  n.s.  indicates  p>0.05.  ****indicates  p<0.0001;;  n.s.  indicates  p>0.05.  
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Figure  3.16.    CCM  formation  is  conferred  to  the  offspring  of  resistant  animals  by  fostering  
to  Swiss-­Webster  mothers.    a,  Schematic  of  the  experimental  design  in  which  timed  matings  of  
resistant  iECre;;Krit1fl/fl  and  resistant  iECre;;Ccm2fl/fl  mating  pairs  were  used  to  generate  E19.5  
offspring  delivered  by  natural  birth  and  raised  by  the  birth  mother  or  C-­section/fostered  to  
conventional  Swiss-­Webster  foster  mothers.  b-­c,  Visual  images  of  hindbrains  from  P10  resistant  
iECre;;Krit1fl/fl  and  iECre;;Ccm2fl/fl  offspring  following  natural  delivery  and  nursing  by  resistant  
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CHAPTER  4:  General  summary  and  discussion  
  
4.1  CCMs  arise  from  gain  of  endothelial  MEKK3—KLF2/4  signaling  
  
   In  Chapter  2,  we  demonstrated  in  the  neonatal  mouse  model  that  early  CCM  lesions  
exhibit  signatures  of  increased  endothelial  MEKK3  signaling,  namely  increased  endothelial  
expression  of  downstream  target  genes:  Klf2,  Klf4,  Adamts4,  and  directly  abluminal  versican  
cleavage  (DPEAAE-­neo  epitope  staining).  Importantly,  we  also  observed  increased  ROCK  
signaling  using  phospho-­MLC  immunohistochemistry  as  a  marker,  consistent  with  previously  
published  reports.  In  contrast  with  previous  studies,  during  early  stages  of  lesion  formation,  there  
was  no  evidence  of  increased  TGFβ,  Notch,  or  canonical  Wnt/β-­catenin  signaling  in  lesional  
endothelial  cells.  The  lack  of  early  TGFβ  signaling  may  be  explained  by  the  recent  report  that  
MEKK3  signaling  drives  expression  of  the  endothelial  BMPs  thought  to  contribute  to  lesion  
progression94.  The  role  of  Notch  or  canonical  Wnt  signaling  in  CCM  pathogenesis  has  yet  to  be  
clearly  defined,  although  this  could  certainly  be  accomplished  through  in  vivo  combinatorial  
genetic  approaches  using  already  developed  loss  and  gain  of  function  alleles.  
   To  functionally  demonstrate  the  role  of  MEKK3  signaling  in  lesion  formation,  we  
introduced  the  endothelial  haploinsufficiency  of  Map3k3  in  the  neonatal  CCM  model.  Strikingly,  
loss  of  one  allele  of  Map3k3  almost  completely  prevented  lesion  formation  and  reversed  the  gain  
of  KLF2/4  expression  and  ROCK  signaling  (pMLC).  Using  the  same  combinatorial  genetic  
approach,  we  demonstrated  that  loss  of  KLF2  or  KLF4  also  prevented  lesion  formation  and  
reversed  ROCK  signaling.  This  series  of  genetic  experiments  demonstrated  that  the  MEKK3—
KLF2/4  pathway  is  required  for  lesion  formation  and  is  upstream  of  ROCK  signaling.  Importantly,  
the  mechanism  by  which  MEKK3—KLF2/4  signaling  affects  Rho  activation  remains  unknown.    
   Finally,  IHC  analysis  of  resected  human  CCM  lesions  showed  increased  endothelial  
expression  of  KLF2  and  KLF4,  consistent  with  gain  of  MEKK3  signaling.  Importantly,  the  lesions  
analyzed  were  from  familial  KRIT1  and  PDCD10  as  well  as  sporadic  patients,  demonstrating  the  
conservation  of  this  MEKK3-­KLF2/4  mechanism  across  multiple  CCM  patient  categories  
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(genotype  and  pathogenesis).  Furthermore,  in  agreement  with  other  recently  published  work,  we  
demonstrated  that  the  CCM2  C-­terminal  helical  harmonin-­domain  (HHD)  directly  binds  to  the  N-­
terminus  of  MEKK3.  We  then  identified  a  familial  CCM  patient  with  a  reported  truncation  mutation  
in  the  CCM2  HHD  and  showed  that  this  mutant  CCM2  maintains  binding  to  KRIT1  and  PDCD10  
but  not  MEKK3.  These  biochemical  results  suggest  that  specific  loss  of  the  CCM2-­MEKK3  
interaction  is  sufficient  to  cause  CCM  disease  in  humans.  
   These  findings  define  proximal  signaling  events  downstream  of  the  CCM  complex  that  
are  required  for  lesion  genesis.  Given  the  significance  of  the  combinatorial  genetic  rescues  along  
with  multiple  lines  of  corroborating  human  evidence,  it  is  tempting  to  conclude  that  MEKK3—
KLF2/4  signaling  is  the  causal  mechanism  of  CCM  disease.  However,  this  statement  must  be  
tempered  with  the  fact  that  requirement  does  not  demonstrate  causality.  Future  studies  
demonstrating  gain  of  MEKK3—KLF2/4  signaling  as  sufficient  for  lesion  formation  would  settle  
this  finer  point.  
4.2  Endothelial  TLR4  and  the  gut  microbiome  drive  CCMs  
  
   In  Chapter  3,  we  demonstrated  that  gram-­negative  bacterial  infections  and  intravenous  
lipopolysaccharide  are  strong  drivers  of  CCM  lesion  formation.  These  experiments  were  borne  
from  the  spontaneous  emergence  of  Krit1  and  Ccm2  mouse  colonies  that  gave  rise  to  neonatal  
animals  resistant  to  lesion  formation.  LPS  administration  followed  by  cerebellar  endothelial  cell  
isolation  and  qPCR  of  downstream  MEKK3  targets  demonstrated  that  LPS  signaling  synergized  
with  loss  of  the  CCM  complex  to  promote  the  transcription  of  Klf2,  Klf4,  Il1b,  and  Sele,  consistent  
with  a  direct  effect  of  LPS  on  cerebellar  endothelium.  The  surface  receptor  for  LPS  is  TLR4,  and  
endothelial  loss  of  TLR4  dose-­dependently  prevents  lesion  formation  in  the  setting  of  
spontaneous  disease,  suggesting  that  there  is  a  basal  level  of  LPS-­TLR4  endothelial  signaling  
that  occurs  in  the  neonatal  disease  model.  A  similar,  but  less  complete  rescue  was  achieved  with  
global  deletion  of  Cd14,  a  soluble  co-­receptor  for  TLR4  that  promotes  the  loading  of  LPS  onto  
TLR4  but  is  not  essential  for  LPS  signaling.  From  a  translational  perspective,  administration  of  
two  TLR4  inhibitors  (TAK242  and  LPS-­RS)  were  found  to  partially  prevent  lesion  formation.  
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   Utilizing  a  cohort  of  188  familial  CCM  patients  all  bearing  an  identical  mutation  in  KRIT1,  
we  identified  two  sets  of  SNPs  significantly  associated  with  altered  disease  severity—one  set  in  
TLR4  and  another  in  CD14.  Further  analysis  demonstrated  that  both  sets  of  SNPs  were  in  the  5’  
UTR  of  either  locus  and  had  been  characterized  as  positive  cis-­eQTLs  that  increase  gene  
expression.  Consistent  with  LPS-­TLR4  signaling  as  a  driver  of  lesion  formation,  in  this  patient  
cohort,  being  a  carrier  of  these  TLR4  or  CD14  SNPs  was  associated  with  significantly  higher  
lesion  burden.  
   We  then  hypothesized  that  the  endogenous  ligand  for  endothelial  TLR4  was  LPS  derived  
from  the  bacterial  microbiome.  Through  a  variety  of  approaches,  including  antibiotic  treatment  
studies  and  germ-­free  rederivation  of  iECre;;Krit1  fl/fl  animals,  we  demonstrated  that  bacteria  are  
a  primary  driver  of  lesion  formation  in  the  neonatal  CCM  model.  Administration  of  antibiotics  
selective  for  gram-­positive  bacteria  did  not  prevent  lesion  formation,  consistent  with  gram-­
negative  LPS-­TLR4  signaling  being  the  primary  driver  of  lesion  formation.  These  experiments  
demonstrated  the  importance  of  bacterial  quantity,  but  the  original  observation  of  lesion  
susceptibility  versus  resistance  in  conventionally  raised  mice  with  normal  amounts  of  bacteria  
suggested  that  qualitative  aspects  of  the  gut  microbiome  may  be  just  as  significant.  To  assess  
differences  in  the  gut  microbiome,  we  collected  maternal  feces  (since  the  neonatal  microbiome  is  
maternally  derived)  and  performed  16S  rDNA  sequencing.  Resistant  and  susceptible  
microbiomes  were  clearly  segregated,  independent  of  Krit1  or  Ccm2  genotype  and  the  most  
significant  difference  was  the  increased  relative  abundance  of  Bacteroidetes  s24-­7  in  susceptible  
animals.  This  highly  prevalent  class  of  gram-­negative  bacteria  has  previously  been  characterized  
as  colitogenic,  consistent  with  its  possible  role  in  promoting  LPS-­TLR4  signaling  to  drive  CCM  
formation.  
   These  findings  demonstrate  bacterial  microbiome-­derived  LPS-­TLR4  signaling  as  a  
primary  upstream  driver  of  lesion  formation.  Broadly,  these  findings  demonstrate  
environmental/genetic  interaction  that  may  have  implications  for  the  human  disease  (e.g.  one  
explanation  for  why  CCM  disease  course  is  highly  variable).  Mechanistically,  our  data  highlight  
the  importance  of  finely  tuned  MEKK3  signaling  via  negative  regulation  by  the  CCM  complex  and  
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activation  by  upstream  innate  immune  receptors.  Importantly,  we  demonstrated  that  other  
inflammatory  ligands  such  as  IL1β  (IL-­1  receptor  ligand)  or  polyIC  (TLR3  ligand)  could  also  drive  
lesion  formation  when  exogenously  administered.  Whether  these  ligands  have  an  endogenous  
role  in  CCM  pathogenesis  remains  to  be  determined,  and  this  could  be  achieved  through  a  similar  
combinatorial  genetic  rescue  approach  as  we  have  utilized  for  the  TLR4—MEKK3—KLF2/4  
pathway.      
4.3  The  molecular  mechanism  of  lesion  formation  
	  
   A  direct  extension  of  the  studies  performed  in  Chapter  2  is  to  identify  the  effector  
molecules  downstream  of  KLF2  and  KLF4  that  are  responsible  for  lesion  formation.  
Understanding  this  final  aspect  of  disease  pathogenesis  would  be  of  great  translational  
importance  from  the  perspective  of  therapeutic  development  and/or  biomarker  identification.  In  
Chapter  2,  we  demonstrated  in  the  neonatal  CCM  model  that  one  of  the  earliest  events  in  lesion  
pathogenesis  is  the  increased  expression  of  ADAMTS4  and  the  histologic  appearance  of  cleaved  
versican  directly  abluminal  to  the  endothelium  of  the  nascent  lesion  (Figure  2.1).  We  further  
showed  in  cultured  endothelial  cells  that  KLF2  and  KLF4  function  upstream  of  Adamts4  
transcription  (Figure  2.11).  Thus,  a  reasonable  hypothesis  would  be  that  over-­secretion  of  
endothelial  ADAMTS4  and  degradation  of  the  extracellular  matrix  is  the  molecular  mechanism  by  
which  CCMs  form.    
To  test  this  hypothesis,  I  performed  a  combinatorial  genetic  rescue  experiment  using  an  
Adamts4  constitutive-­null  allele.  Contrary  to  our  hypothesis,  global  knockout  of  Adamts4  in  the  
neonatal  CCM  model  did  not  appreciably  prevent  lesion  formation  (Figure  4.1a).  ADAMTS4  is  
one  of  several  ADAMTS  proteases  (ADAMTS1/4/5/9/20)  that  are  known  to  cleave  versican,  
suggesting  there  may  be  functional  redundancy.  Consistent  with  this  notion,  
immunohistochemistry  demonstrated  persistent  versican  cleavage  around  nascent  lesions  in  the  
global  ADAMTS4  KO  animals  (Figure  4.1b).    I  then  isolated  cerebellar  endothelium  from  the  
neonatal  CCM  model  and  used  qPCR  to  assess  transcription  of  all  known  ADAMTS  
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aggrecanases,  finding  that  Adamts1  expression  was  also  elevated  (Figure  4.1c).  Adamts1	  was  
previously  characterized  as  an  endothelial  gene  transcribed  in  response  to  LPS  challenge,  
downstream  of  ERK5-­KLF4  signaling  in  cultured  endothelial  cells,  and  Adamts1/4  or  Adamts1/5  
double  knockout  mice  were  characterized  as  embryonic  lethal155-­159.  These  prior  findings  
suggested  that  Adamts1  was  likely  to  be  downstream  of  KLF2/4  signaling  in  cerebellar  
endothelial  cells  and  potentially  involved  in  CCM  formation.  Thus,  I  performed  a  genetic  rescue  
experiment  using  the  Adamts1  conditional  and  null  alleles  since  Adamts1  constitutive  knockouts  
exhibit  a  spontaneous  phenotype157,160.  The  deletion  of  Adamts1  from  endothelial  cells  in  the  
neonatal  CCM  model  did  not  prevent  lesion  formation,  like  our  experience  with  Adamts4  (Figure  
4.2).  
   The  finding  that  loss  of  Adamts1  or  Adamts4  did  not  prevent  lesion  formation  suggested  
that  there  was  functional  redundancy  among  the  versican-­cleaving  ADAMTS  proteases  in  the  
process  of  lesion  formation.  Our  work  on  CCM  signaling  in  the  developing  endocardium  revealed  
that  Adamts5  was  also  upregulated  downstream  of  MEKK3—KLF2/4  signaling  and  morpholino  
knockdown  of  adamts5  in  embryonic  zebrafish  rescued  the  krit1  morpholino-­induced  dilated-­heart  
phenotype.  The  redundancy  of  the  ADAMTS  proteases  in  other  disease  contexts  has  been  well-­
studied,  particularly  in  osteoarthritis  where  ADAMTS4  and  ADAMTS5  play  a  major  role  in  the  
destruction  of  joint  cartilage  matrix161,162.  Intriguingly,  in  osteoarthritis  mouse  models,  ADAMTS5  
was  found  to  be  the  key  protease,  despite  the  dynamic  regulation  of  ADAMTS4  in  response  to  
injury  and  inflammation.  Future  attempts  to  genetically  demonstrate  a  role  for  ADAMTS  proteases  
in  lesion  formation  will  likely  require  the  combinatorial  loss  of  multiple  ADAMTS  family  members.  
Regardless  of  functional  redundancy  or  other  explanations  for  our  negative  results,  it  is  
important  to  consider  the  possibility  that  the  hypothesis  is  simply  not  correct  and  that  ADAMTS  
activity  is  correlated  with  lesion  formation  but  not  actually  required  or  causal.  An  unbiased  
approach  would  be  to  transcriptionally  profile  cerebellar  endothelial  cells  from  the  neonatal  CCM  
model  compared  to  CCM  animals  with  genetic  endothelial  deletion  of  the  MEKK3—KLF2/4  
pathway.  One  potential  issue  with  this  experiment  is  that  neonatal  CCM  lesions  arise  exclusively  
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from  the  post-­capillary  venule,  a  subset  of  the  endothelium  that  would  be  collected  and  profiled  
since  the  Cdh5(PAC)-­Cre/ERT2  driver  deletes  in  all  endothelial  cells.  Thus,  many  gene  targets  
may  not  be  relevant  to  the  mechanism  of  lesion  formation.    
   Beyond  the  ADAMTS  proteases,  a  key  future  direction  will  be  to  address  what  the  
extracellular  ADAMTS  substrate(s)  is  that  causes  lesion  formation.  In  Chapter  2,  we  found  
histologic  evidence  of  versican  cleavage  directly  abluminal  to  the  nascent  lesional  endothelium.  In  
the  developing  heart,  ADAMTS  cleavage  of  versican-­containing  cardiac  jelly  was  found  to  cause  
embryonic  lethality  upon  loss  of  the  endocardial  CCM  complex.  Whether  versican  cleavage  is  
functionally  important  in  CCM  disease  remains  an  important  question.  While  cardiac  jelly  is  
primarily  comprised  of  versican  and  hyaluronic  acid,  the  ADAMTS  aggrecanases  cleave  
numerous  other  extra-­cellular  matrix  proteins  including  aggrecan,  brevican,  and  neurocan,  which  
have  all  been  reported  to  be  expressed  in  CNS  tissues163-­165.  Thus,  it  is  possible  that  our  versican  
cleavage  observation  is  only  a  marker  for  lesion  generation,  downstream  of  endothelial-­derived  
ADAMTS  activity.  The  role  of  versican  in  CCM  pathogenesis  could  initially  be  tested  through  
introducing  the  genetic  deficiency  of  versican  in  the  neonatal  CCM  model  (iECre;;Krit1  fl/fl;;Vcan  
+/-­).  Constitutive  Vcan  null  animals  are  embryonic  lethal,  so  one  limitation  to  this  experiment  
would  be  the  achievable  level  of  versican  deficiency166.  Understanding  the  paracrine  signaling  
mechanisms  by  which  endothelial  cells  affect  the  surrounding  cellular  environment  is  an  exciting,  
albeit  challenging,  area  of  investigation  in  vascular  biology.  
4.4  The  human  gut  microbiome  and  CCM  disease  
  
The  most  outstanding  question  from  the  work  presented  in  Chapter  3  regarding  the  gut  
microbiome  and  CCM  disease  is  whether  the  gut  microbiome  has  an  appreciable  role  in  human  
CCM  disease.  Can  we  correlate  distinct  patterns  in  the  gut  microbiome  to  CCM  disease  severity?  
Are  bacterial  species  or  microbiome  “fingerprints”  risk  factors  for  disease?  Answering  these  
questions  is  the  next  rational  step  towards  determining  whether  a  microbiome-­based  therapy  may  
benefit  CCM  patients.  To  accomplish  this,  we  have  initiated  a  multi-­center  study  to  gather  fecal  
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samples  from  familial  CCM  patients  that  have  already  been  genotyped  and  had  at  least  one  MRI  
scan  with  lesion  burden  assessment  done  by  a  trained  neuro-­radiologist.  Fecal  samples  will  be  
shipped  directly  to  the  PennCHOP  Sequencing  and  Analysis  Core  for  biobanking  and  
downstream  sequencing/analysis.    
There  are  numerous  challenges  associated  with  attempting  such  an  endeavor  besides  
the  usual  issues  of  sample  variability  and  powering  a  rare  disease  study.  The  foremost  challenge  
is  accounting  for  genetic  variability  along  with  microbiome  variability  in  the  analysis  of  effects  on  
disease  severity.  In  Chapter  3,  we  defined  genetic  variation  in  TLR4  and  CD14  loci  as  important  
risk  factors  for  lesion  formation.  Therefore,  patient  genetics  are  a  confounding  factor  and  under  
ideal  circumstances,  these  effects  would  be  assessed  through  genome-­wide  SNP  arrays.  
Another  foreseeable  challenge  is  the  issue  of  finding  familial  CCM  patients  who  do  not  
have  symptomatic  disease  or  significant  lesion  burden,  who  would  constitute  the  critical  control  
group  with  which  to  compare  the  microbiomes  of  patients  with  severe  disease.  This  population  
likely  does  not  have  pre-­existing  MRIs,  nor  are  they  likely  to  be  clinically  followed  for  CCM  
disease,  further  complicating  their  inclusion  in  the  study.  One  possible  solution  to  this  is  to  
genotype  and  recruit  family  members  of  the  CCM  patients  already  part  of  this  study,  since  they  
may  be  likely  to  also  harbor  a  CCM  gene  mutation.  
Is  there  any  preliminary  evidence  for  the  role  of  the  microbiome  in  human  CCM  disease?  
Interestingly,  epidemiological  studies  of  the  New  Mexico  KRIT1  familial  cohort  unexpectedly  
revealed  that  obesity  is  a  powerful  protective  factor  for  CCM  disease167.  In  KRIT1  familial  
patients,  obesity  is  associated  with  lower  lesion  burden  throughout  life  (Figure  4.3).  Many  studies  
looking  at  changes  in  the  gut  microbiome  associated  with  obesity  have  consistently  found  that  
obesity  alters  the  balance  of  Bacteroidetes/Firmicutes,  the  two  major  phyla  of  gram  negative  
(Bacteroidetes)  and  gram  positive  (Firmicutes)  commensal  intestinal  bacteria168,169.  Obese  mice  
and  humans  exhibit  lower  abundance  of  Bacteroidetes  and  greater  amounts  of  Firmicutes—a  
balance  that  is  reversed  upon  dieting168-­170.  One  possible  interpretation  is  that  obese  CCM  
patients  have  lower  levels  of  Bacteroidetes,  less  gram-­negative  bacteria,  and  less  potential  LPS  
to  drive  endothelial  TLR4-­MEKK3  signaling  and  lesion  formation.  This  interpretation  is  potentially  
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confounded  by  other  studies  suggesting  that  obesity  is  associated  with  higher  levels  of  circulating  
LPS  and  increased  LPS  in  the  intestine,  a  metabolic  endotoxemia,  which  is  contrary  to  the  gut  
microbiome  studies171,172.  It  is  important  to  note  that  these  studies  of  metabolic  endotoxemia  
attempt  to  measure  LPS  through  in  vitro  assays,  which  are  universally  sensitive  to  many  other  
components  in  serum  and  biological  samples173.  Measuring  LPS  levels  from  biological  samples  is  
difficult  and  one  must  also  question  the  biological  relevance  of  an  LPS  measurement  taken  at  a  
single  point  in  time.  
4.5  Gut  barrier  physiology  and  CCM  disease  
     
   The  gut  barrier  is  a  catch-­all  term  that  refers  to  the  numerous  host-­mechanisms  in  place  
to  separate  the  gut  microbiome  and  microbial  byproducts  from  distal  organs.  A  direct  extension  of  
the  work  presented  in  Chapter  3  is  to  test  whether  altering  gut  barrier  physiology  might  influence  
CCM  disease  severity.  Potential  experiments  to  break  down  the  gut  barrier,  increasing  
bacteria/LPS  leak,  would  include  utilizing  colitis  models  such  as  dextran  sodium  sulfate  (DSS)  or  
genetic  models  such  as  Il10-­null  mice  that  develop  a  spontaneous  auto-­immune  colitis174,175.  
Intriguingly,  experiments  utilizing  previously  described  agents  that  promote  the  gut  barrier  such  
as  short-­chain  fatty  acids  or  pro-­biotics,  presumably  decreasing  bacteria/LPS  leak,  may  prevent  
lesion  formation.  These  studies  are  translationally  important  as  they  would  suggest  another  
source  of  disease  variability  e.g.  a  CCM  patient  with  inflammatory  bowel  disease  or  chronic  
diverticulitis  might  be  at  greater  risk  for  lesion  formation.  Moreover,  these  studies  would  also  
suggest  that  therapeutics  aimed  at  promoting  the  gut  barrier  or  decreasing  bacterial  
translocation/byproduct  leak  may  be  of  benefit  to  patients.  
   One  issue  that  arises  from  these  proposed  studies  is  the  limitations  of  the  neonatal  CCM  
disease  model  where  lesions  form  aggressively  within  the  first  ten  days  of  life—a  period  in  which  
the  gut  barrier  is  also  developing.  Because  the  neonatal  microbiome  is  maternally  derived,  we  
previously  could  alter  the  microbiome  of  adult  animals  raising  the  phenotypic  neonate.  This  
paradigm  cannot  be  applied  to  studies  of  gut  barrier  physiology  where  CCM  lesions  and  gut  
barrier  alterations  must  occur  in  the  same  animal.  Currently,  there  are  adult  mouse  models  of  
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CCM  disease  that  entail  the  use  of  a  “sensitizing”  genetic  background  where  a  CCM  heterozygote  
is  bred  onto  a  DNA-­repair  deficient  background176,177.  These  animals  develop  an  appreciable  
lesion  burden  by  six  months  of  age;;  however,  the  mechanism  by  which  sensitization  occurs  
remains  unclear  as  they  exhibit  spontaneous  hematopoietic  and  intestinal  pathology.  Moreover,  
lesion  burden  in  these  animals  is  highly  variable,  likely  due  to  the  stochastic  nature  of  acquiring  
the  loss  of  heterozygosity  event.  Thus,  it  will  be  important  to  develop  models  of  adult  CCM  
disease  that  are  genetically  defined  and  produce  a  robust  lesion  phenotype  in  a  time-­frame  that  is  
amenable  to  laboratory  research.  
4.6  Endogenous  LPS-­TLR4  and  CCM-­MEKK3  signaling  
    
   Our  studies  in  Chapter  3  suggest  that  LPS-­TLR4  signaling  occurs  even  under  
homeostatic  conditions  and  that  the  source  of  LPS  is  likely  derived  from  the  gut  microbiome.  Are  
there  physiologic  roles  for  the  gut  microbiome  and  LPS-­TLR4  signaling?  Is  there  appreciable  gut  
microbiome-­derived  LPS-­TLR4  signaling  and  what  cell  types  might  be  responding?  Do  different  
gut  microbiomes  differentially  activate  TLR4  signaling?  It  has  been  demonstrated  that  gut  
epithelial  cells  rely  on  TLR-­MYD88  recognition  of  commensal  flora  to  promote  intestinal  
homeostasis178,  but  what  of  distal  organs  and  other  cell  types  that  are  not  in  proximity  to  the  gut  
microbiome?  Based  on  our  work,  it  seems  likely  that  endothelial  cells  would  be  among  those  
sentinel  cell  types  that  detect  basal  levels  of  circulating  LPS.  
   Detection  of  in  vivo  basal  TLR4  signaling,  in  the  absence  of  exogenous  LPS  or  other  
inflammatory  stimuli,  has  never  been  accomplished.  Attempting  to  do  so  is  further  complicated  by  
the  fact  that  there  is  not  a  specific  downstream  target  for  TLR4  signaling,  as  it  shares  its  
intracellular  signaling  components  (MYD88,  TRIF,  TRAF6,  NFκB,  etc)  with  many  other  innate  
immune  receptors.  One  possible  approach  may  be  to  leverage  the  observation  that  LPS  
complexes  with  MD-­2  to  induce  dimerization  of  TLR4,  an  event  that  is  required  for  initiating  
intracellular  signaling53.  This  receptor  dimerization  could  be  detected  and  signal-­amplified  using  
TEV  protease  (TEVp)  cleavage  and  release  of  a  tTA,  an  approach  that  has  been  used  to  study  
GPCR  signaling  as  well  as  other  synthetic  dimerization-­dependent  receptors179-­182.  Such  an  
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approach  would  entail  the  creation  of  two  TLR4  knock-­in  alleles  where  the  TEVp  or  TEVp  
cleavage  site-­tTA  is  fused  in-­frame  to  the  C-­terminus  of  Tlr4.  These  animals  would  need  to  be  
mated  onto  a  tetO-­reporter  transgenic  background;;  thus,  the  final  reporter  system  requires  three  
distinct  alleles.  Ultimately,  such  a  reporter  system  may  not  be  worth  the  effort,  as  even  the  perfect  
reporter  would  only  detect  the  distal  activation  of  a  single  aspect  (LPS)  of  the  gut  microbiome  
while  there  are  many  other  microbiome-­derived  pathogen-­associated  molecular  patterns  (e.g.  
peptidoglycan,  flagellin,  unmethylated  CpG).  It  is  also  important  to  recognize  that  phenotypes  and  
biology  beyond  CCM  disease  may  involve  far  more  than  just  LPS-­TLR4  signaling—a  key  
distinction  between  reporter  and  functional  evidence.  Uncovering  the  functional  role  of  LPS-­TLR4  
signaling  would  likely  be  far  more  challenging  
One  possible  application  of  mice  that  detect  basal  levels  of  LPS-­TLR4  signaling  would  be  
to  potentially  address  the  natural  role  of  the  CCM  complex  in  the  blood  brain  barrier  and  other  
vascular  beds.  Based  on  our  understanding  of  CCM  signaling,  the  endothelial  CCM  complex  
likely  acts  as  an  MEKK3  rheostat,  ensuring  that  signaling  through  the  MEKK3  pathway  is  
sufficient  to  promote  homeostasis.  Consistent  with  this  hypothesis,  mouse  genetic  studies  
support  an  essential  role  for  endothelial  MEKK3  signaling  in  the  vasculature.  While  over-­
activation  of  MEKK3  is  required  for  CCM  formation,  loss  of  endothelial  MEKK3  after  birth  leads  to  
permeability  defects  in  the  blood  brain  barrier  and  hemorrhagic  phenotypes  in  other  vascular  
beds28.  Intriguingly,  germ-­free  mice  also  exhibit  increased  blood  brain  barrier  permeability  thought  
to  be  primarily  caused  by  dysfunctional  endothelial  tight  junctions,  a  phenotype  that  is  rescued  
upon  reintroduction  of  gut  bacteria183.  Taken  together,  a  reasonable  hypothesis  would  be  that  the  
gut  microbiome/LPS  signals  upstream  of  MEKK3  to  promote  vascular  integrity.    
4.7  New  challenges  in  CCM  biology  and  translation  to  patients  
  
   It  is  important  to  note  that  all  studies  of  CCM  disease  have  focused  on  the  molecular  
mechanism  of  lesion  formation  and  therapeutic  prevention  of  lesion  formation.  This  remains  an  
important  area  of  investigation  that  is  likely  to  be  translationally  significant.  However,  it  does  not  
address  the  realistic  scenario  whereby  CCM  patients  come  to  clinical  attention  upon  developing  
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one  or  more  symptomatic  lesions  that  are  already  large  enough  or  bleeding  to  cause  neurologic  
deficits.  What  are  the  signaling  pathways  altered  in  mature  lesions?  Can  lesions  regress  or  at  
least  be  stabilized  to  prevent  continued  enlargement  or  bleeding?  These  questions  are  critical  for  
the  treatment  of  CCM  patients,  but  difficult  to  answer  with  current  experimental  mouse  models.  
For  example,  to  test  if  loss  of  MEKK3  signaling  could  induce  lesion  regression,  one  would  have  to  
first  induce  CCM  gene  deletion  in  the  cerebellar  vasculature,  allow  lesions  to  form  and  then  
delete  Map3k3.  This  could  be  accomplished  through  sequential  induction  of  loxP  and  Frt  
recombination  using  brain-­endothelial  specific  Cre  and  FLP  recombinases,  although  it  would  
require  the  generation  of  several  new  transgenic  lines.  Perhaps  a  more  translationally  relevant  
investigation  would  be  to  analyze  the  effects  of  the  gut  microbiome  on  mature  lesions.  If  the  
human  microbiome  studies  of  CCM  patients  revealed  a  protective  microbiome  fingerprint,  a  
fascinating  experiment  would  be  to  attempt  microbiome  manipulation  via  fecal  transplant  in  an  
adult,  mature  lesion  setting.  Importantly,  another  technical  challenge  that  accompanies  studies  of  
mature  lesion  biology  will  be  to  develop  a  live-­imaging  modality  that  allows  for  longitudinal  
imaging/quantification  of  CCM  burden  in  mice.  It  is  doubtful  that  neonatal  mice  and  lesions  would  
be  amenable  to  extended  live  imaging,  but  it  is  possible  that  adult  animals  could  be  followed  
using  MRI.  
   While  numerous  pharmacologic  agents  are  being  developed  for  the  treatment  of  CCM  
disease,  there  remain  significant  challenges  in  the  actual  implementation.  Once  a  potential  
therapy  is  tested  in  patients,  how  would  we  determine  efficacy?  Current  attempts  at  clinical  trials  
propose  performing  longitudinal  MRIs  and  assessing  lesion  burden—an  endpoint  that  is  likely  
cost-­prohibitive  and  will  not  help  with  the  actual  pharmacologic  dosing.  If  a  therapy  was  approved  
for  use  in  patients,  who  should  be  treated?  More  than  half  of  familial  KRIT1  patients  over  the  age  
of  fifty  do  not  exhibit  clinically  significant  disease  and  do  not  require  treatment2,11.  However,  CCM  
is  a  progressive  disease  and  for  many  patients  it  can  be  a  lifelong,  debilitating  health  issue.  
Which  patients  would  benefit  from  long-­term  treatment,  and  how  would  we  clinically  determine  
this?  When  would  we  initiate  treatment?  This  stratification  becomes  particularly  complex  when  
one  considers  that  familial  CCM  patients  are  germline  heterozygous,  are  at  lifelong  risk  for  lesion  
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formation,  and  that  all  proposed  pharmacologic  agents  have  been  tested  in  models  of  lesion  
formation.  There  is  a  real  possibility  that  we  will  develop  pharmacologic  agents,  bring  them  to  
CCM  patients,  and  yet  have  no  rational  idea  of  who,  when,  or  how  to  administer  treatment.  
   I  would  like  to  think  that  the  work  presented  here  begins  to  address  these  issues.  
Understanding  the  molecular  mechanism  of  lesion  formation  will  reveal  relevant  biomarkers  (as  
well  as  potential  therapeutic  targets)  that  may  be  applicable  to  patients  with  regards  to  clinical  
trials  as  well  as  longitudinal  care.  For  example,  understanding  the  downstream  effectors  of  the  
MEKK3—KLF2/4  pathway  could  reveal  that  secreted  ADAMTS  proteases  and  extracellular  matrix  
substrate  degradation  underlie  lesion  formation.  These  molecules  could  potentially  serve  as  
causal  biomarkers  that  would  be  a  measure  of  lesion  formation  risk  as  well  as  clinical  therapeutic  
dosing/efficacy.  Determining  which  CCM  patients  should  be  treated,  as  well  as  when  and  how  
therapy  should  be  administered,  will  be  influenced  by  our  understanding  of  important  risk  factors  
that  predispose  patients  towards  an  aggressive  disease  course.  Genetic  risk  factors  (e.g.  SNPs  in  
TLR4  and  CD14)  will  certainly  be  considered  and  our  future  studies  will  determine  if  the  gut  
microbiome  should  also  be  assessed.    
Manipulation  of  the  gut  microbiome  may  be  an  ideal  preventative  treatment  strategy  for  
CCM  disease.  Fecal  transplantation  is  well-­tolerated,  already  being  performed  for  several  
intestinal  pathologies,  and  clinical  trials  are  underway  for  other  conditions,  although  long-­term  
safety  and  efficacy  studies  are  still  ongoing184,185.  It  is  fascinating  to  think  that  if  a  protective  gut  
microbiome  “fingerprint”  is  found,  we  may  be  able  to  permanently  alter  disease  course  through  
fecal  transplantation—a  therapeutic  approach  that  could  circumvent  many  of  the  aforementioned  
issues  associated  with  a  traditional  pharmacologic  approach.  
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Figure  4.1  
  
Figure  4.1.  Constitutive,  global  loss  of  ADAMTS4  does  not  alter  lesion  formation  or  
versican  cleavage  around  nascent  lesions.  a,  Lesion  formation  in  iECre;;Krit1fl/fl;;Adamts4+/+  
animals  at  P10  compared  to  iECre;;Krit1fl/fl;;Adamts4+/-­  and  iECre;;Krit1fl/fl;;Adamts4-­/-­  littermates.  b,  
Immunohistochemistry  of  nascent  CCM  lesions  in  the  cerebellar  white  matter  comparing  versican  
cleavage  (DPEAAE)  between  iECre;;Krit1fl/fl;;Adamts4+/+  and  iECre;;Krit1fl/fl;;Adamts4-­/-­  P6  
littermates.  c,  qPCR  for  versican-­cleaving  ADAMTS  proteases  performed  on  freshly  isolated  brain  
endothelial  cells.  Red  asterisk  indicates  Adamts8  and  Adamts20  genes  with  undetectable  
expression.  
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Figure  4.2  
  
Figure  4.2.  Endothelial  loss  of  Adamts1  does  not  alter  lesion  formation.  a,  Lesion  formation  
comparing  iECre;;Krit1fl/fl;;Adamts1fl/+  to  iECre;;Krit1fl/fl;;Adamts1fl/-­  P10  littermates.  b,  Blinded  
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Figure  4.3  
  
Figure  4.3.    Obesity  is  associated  with  reduced  CCM  formation  in  humans.  a,  Sex  and  age  
adjusted  CCM  lesion  count  (shown  as  natural  log)  in  KRIT1  Q455X  patients  is  plotted  against  
body  mass  index  (BMI)  for  individuals  >18  years  of  age.    Note  the  inverse  relationship  between  
adjusted  lesion  count  and  BMI  (line  of  least  squares).  b,  Lesion  count  (shown  as  natural  log)  in  
KRIT1  Q455X  patients  is  plotted  against  age  for  obese  and  non-­obese  individuals.  Significance  
determined  by  logistic  regression  analysis  and  correction  for  multiple  testing.  Note  that  LOWESS  
curves  show  the  protective  effect  of  obesity  is  present  across  all  age  groups.  ***indicates  
p<0.001.  
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